





which is at least, but is not limited to, twelve months from the end of the reporting year. The Company is in substantial doubt to continue as a going concern; As of September 30, 2024, the Company had negative shareholder's equity of \$9.1 million (December 31, 2023 negative shareholder's equity of \$2.9 million); an accumulated deficit of approximately \$539.4 million (December 31, 2023, \$515.5 million); during the nine months period ended September 30, 2024, the Company incurred a net loss of \$23.8 million (2023 - \$39.3 million) and as of September 30, 2024 we had a working capital of approximately \$477 thousand (December 31, 2023, negative working capital of \$3.4 million), including approximately \$8 million (December 31, 2023, \$9.3 million) in cash and cash equivalent balance, and current liabilities of approximately \$9.8 million (December 31, 2023, \$15.3 million). The Company faces increasingly challenging financial and business conditions, including an inability to raise sufficient equity and equity-linked financing to fully fund execution of its business plans and to satisfy its \$2.5 million Nasdaq shareholder's equity requirement. The Company has financed its activities to date through the issuance of Common Shares and continues to seek capital through various means including the issuance of equity and/or debt. During this year to September 30, 2024, the Company has explored numerous alternatives to ensure the funding of the Company's clinical trials, services and repay its outstanding vendors and increase its equity level, which level has resulted in a major hurdle for the Company to secure required financing. Management recognizes that in order to meet the capital requirements, and continue to operate, additional financing will be necessary. The Company is evaluating strategies to obtain the required additional funding for future operations. These strategies may include, but are not limited to, obtaining equity financing, debt financing, committed equity facilities or other financing instruments and restructuring of operations to decrease expenses. However, given the impact of the volatile financial markets on micro-cap market capitalization companies such as the Company and the matter in Note 10, Share capital and 12, Subsequent events, the Company may be unable to access further equity when needed. As the Company is primarily pursuing one compound that is licensed from a related party with significant licensing payments who will have influence on the Company, other investors may not be willing to invest in the Company. As such, there can be no assurance that the Company will be able to obtain additional liquidity when needed or under acceptable terms, if at all. The Company's current cash and cash equivalents are projected to support operations through January 2025. We have based these estimates on assumptions and plans, which may change and which could impact the magnitude and/or timing of operating expenses and our cash runway. The unaudited condensed consolidated interim financial statements do not reflect any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern. Such adjustments could be material.

**Basis of consolidation:** These condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions, balances, revenue, and expenses are eliminated on consolidation.

**Significant accounting policies, estimates and judgments:** During the nine months ended September 30, 2024, there have been no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024. The preparation of the unaudited condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the unaudited condensed consolidated interim financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The unaudited condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the unaudited condensed consolidated interim financial statements and may require accounting adjustments based on future occurrences. The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

**Recent Accounting Pronouncements** We have adopted no new accounting pronouncements during the three months and nine months ended September 30, 2024. There were various accounting standards and interpretations issued recently, none of which are expected to have a material impact on our financial position, operations or cash flows.

**Foreign currency:** The functional and presentation currency of the Company is the US dollar.

**Concentration of risk:** The Company is subject to credit risk from the Company's cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of "low" or "low" investments and the Company invests only in highly rated corporations and treasury bills, which are capable of prompt liquidation.

**Cash and cash equivalents:** Cash and cash equivalents as of September 30, 2024, consist of restricted cash of \$1,416 thousand (December 31, 2023 \$2,764 thousand) and of restricted deposits in high interest savings accounts, money market funds and accounts with maturities of less than 90 days totaling of \$6,546 thousand (December 31, 2023 \$6,488 thousand). On August 27, 2024, the Company received \$10 million from a loan payable to a third party. Under the terms of the loan agreement (the "Hanmi Loan Agreement"), the proceeds of \$10 million are restricted for use solely in connection of Tuspetinib related business operations, unless otherwise authorized by the related party. See Note 9, Related party transactions.

**4. Prepaid expenses:** Prepaid expenses as of September 30, 2024 and December 31, 2023 are shown below. Other prepaid expenses primarily consist of subscriptions, software, conference deposits and deposits for general and administrative items.

	September 30, 2024	December 31, 2023
Prepaid research and development expenses	\$ 662	\$ 720
Prepaid insurance	\$ 71	\$ 882
Other prepaid operating expenses	\$ 179	\$ 440
Total	\$ 912	\$ 2,042

**5. Right-of-use assets:**

	September 30, 2024	December 31, 2023
Right-of-use assets, beginning of period	\$ 3,124	\$ 3,100
Additions to right-of-use assets	\$ 2	\$ 24
Right-of-use assets, end of period	\$ 3,124	\$ 3,124
Accumulated amortization	\$ (2,460)	\$ (2,181)
Right-of-use assets, NBV	\$ 664	\$ 943

**6. Fair value measurements and financial instruments:** The fair value hierarchy establishes three levels to classify the inputs to valuation techniques used to measure fair value. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are quoted prices in markets that are not active, quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, or inputs that are derived principally from or corroborated by observable market data or other means; and Level 3 inputs are unobservable (supported by little or no market activity). The fair value hierarchy gives the highest priority to Level 1 inputs and the lowest priority to Level 3 inputs. The following table presents the fair value of Company's assets that are measured at fair value on a recurring basis for the periods presented:

	September 30, 2024	December 31, 2023
Level 1 Assets	\$ 6,546	\$ 6,546
Level 2 Assets	\$ 4	\$ 4
Level 3 Assets	\$ 2,002	\$ 2,002
Total	\$ 8,552	\$ 8,552

**High interest savings accounts** \$ 6,546  
**Accumulated amortization** \$ (2,460)  
**United States Treasury Bills** \$ 4,486  
**Accrued research and development expenses** \$ 6,466  
**Other accrued expenses** \$ 170  
**Total** \$ 7,512  
**Lease liability:** Aptose leases office space in San Diego, California. The lease for the San Diego office space is scheduled to expire in May 31, 2026. We leased office space in Toronto, Ontario, Canada, which lease expired on June 30, 2024. The Company has not included any extension periods in calculating its right-to-use assets and lease liabilities. The Company also enters into leases for small office equipment. Minimum payments, undiscounted, under our operating leases are as follows:

Years ending	December 31, 2024	2025	2026	2027	2028	2029	Total
Weighted average remaining term	1.7	2.4	3.1	3.8	4.5	5.2	24.7

**Weighted-average discount rate** 7.90%  
**Lease liability, current portion** \$ 416  
**Lease liability, long-term portion** \$ 305  
**Total** \$ 721  
**Operating lease costs and operating cash flows from our operating leases are as follows:**

Months ended	September 30, 2024	2023	2024	2023
Operating lease cost	\$ 107	\$ 114	\$ 331	\$ 359
Operating cash flows from operating leases	\$ 112	\$ 117	\$ 346	\$ 290

**9. Related party transactions:** Hanmi Pharmaceutical Co. Ltd. On November 4, 2021, Aptose entered a licensing agreement (the "Hanmi Licensing Agreement") with the South Korean company Hanmi Pharmaceutical Co. Ltd. ("Hanmi") for the clinical and commercial development of tuspetinib. Under the terms of the Hanmi Licensing Agreement, Hanmi granted Aptose exclusive worldwide rights to tuspetinib for all indications. Hanmi received an upfront payment of \$12.5 million, including \$5 million in cash and \$7.5 million in Common Shares. Aptose issued Hanmi 215,703 Common Shares under this upfront licensing payment. Hanmi will also receive up to \$407.5 million in future milestone payments contingent upon achieving certain clinical, regulatory and sales milestones across several potential indications, as well as tiered royalties on net sales. The Hanmi milestone payments based on progression of research as outlined in Note 13 to the Annual report on Form 10-K for the year ended December 31, 2023. The term of the agreement will continue on a product-by-product and country-by-country basis until the expiration of the royalty period for such product in such country. The licenses to Aptose pursuant to the Hanmi Licensing Agreement will survive and become non-exclusive, perpetual, irrevocable and fully paid-up on a product-by-product and country-by-country basis, upon their natural expiration under the terms of the Hanmi Licensing Agreement. In 2022, the Company and Hanmi also entered into a separate supply agreement for additional production of new drug substance ("API") and drug product to support further tuspetinib clinical development, for which the Company pays Hanmi per batch of production. Expenses related to this supply agreement have been recognized by the Company, amounting to nil and \$3.1 million for the nine months ended September 30, 2024 and 2023, respectively. Since inception to September 30, 2024, \$7.1 million has been recognized for the period under the supply agreement. The Company paid supply costs to Hanmi of \$2.6 million and \$4.5 million in the nine months ended September 30, 2024 and 2023, respectively. Since inception to September 30, 2024, payments of \$7.1 million have been made under the supply agreement. At September 30, 2024, the Company did not have either accounts payable or accrued liabilities related to the Hanmi supply agreement. At December 31, 2023, there was \$2.6 million in accounts payable and nil in accrued liabilities. On August 27, 2024, the Company entered into a loan agreement (the "Hanmi Loan Agreement") with the South Korean Company Hanmi Pharmaceutical Co. Ltd. ("Hanmi") for \$10 million. Under the terms of the Hanmi Loan Agreement, the loan proceeds are restricted to be used for Tuspetinib related business operation purposes, unless otherwise authorized by Hanmi. The use of the funds is also contingent upon the Company meeting specific manufacturing and clinical milestones as outlined in the agreement. The loan is repayable in full on January 31, 2027, with an initial interest period ended on September 30, 2024 and subsequent interest payments due at the end of each three-month period thereafter. Aptose may repay all or any portion of the outstanding principal at any time without penalty, provided that any accrued and unpaid interest on the principal amount being repaid is also settled. The accrued interest on the unpaid principal loan amount is payable at the periods specified on the Hanmi Loan agreement at a rate of 6% per annum. During the nine months period ended September 30, 2024, Aptose paid \$51 thousand of interest on the loan. On September 2, 2024, and in connection with the Hanmi Loan Agreement, Aptose and Hanmi executed a letter of understanding ("LOU"), which outlines the steps associated with the negotiation of the Future Collaboration Agreement (the "Future Collaboration Agreement"). This agreement will establish a co-development collaboration for the advancement of tuspetinib. Under the terms of the Future Collaboration Agreement, upon execution, the loan principal and any accrued and unpaid interest under the "Hanmi Loan Agreement" will automatically convert to Hanmi's prepayment of future milestone obligations under the Future Collaboration Agreement. Upon conversion, the Hanmi Loan Agreement, consisting of the \$10 million loan principal with any accrued and unpaid interest, will be deemed fully paid and satisfied. See Note 10, Share capital, for share capital transactions with Hanmi.

**10. Share capital:** On April 2, 2024, the Company received a letter (the "Notification Letter") from Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the "Rule") because the stockholders' equity of the Company as of December 31, 2023, as reported in the Company's Annual Report on Form 10-K, was below the minimum requirement of \$2.5 million (the "Stockholders' Equity Requirement"). The Company submitted a Compliance Plan on May 17, 2024. On June 28, 2024, the Company received a letter from Nasdaq stating that Nasdaq had granted the Company an extension until September 30, 2024 to regain compliance with the Rule. On August 1, 2024 the Company filed a preliminary S-1 prospectus to raise financing as part of its Compliance Plan, in addition to funds raised in the 10a.(i). June 2024 Registered Direct Offering. On July 16, 2024, the Company received a deficiency letter (the "Deficiency Letter") from the Staff of the Nasdaq Stock notifying the Company that, for the prior thirty consecutive business days, the closing bid price for the Company's Common Shares have been below the minimum \$1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Deficiency Letter had no immediate effect on the listing of the Company's Common Shares, and its Common Shares will continue to trade on Nasdaq. The Company's Common Shares continue to trade on the Toronto Stock Exchange (the "TSX") under the symbol "AAPS". The Company's listing on the TSX is independent and will not be affected by the Nasdaq listing status. The Company has been given 180 calendar days, or until January 13, 2025, to regain compliance with the Minimum Bid Price Requirement. If at any time before January 13, 2025, the bid price of the Company's Common Shares closes at \$1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance with the Minimum Bid Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by January 13, 2025, the Company may, at Nasdaq's discretion, be afforded a second 180 calendar day period to regain compliance, but if Nasdaq does not grant such extension, the Company's common shares could be delisted from Nasdaq. To qualify for the extension, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement. The Company intends to monitor the closing bid price of its Common Shares and may, if appropriate, consider available options, including the possibility of seeking shareholder approval of a reverse stock split, to regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules. As of September 30, 2024, the Company had not gained compliance with the requirement. The Company's stockholder's equity as of September 30, 2024 was negative \$9.1 million. On October 1, 2024, the Company received a staff determination letter from the Listing Department stating that the Company did not meet the terms of the extension because it did not complete its proposed financing initiatives to regain compliance. On October 8, 2024, the Company requested an appeal and hearing; such hearing is scheduled for November 21, 2024. The hearing request has automatically stayed Nasdaq's delisting of the Company's Common Shares pending the Panel's decision. At or prior to the hearing, the Company plans to present to Nasdaq information demonstrating that it has regained compliance with the continued listing standards under the Nasdaq Listing Rules, or alternatively a plan to regain compliance and a request for an extension of time to effectuate the plan. Notwithstanding the foregoing, there can be no assurance that the Company will regain compliance with the continued listing standards under the Nasdaq Listing Rules, or that the Panel will grant the Company an extension of time to regain compliance, in the event the Company requests such an extension. On October 30, 2024, the Company filed Amendment 1 to this S-1, see note 12, Subsequent Events. The Company has authorized share capital of an unlimited number of Common Shares. Equity issuances: (i) June 2024 Registered Direct Offering 15.5 On June 3, 2024, the Company closed a registered direct offering priced at-the-market under Nasdaq rules of 1,800,000 Common Shares at a purchase price of \$1.15 per share and 2,055,000 pre-funded warrants at a purchase price of \$1.149 per pre-funded warrant. Additionally, in a concurrent private placement, Aptose issued unregistered series A warrants to purchase up to 3,855,000 Common Shares and series B warrants to purchase up to 3,855,000 Common Shares, each at an exercise price of \$1.15 per share. The series A and series B unregistered warrants became exercisable beginning on the effective date of shareholder approval of the issuance of the shares issuable upon exercise of the warrants which was obtained on September 5, 2024. The series A warrants will expire five years from September 5, 2024 and the series B warrants will expire eighteen months from September 5, 2024. The gross proceeds to the Company from the offering was approximately \$4.43 million, before deducting the placement agent's fees and other offering expenses. Financing costs of approximately \$408 thousand included underwriting costs of 7% and professional fees. In addition, the underwriter received 192,750 warrants, each at an exercise price of \$1.44. The unregistered warrants are exercisable on September 5, 2024 and will expire five years from September 5, 2024. On September 5, 2024, the Company held a Special Meeting of Shareholders pursuant to which, shareholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Common Shares underlying certain warrants in an amount equal to or in excess of 20% of the Common Shares outstanding immediately prior the issuance of such warrants issued pursuant to that certain securities purchase agreement dated as of May 30, 2024 by and among the Company and certain institutional and accredited investors in connection with the Company's registered direct offering and private placement which closed on June 3, 2024. On September 11, 2024, the Company issued 1,395,000 Common Shares upon the exercise of 1,395,000 Pre-Funded Warrants for a cash proceeds of \$1 thousand at an exercise price of \$0.001. (ii) January 2024 Public Offering and Private Placement On January 31, 2024, the Company announced the closing of a \$9.7 million public offering (the "Public Offering") and a \$4 million private placement (the "Private Placement") with Hanmi. The Public

Offering comprised 5,649,122 Common Shares and warrants at a combined offering price of \$1.71. This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. The Private Placement comprised 2,105,263 Common Shares sold at a price of \$1.90, representing an 11% premium over the price of the Common Shares issued as part of the Public Offering. Nasdaq subsequently issued a letter to the Company regarding the value and the date of the Private Placement, as discussed in this note, below. Financing costs of approximately \$1.4 million included underwriting costs of 7% and approximately \$0.4 million in professional fees. The Company also issued Hammi warrants to purchase Common Shares at an exercise price of \$1.71 per Share. On February 29, 2024, the Company received a deficiency letter (the "February Deficiency Letter") from the Nasdaq Listing Qualifications Department of Nasdaq notifying the Company that the Company's Private Placement violated Nasdaq Listing Rule 5635(d) because the Company did not obtain shareholder approval prior to such issuance. Nasdaq stated that the Private Placement involved the issuance of greater than 20% of the issued and outstanding Common Shares of the Company at a discount to the Nasdaq official closing price on January 25, 2024, the date of the subscription agreement between the Company and Hammi. The February Deficiency Letter had no immediate effect on the listing of the Company's Common Shares. In accordance with the Nasdaq Listing Rules, the Company was given 45 calendar days to submit a plan to regain compliance. The approval of the potential issuance of Common Shares in connection with the Hammi investment, which would exceed 19.99% of the Corporation's outstanding shares as of the closing date of the Hammi investment, as required by Nasdaq listing rules, was approved at the June 2024 Annual and General meeting. In response to a Deficiency Letter from Nasdaq received on February 29, 2024 regarding the private placement with Hammi and the resulting claimed violation of Nasdaq Listing Rule 5635(d), the Company submitted a plan to regain compliance on April 15, 2024. On April 25, 2024, the Company received a letter from the Listing Qualifications Department (the "Staff") of Nasdaq notifying the Company of the Staff's determination that the Company had regained compliance with Nasdaq Listing Rule 5635(d) and the Staff has determined that the matter is now closed. Pursuant to the Company's plan to regain compliance, on April 26, 2024, the Company announced that it had amended the warrant agreement with Hammi to prohibit the exercise of the Hammi warrants in excess of the Nasdaq 19.99% limitation (the "Nasdaq 19.99% Cap"), unless shareholder approval is first obtained to exceed the Nasdaq 19.99% Cap. (iii) Hammi 2023 Investment On August 10, 2023, the Company entered into a binding term sheet with Hammi whereby Hammi agreed at their sole discretion to invest, up to a maximum of \$7 million in Aptose up to a total ownership of 19.99% of Aptose by Hammi. On September 6, 2023, the Company entered into a subscription agreement with Hammi, pursuant to which the Corporation 16A A agreed to sell 668,449 Common Shares to Hammi for proceeds of \$3 million. Hammi held 2,989,415 Common Shares of Aptose as of September 30, 2024. (iv) 2023 Committed Equity Facility On May 25, 2023, the Company and Keystone Capital Partners, LLC ("Keystone") entered into a committed equity facility, (the "2023 Committed Equity Facility"), which provides that subject to the terms and conditions set forth therein, we may sell to Keystone up to the lesser of (i) \$25.0 million of the Common Shares and (ii) a number of Common Shares equal to 19.99% of the Common Shares outstanding immediately prior to the execution of the 2023 Committed Equity Facility Agreement, with Keystone which respect to the 2023 Committed Equity Facility (subject to certain exceptions) (the "Total Commitment"), from time to time during the 24-month term of the 2023 Committed Equity Facility. Additionally, on May 25, 2023, the Company entered into a Registration Rights Agreement with Keystone, pursuant to which the Company agreed to file a registration statement with the SEC covering the resale of Common Shares that are issued to Keystone under the 2023 Committed Equity Facility. This registration statement became effective on June 30, 2023 and the 2023 Committed Equity Facility commencement date was July 12, 2023 (the "Commencement Date"). Upon entering into the 2023 Committed Equity Facility, the Company agreed to issue to Keystone an aggregate of 25,156 Common Shares (the "Commitment Shares") as consideration for Keystone's commitment to purchase Common Shares upon the Company's direction under the 2023 Committed Equity Facility. The Company issued 7,547 Common Shares, or 30% of the Commitment Shares, on the date of the 2023 Committed Equity Facility Agreement. An additional 7,547 Common Shares, or 30% of the Commitment Shares, were issued to Keystone in October 2023. In the nine months ended September 30, 2024, the Company's issuance of Common Shares to Keystone consisted of 10,062 Commitment Shares. In the year ended December 31, 2023, the Company's issuance of Common Shares to Keystone comprised 720,494 Common Shares sold to Keystone at an average price of \$2.91 per Common Share for cash proceeds of \$2.1 million and 15,094 Commitment Shares. During the nine months ended September 30, 2024, the Company issued 510,101 Common Shares to Keystone at an average price of \$1.36 per Common Share for cash proceeds of \$694 thousand and 10,062 Commitment Shares. The Company recognized \$82 thousand of financing costs associated with professional fees during the nine months ended September 30, 2024. Since inception to April 2024, the time the Committed Equity Facility was terminated, the Company's issuance of Common Shares to Keystone comprised of an aggregate of 1,230,595 Common Shares at an average price of \$2.27 per Common Share for aggregate gross cash proceeds of \$2.8 million and 25,156 Commitment Shares. From inception to the termination of the Committed Equity Facility, the Company recognized \$168 thousand of financing costs associated with professional fees. In April 2024, the Company's issuances of Common Shares to Keystone reached the Total Commitment of the Committed Equity Facility, i.e. 19.99% of the Common Shares outstanding immediately prior to the execution of the 2023 Committed Equity Facility Agreement. (v) 2022 At-The-Market Facility ("ATM") On December 9, 2022, the Company entered into an equity distribution agreement pursuant to which the Company may, from time to time, sell Common Shares having an aggregate offering value of up to \$50 million through Jones Trading Institutional Services LLC ("Jones Trading") on Nasdaq (the "2022 ATM Facility"). During the current year up to May 30, 2024, the date on which the Company terminated the 2022 ATM Facility, the Company issued 81,591 Common Shares under this 2022 ATM Facility at an average price of \$1.22 per share for gross proceeds of \$100 thousand (\$97 thousand net of share issuance costs). On May 30, 2024, the Company terminated the 2022 At-The-Market Facility. Since inception to May 30, 2024, the date the Company terminated the 2022 ATM Facility, the Company raised a total of \$2.1 million of gross proceeds (\$2.0 million net of share issuance costs) under the 2022 ATM Facility. Costs associated with the proceeds consisted of a 3% cash commission. A 17A A b. Loss per share: Loss per share is calculated using the weighted average number of Common Shares outstanding and is presented in the table below: A A Three months ended September 30, A A Nine months ended September 30, A A 2024 A A 2023 A A 2024 A A 2023 A A Net loss per share A A \$ (6,953) A A \$ (11,447) A A \$ (23,845) A A \$ (39,252) Weighted-average common shares A A basic and A A diluted (in thousands) A A 18,560 A A 6,495 A A 16,107 A A 6,391 A A Net loss per share A A basic and diluted A A \$ (0.37) A A \$ (1.76) A A \$ (1.48) A A \$ (6.14) A A The effects of any potential exercise of the Company's stock options outstanding during the three-month and nine-month periods ended September 30, 2024, and September 30, 2023 have been excluded from the calculation of diluted loss per share, since such securities would be anti-dilutive. A 11. Stock-based compensation: All references in this report to historical Common Share prices, numbers of Common Shares, and earnings per share calculations have been presented to reflect the effect of the Reverse Stock Split. A Stock option plan and employee stock purchase plan Effective June 1, 2021, the Company adopted a new stock incentive plan (the "New Incentive Plan") and an employee stock purchase plan (the "ESPP"). The New Incentive Plan authorizes the Board of Directors to administer the New Incentive Plan to provide equity-based compensation in the form of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalents. The Corporation currently maintains its existing share option plan ("Share Option Plan") and 2015 Stock Incentive Plan ("2015 SIP"). Effective June 1, 2021 no further grants will be made under the Share Option Plan or 2015 SIP, though existing grants under the Share Option Plan will remain in effect in accordance with their terms. The aggregate number of our Common Shares, no par value, that may be issued under all awards under the New Incentive Plan is (i) 691,400, plus (ii) any of our Common Shares subject to any outstanding award under our prior plans that, after June 1, 2021, are not purchased or are forfeited or reacquired by us, or otherwise not delivered to the participant due to termination, cancellation or cash settlement of such award subject to the share counting provisions of the New Incentive Plan. Under both the Share Option Plan and the New Incentive Plan, the exercise price of each option equals the closing trading price of the Company's stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no greater than ten years from the date of grant. The Company uses the fair value-based method of accounting for employee awards granted under both plans. The Company calculates the fair value of each stock option grant using the Black-Scholes option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. The ESPP, which is administered by the Board of Directors, allows eligible employees of the Company to purchase Common Shares through accumulated payroll deductions up to a maximum 15% of eligible compensation. The ESPP is implemented in consecutive offering periods with a new offering period commencing on the first trading day on or after February 1 and August 1 each year, or on such other date as the Board of Directors will determine and continuing thereafter until terminated in accordance with the Plan. Unless the Board of Directors provides otherwise, the purchase price will be equal to eighty-five percent (85%) of the fair market value of a Common Share on the offering date or the exercise date, whichever is lower. A 18A A The maximum number of Common Shares which will be available for sale under the ESPP is 113,333 Common Shares. There were 27,681 and 5,991 Common Shares issued under the ESPP during the nine months ended September 30, 2024 and September 30, 2023, respectively. Stock option transactions for the nine months ended September 30, 2024 and September 30, 2023 are summarized as follows: A A A A Nine months ended September 30, 2024 A A A A A A Options (in thousands) A A Weighted average exercise price A A Weighted average remaining contractual life (years) A A Outstanding, beginning of period A A 1,184 A A \$ 44.78 A A A A Granted A A 408 A A 2.00 A A A A Exercised A A 800 A A A A Forfeited A A (356) A A 16.05 A A A A Outstanding, end of period A A 1,236 A A \$ 38.75 A A A A 6.73 A A Exercisable, end of period A A 800 A A A A 55.34 A A A A 5.67 A A Vested and expected to vest, end of period A A 1,145 A A \$ 41.18 A A A A 6.57 A A A A A A Nine months ended September 30, 2023 A A A A A A Options (in thousands) A A Weighted average exercise price A A Weighted average remaining contractual life (years) A A Outstanding, beginning of period A A 1,100 A A \$ 52.22 A A A A 8.00 A A A A 217 A A A A 9.87 A A A A Exercised A A 800 A A A A 1.25 A A A A 49.58 A A A A 6.00 A A A A 7.1 A A Exercisable, end of period A A 718 A A \$ 58.98 A A A A 6.1 A A Vested and expected to vest, end of period A A 1,107 A A \$ 46.42 A A A A 7.0 A A As of September 30, 2024, there was \$544 thousand of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over an estimated weighted-average period of 1.46 years. As of September 30, 2024, total compensation cost not yet recognized related to grants under the ESPP was nil. The following table presents the weighted average assumptions that were used in the Black-Scholes option pricing model to determine the fair value of stock options granted during the period, and the resulting weighted-average fair values: A A A A Nine months ended September 30, 2024 A A A A Nine months ended September 30, 2023 A A Risk-free interest rate A A 4.07 % A A 3.42 % Expected dividend yield A A A A A A Expected volatility A A 83.1 % A A 80.3 % Expected life of options (years) A A 5 years A A 5 years Grant date fair value A A \$ 1.36 A A \$ 6.53 A A The Company uses historical data to estimate the expected dividend yield and expected volatility of its Common Shares in determining the fair value of stock options. The expected life of the options represents the estimated length of time the options are expected to remain outstanding. A 19A A The following table presents the vesting terms of options granted in the period: A A A A Nine months ended September 30, 2024 A A A A Nine months ended September 30, 2023 A A A A Number of options (in thousands) A A Number of options (in thousands) A A 3-year vesting (50%-25%-25%) A A 20 A A 48 A A 4-year vesting (50%-16 2/3%-16 2/3%-16 2/3%) A A 388 A A 169 A A Total stock options granted in the period A A 408 A A 217 A A The Company has a stock incentive plan (SIP) pursuant to which the Board may grant stock-based awards comprised of restricted stock units or dividend equivalents to employees, officers, consultants, independent contractors, advisors and non-employee directors of the Company. Each restricted unit is automatically redeemed for one common share of the Company upon vesting. During the nine-month period ended September 30, 2024, the Company granted nil (September 30, 2023 - 38,000) restricted stock units ("RSUs") with immediate vesting and an exercise price of \$9.90. On February 6, 2023, all of these RSUs were redeemed for 38,000 Common Shares. The following table presents the vesting and redemption of the RSUs granted in the three months and nine months ended September 30, 2024 and 2023: A A A A Nine months ended September 30, 2024 A A Nine months ended September 30, 2023 A A Number of options (in thousands) A A Weighted average grant date fair value A A Number of options (in thousands) A A Weighted average grant date fair value A A Outstanding, beginning of period A A A A A A Granted A A A A A A 38 A A 9.90 A A Vested and redeemed A A A A A A (38) A A 9.90 A A Outstanding, ending of period A A A A A A A A b. Share-based payment expense The Company recorded share-based payment expense related to stock options and RSUs as follows: A A A A Three months ended September 30, A A A A Nine months ended September 30, A A A A 2024 A A 2023 A A 2024 A A 2023 A A Research and development A A \$ (81) A A \$ 259 A A A A \$ 317 A A A A \$ 1,182 A A General and administrative A A 68 A A A A 340 A A A A 686 A A A A 2,060 A A A A (13) A A \$ 599 A A A A \$ 1,003 A A A A 3,242 A A 12. Subsequent events On October 30, 2024, the Company filed an Amendment to the S-1 preliminary prospectus filed on August 1 (the "S-1/A") to raise financing as part of the Compliance Plan. The S-1/A relates to the offering of up to 21,528,525 Common Shares, no par value (the "Offered Shares") together with warrants to purchase up to 10,764,263 Common Shares. Each Offered Share, or a pre-funded warrant (the "Pre-Funded Warrants") in lieu thereof, is being sold together with one half (1/2) common warrant (the "Common Warrants") and together, with the Pre-Funded Warrants, the Warrants exercisable for one Common Share. The assumed combined public offering price for each Offered Share and accompanying Common Warrant is \$0.3716, which is the last reported sale price of the Company's Common Shares on Nasdaq on October 29, 2024. The completion of the offering is conditional upon the approval of the TSX. In addition, this S-1/A relates to the issuance of Placement Agent Warrants (as defined below) to purchase up to 861,141 shares of the Company's Common Shares issuable to the Placement Agent (as defined below), based on an assumed public offering price of the Offered Shares and Warrants and the underlying Common Shares issuable upon the exercise of Placement Agent Warrants. Each Common Warrant has an assumed exercise price of \$0.3716 per Common Share, which is the last reported sale price of the Company's Common Shares on Nasdaq on October 29, 2024, will be exercisable immediately upon issuance, subject to certain limitations based on the holder's beneficial ownership of the Company's Common Shares, and will expire five years from the date of issuance. The Offered Shares and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The Company is also offering Pre-Funded Warrants to purchase up to 21,528,525 Common Shares to those purchasers whose purchase of Offered Shares in this offering would result in the purchaser beneficially owning more than 20% A 4.99% (or, at the election of the purchaser, 9.99%) of the Company's outstanding Common Shares following the consummation of this offering in lieu of the Offered Shares that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) following the consummation of this offering. Each Pre-Funded Warrant will be exercisable for one Common Share at an exercise price of \$0.0001 per Common Share. Each Pre-Funded Warrant is being issued together with the same Common Warrants described above being issued with each Offered Share. The assumed combined public offering price for each such Pre-Funded Warrant, together with the Common Warrants, is \$0.3715, which is equal to the assumed public offering price in this offering of an Offered Share and accompanying Common Warrant less the \$0.0001 per Common Share exercise price of each such Pre-Funded Warrant. Each Pre-Funded Warrant will be exercisable immediately upon issuance, subject to certain limitations based on the holder's beneficial ownership of the Company's Common Shares, and may be exercised at any time until the Pre-Funded Warrant is exercised in full. The Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. A 21A A ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created by those sections. For more information, see Cautionary Note Regarding Forward-Looking Statements. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that impact our business. In particular, we encourage you to review the risks and uncertainties described in Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023. These risks and uncertainties could cause actual results to differ materially from those projected or implied by our forward-looking statements contained in this report. These forward-looking statements are made as of the date of this management's discussion and analysis, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes thereto contained in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and with our audited consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. All amounts are expressed in United States dollars unless otherwise stated. OVERVIEW Aptose Biosciences Inc. (the "Aptose," the "Company," "we," "us," "our," "it" or "our") is a science-driven clinical stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to

enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company's executive offices are located in San Diego, California, and our head office is located in Toronto, Canada. Aptose Programs Tuspentinib, ("Tuspentinib" or "TUS"), Aptose's lead program, is being developed for frontline combination therapy in newly diagnosed acute myeloid leukemia ("AML&eacute;t patients to unlock the most significant patient impact and greatest commercial opportunity. AML is a highly aggressive cancer of the bone marrow and blood, and there is a tremendous unmet need for an improved frontline therapy that can extend survival of newly diagnosed AML patients and improve their quality of life. Newly diagnosed AML patients typically fall all frontline (1L) therapies, and responses to subsequent salvage therapies in the relapsed or refractory (R/R) setting are limited, highlighting the need for a more effective triple drug (ac&eacute;tripletac&eacute;) combination therapy to increase survival in the frontline setting. Current standard of care treatment in the 1L setting for many newly diagnosed AML patients includes a doublet combination of venetoclax and a hypomethylating agent (VEN+HMA). Exploratory triplet therapies using current agents added to VEN+HMA have achieved notable response rates but are compromised because of toxicities and the limited activity across subpopulations of AML patients. In contrast, tuspentinib is a convenient, orally administered, once-daily kinase inhibitor that targets select kinases operative in AML and exerts broad activity across AML populations with adverse genetics. However, tuspentinib avoids kinases that typically cause toxicities associated with other kinase inhibitors and has demonstrated an excellent safety profile. These properties position tuspentinib as an ideal agent for addition to the VEN+HMA backbone therapy to create a superior triplet (TUS+VEN+HMA) frontline therapy to treat newly diagnosed AML. Aptose plans to develop Tuspentinib in the TUS+VEN+HMA triplet drug combinations in newly diagnosed AML patients, and once the study enrolls, we expect to deliver important clinical data (CR and MRD negativity rates, safety, and survival) over the following 6 to 12 months. It was essential to understand the safety, tolerability, and response activities of tuspentinib as a single agent and as the TUS+VEN doublet combination before advancing to the TUS+VEN+HMA triplet. We therefore performed a clinical trial (TUS) in patients with relapsed or refractory (R/R) AML and then performed a trial with the TUS+VEN doublet therapy in R/R AML patients and now have advanced the TUS+VEN+HMA frontline therapy into newly diagnosed AML patients. See Note 2(a) and Item 1A -Risk Factors. To be precise, we have now completed a dose escalation and dose exploration international Phase 1/2 clinical trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamic responses, and efficacy of TUS single agent in patients with R/R AML. Significant bone marrow blast reductions and clinical responses without dose limiting toxicities were achieved at four dose levels across a broad diversity of mutationally-defined AML populations and with a highly favorable safety profile. Tuspentinib to date has A 22A A A demonstrated a favorable safety profile and has caused no drug-related QTc prolongations, liver or kidney toxicities, muscle damage, or differentiation syndrome, and no myelosuppression with continuous dosing of patients in remission. At a dose of 80 mg, tuspentinib demonstrated notable response rates in R/R AML patients that had never been treated with venetoclax (VEN-naive AML). CR/CRh=36% among all-comers, CR/CRh=50% among patients with mutated FLT3, and CR/CRh=25% in patients with wildtype FLT3. Following completion of the single agent dose escalation and exploration trial, tuspentinib advanced into the APTIVATE expansion trial of the Phase 1/2 program to evaluate the TUS+VEN doublet in R/R AML patient populations. The TUS+VEN doublet combination therapy maintained a favorable safety profile: no new or unexpected safety signals were observed, and there were no reported drug-related adverse events of QTc prolongation, differentiation syndrome, or deaths. The TUS+VEN doublet combination also achieved significant bone marrow reductions and clinical responses in heavily pretreated R/R AML patients, including those with mutated TP53, mutated NKRA5, wildtype or mutated FLT3, and those who failed prior therapy with venetoclax ("Prior-VEN") or FLT3 inhibitors ("Prior-FLT3"). Collectively, the clinical safety and efficacy data with TUS single agent and TUS+VEN doublet in R/R AML patients position tuspentinib for development as the TUS+VEN+HMA triplet in newly diagnosed AML patients. Newly diagnosed AML patients are VEN-na&eacute;ve, FLT3i-na&eacute;ve, and HMA-na&eacute;ve ac&eacute; this patient population is expected to be highly responsive to a tuspentinib-containing triplet therapy. Based on the safety and efficacy profile of tuspentinib, we believe that tuspentinib as part of the TUS+VEN+HMA triplet, if approved, could establish a new standard of care therapy for newly diagnosed patients with mutated or unmutated FLT3 and in patients with other adverse genetic abnormalities. These beliefs related to the potential patient treatment and commercial opportunities are based on management's current assumptions and estimates, which are subject to change, and there can be no assurance that tuspentinib will ever be approved or successfully commercialized and, if approved and commercialized, that it will ever generate significant revenues. See our ac&eacute;Risk Factors ac&eacute; ac&eacute;We are an early-stage development company with no revenues from product sales. ac&eacute; ac&eacute;We have a history of operating losses. We expect to incur net losses and we may never achieve or maintain profitability. ac&eacute; in our Annual Report on Form 10-K filed with the SEC on March 26, 2024. Luxetpinib ("LUX") is an orally administered, highly potent kinase inhibitor that selectively targets defined clusters of kinases that are operative in hematologic malignancies. LUX has demonstrated clinical activity in R/R AML and in R/R B-cell cancer patients but was not consistently achieving the desired exposure levels to drive responses. Absorption of the original G1 formulation hindered the effectiveness of luxetpinib, so a new G3 formulation was developed. Clinical evaluation of the G3 formulation has been completed in a single dose bioavailability study across five dose levels and then with continuous dosing using two different dose levels. The G3 formulation achieved our desired plasma exposure benchmark, with approximately 10-fold better absorption, and better tolerability than the original formulation. We are seeking alternative development paths and collaborations for LUX. Given current funding and our prioritization of tuspentinib, we have decided to pause funding the development of luxetpinib. PROGRAM UPDATES Tuspentinib Indication and Clinical Trials: Tuspentinib is an oral, highly potent, small molecule inhibitor of kinases operative in myeloid malignancies and known to be involved in tumor proliferation, resistance to therapy and differentiation. Preclinical in vitro and in vivo studies suggest that Tuspentinib may be an effective monotherapy and combination therapy in patients with hematologic malignancies including AML. An international Phase 1/2 clinical trial in patients with relapsed or refractory AML is ongoing. The dose escalation portion of this study to date has observed evidence of robust clinical activity, including multiple complete responses in R/R AML patients with various disease genotypes, and no toxicity trends that should prevent further dose escalation. The FDA granted orphan drug designation to tuspentinib for the treatment of patients with AML in October 2018. Orphan drug designation is granted by the FDA to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States. Orphan drug status provides research and development tax credits, an opportunity to obtain grant funding, exemption from FDA application fees and other benefits. The orphan drug designation also provides us with seven additional years of marketing exclusivity in this indication. Manufacturing: Following the Tuspentinib licensing agreement between Aptose and Hammi on November 4, 2021 (the "Tuspentinib Licensing Agreement"), Aptose received from Hammi an existing inventory of drug product expected to support continuation of the current Phase 4 23A A A 1/2 study. The Company and Hammi also entered into a separate supply agreement in 2022 for additional production of new drug substance and drug product to support further clinical development. Additional batches of API and drug product have been produced by other companies during 2022 and 2023. Program Updates at Recent Scientific Forums: Aptose plans to initiate the tuspentinib + venetoclax + azacitidine (TUS+VEN+AZA) triple drug combination study in newly diagnosed AML patients with 40 mg tuspentinib and then to dose escalate the tuspentinib dose to 80 mg, and then to potentially higher doses as appropriate. Safety and activity as a single agent were demonstrated with the 40 mg dose of tuspentinib in R/R AML patients. This 40 mg dose represents one dose level below the 80 mg single agent recommended phase 2 dose (RP2D) of tuspentinib in R/R AML patients, this dose escalation approach which is the typical FDA recommended starting dose for drug combination studies. On June 14, 2024, Aptose presented tuspentinib (TUS) clinical findings as a clinical poster presentation and preclinical findings as a e-poster at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. Highlights of the findings include: ac&eacute;Tuspentinib Monotherapy (TUS) and Tuspentinib + Venetoclax (TUS+VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML ac&eacute;TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML ac&eacute;TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study ac&eacute;Tuspentinib + Venetoclax + Azacitidine (TUS+VEN+AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being Activated Our APTIVATE clinical trial of Tuspentinib as a monotherapy (TUS) and in combination treatment with Venetoclax (TUS+VEN) in a very ill AML patient population, yielded excellent and consistent safety findings and demonstrated clinical activity across a broad range of AML ac&eacute; including many with highly adverse genetic mutations. These findings supported advancement of Tuspentinib as an ideal third agent to add to a venetoclax and hypomethylating agent regimen for the frontline treatment of Newly Diagnosed AML patients. Conclusions from the clinical poster, entitled ac&eacute;Safety and Efficacy of Tuspentinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia ac&eacute; include: ac&eacute;Extensive dose exploration was performed with TUS (93 patients) and TUS+VEN (79 patients) in highly treatment experienced R/R AML patients (prior VEN, FLT3i, HMA, chemotherapy, HSCT) ac&eacute;TUS monotherapy achieved complete remissions at 40, 80, 120, and 160 mg with no DLT, achieved a 42% CRc and 50% ORR in VEN na&eacute;ve and FLT3i-mutation harboring patients, and achieved responses in patients harboring highly adverse genetics (TP53MUT, RASMUT, other) ac&eacute;TUS+VEN Doublet remained safe and well tolerated (40mg TUS + 400mg VEN | 80mg TUS + 400mg VEN), and achieved bone marrow blast reductions and responses among diverse R/R AML patients with adverse mutations and prior failure of VEN ac&eacute;TUS targets known VEN resistance mechanisms in vitro and is clinically active in both FLT3MUT & FLT3WT R/R AML populations even after prior VEN exposure. The greatest unmet medical need in AML is for an improved frontline therapy in Newly Diagnosed AML patients. Tuspentinib is now being developed as the TUS+VEN+HMA to establish a new standard of care for the treatment of these Newly Diagnosed AML patients that may increase response rates, extend survival, safely improve quality of life, treat a broad spectrum of genetically unique AML patient populations, and blunt the development of resistance to Venetoclax. ac&eacute;Progress has been made with VEN+HMA in 1L therapy but 1/3 do not respond and median OS <15 months with <25% alive at 3-years. ac&eacute;Response rates and OS need improvement, especially in adverse genetic subgroups ac&eacute;Emergence of VEN resistance via RAS/MAPK, TP53, and FLT3 clonal expansion, among other mechanisms, leads to relapse or refractory (R/R) AML that does not respond well to subsequent salvage therapies in R/R setting. Indeed, a recent publication (Matthews et al., Blood 2022; 140, Supplement 1: 1022ac&eacute;1024) showed survival of R/R AML patients receiving chemotherapy after failing prior therapy with HMA-VEN was limited; median OS was a mere 7.2 months, and for older patients (65 and older) the median OS was only 4.3 months A 24A A A ac&eacute;These findings illustrate that the addition of a 3rd ac&eacute; agent ac&eacute; is needed to boost responses with VEN+HMA standard of care therapy in frontline therapy of newly diagnosed AML patients, to increase the durability of responses in these patients, and to broadly act across genetic subgroups of patients. ac&eacute;We believe Tuspentinib is the ideal 3rd Agent for Addition to VEN+AZA to Treat Newly Diagnosed AML ac&eacute;TUS has excellent safety alone and in combination with VEN when co-administered ac&eacute;TUS has broad activity across genetic subgroups including TP53, RAS/MAPK, & FLT3 mutants ac&eacute;TUS mechanism may minimize drug resistance to VEN via inhibition of key AML kinases ac&eacute;TUS can be administered with or without food allowing co-administration with VEN ac&eacute;Preliminary PK data suggest no clinically meaningful interaction between TUS and VEN requiring dose modification for co-administration. In addition to the Tuspentinib clinical poster, a separate preclinical abstract was published as an e-poster publication at EHA, entitled ac&eacute;Tuspentinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax ac&eacute;. The study demonstrated that TUS targets known venetoclax (VEN) resistance mechanisms, retaining nanomolar potency against AML cells engineered to express the NRAS-G12D mutation or selected for resistance to VEN, and in combination with VEN, could prevent emergence of resistance to both agents. TUS resistant cells showed hypersensitivity to VEN such that treatment with both drugs could also interfere with the emergence of TUS resistance. On March 26, 2024, Aptose announced that more than 170 patients to date received TUS alone or in combination with the BCL-2 inhibitor venetoclax (VEN) during the Phase 1/2 clinical program in the very ill relapsed or refractory (R/R) AML patient population. At the single agent 80 mg dose, TUS achieved a favorable safety profile and an impressive response rate among patients who were naive to VEN. The safety profile of TUS remained favorable when TUS was combined with VEN in R/R AML patients, and responses were achieved in both patients naive to VEN and those who failed prior therapy with VEN. TUS avoids many typical toxicities observed with other agents and achieves broad activity across AML patients with a diversity of adverse genetic abnormalities. On December 9, 2023, Aptose featured tuspentinib in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition and announced that a growing body of clinical data for Aptose's lead compound tuspentinib, demonstrates significant benefit as a single agent and in combination with venetoclax in patients with R/R AML in the ongoing APTIVATE Phase 1/2 study. Data were presented in an oral presentation by lead investigator Naval G. Daver, M.D., Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Daver reported data from more than 100 relapsed/refractory patients from multiple international clinical sites, who had failed prior therapy and then were treated with TUS as a single agent or TUS+VEN. Both TUS and TUS+VEN delivered multiple composite complete remissions (CRc) in this very ill AML population, while maintaining a favorable safety profile across all treated patients. The data demonstrated tuspentinib is active and well tolerated in one of the most challenging and heterogeneous disease settings in oncology ac&eacute; relapsed and refractory AML. Tuspentinib demonstrated broad activity, including activity in patients with FLT3 wild-type AML (accounting for more than 70% of the AML population), FLT3 mutated AML, NPM1 mutated AML, as well as in patients with mutations historically associated with resistance to targeted therapy. Most notably, TUS targets VEN resistance mechanisms, enabling TUS+VEN uniquely to treat the very ill prior-VEN AML population, including both FLT3 mutant and FLT3 wildtype disease. From a broader perspective, the growing body of antileukemic activity, and continued favorable safety profile, support advancement of tuspentinib in a TUS+VEN+HMA triplet for the treatment of frontline newly diagnosed AML patients. ac&eacute; Dr. Daver also pointed out that while patients on the TUS+VEN therapy are early in their treatment cycles, most achieving a response remained on treatment and that responses have begun to mature as dosing continues. Highlights of Dr. Daver's ASH oral presentation include: ac&eacute;As a single agent at therapeutic doses of 80-160 mg in 68 evaluable patients, TUS was more active in VEN-naive patients, with an overall CRc rate of 29% (8/28). This included a 42% CRc rate (5/12) in FLT3-mutated patients and a 19% CRc rate (3/16) in FLT3-unmutated, or wildtype, AML patients. Responses and blood counts improved with continuous dosing, many patients bridged to an allogeneic stem cell transplant ("HSCT"), durability was observed when HSCT was not performed, and 80 mg was selected as the RP2D. Overall, tuspentinib showed a favorable safety profile with only mild adverse events ("AEs") and no dose-limiting toxicities ("DLTs") up to 160 mg per day, and no drug discontinuations from drug-related toxicity. A 25A A A ac&eacute;In the TUS+VEN doublet study, 49 patients were dosed with 80 mg of tuspentinib and 200 mg of venetoclax, with 36 evaluable (and 13 patients too early to assess). Patients were heavily exposed to Prior-VEN and Prior-FLT3 inhibitor treatment. TUS+VEN was active in both VEN-naive and prior Prior-VEN R/R AML patients. TUS demonstrated compelling composite complete remission (CRc) rates. Among all evaluable patients, TUS+VEN demonstrated a CRc rate of 25% (9/36); 43% (3/7) in VEN-naive patients, and 21% (6/29) in Prior-VEN patients. Among FLT3 wildtype patients, TUS+VEN demonstrated an overall CRc rate of 20% (5/25); 33% (2/6) in VEN-naive patients, and 16% (3/19) in Prior-VEN patients. Among FLT3 mutant patients, TUS+VEN demonstrated an overall CRc rate of 36% (4/11); a complete response in a VEN-naive patient (1/1); a 30% (3/10) in Prior-VEN patients; and 44% (4/9) in patients treated prior with a FLT3 inhibitor. On October 29, 2023, Aptose presented two posters related to the clinical and preclinical activity of tuspentinib at the European School of Haematology 6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment, held October 29-31, 2023, in Estoril, Portugal. Clinical findings included 1) data from the APTO-TUS-HV01 clinical trial (the "Food Effect Study") evaluating the pharmacokinetic (PK) properties of tuspentinib in healthy human volunteers in which tuspentinib was administered with or without food, and 2) from an international Phase 1/2 study of tuspentinib as a single agent (TUS) and in combination with venetoclax in patients with R/R AML from across clinical centers in the United States, South Korea, Spain, Australia and other sites. Data from the Food Effect Study in healthy human volunteers demonstrated tuspentinib can be administered with or without food and foresee no clinically meaningful difference in exposure. This is an important finding for patient convenience, as venetoclax is dosed with food and tuspentinib can now be co-administered with venetoclax rather than in staggered dosing. Findings from the Phase 1/2 clinical trial demonstrated tuspentinib as a single agent was well-tolerated and highly active among R/R AML patients with a diversity of adverse genotypes and delivered a 42% CR/CRh cross-evaluable venetoclax (VEN) naive patients at the 80mg daily RP2D. The TUS+VEN doublet has been well tolerated in the APTIVATE international Phase 1/2 expansion trial in R/R AML patients and achieved multiple responses in patients who previously failed venetoclax ("Prior-VEN failure AML"), including Prior-VEN failure patients who also previously failed FLT3 inhibitors, all of whom represent emerging populations of high unmet medical need. Notably, tuspentinib targets venetoclax resistance mechanisms that may re-sensitize Prior-VEN failure patients to venetoclax. Separate from the clinical studies, the preclinical study (entitled: ac&eacute;Tuspentinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax ac&eacute;) presented by Aptose during the ESH Conference investigated the effects of tuspentinib on key elements of the phosphokinome and apoptotic proteome in both parental and TUS-resistant AML cells. In parental cells, tuspentinib inhibits key oncogenic signaling pathways and shifts the balance of pro- and anti-apoptotic proteins in favor of apoptosis, suggesting that it may generate vulnerability to venetoclax. In addition, acquired resistance in the AML cells to tuspentinib generated a synthetic lethal vulnerability to venetoclax of unusually high magnitude. Concurrent administration of TUS+VEN therefore may discourage the emergence of resistance to

tuspetinib during treatment. In conjunction with poster presentations at the ESH Conference, on October 30, 2023, Aptose held a "Clinical Update and KOL Data Review of AML Drug Tuspetinib" that was webcast and featured Dr. Naval Daver, MD, Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Dr. Daver is the lead investigator on Aptose's APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies. Aptose presented data in 49 patients who received the TUS+VEN doublet, showing an overall response rate ("ORR") of 48% among all patients that had achieved an evaluable stage, as well as a 44% ORR among Prior-VEN failure AML patients, including FLT3-unmutated ("wildtype") patients (43% ORR) and FLT3-mutated patients (60% ORR), some of whom also had failed prior therapy with FLT3 inhibitors. The TUS+VEN doublet was well tolerated with no unexpected safety signals. The TUS+VEN doublet may serve the Prior-VEN failure R/R AML patients that represent a rapidly growing population that is highly refractory to any salvage therapy. The compelling data with the TUS+VEN doublet in R/R AML patients suggest a TUS+VEN+HMA triplet may also serve the needs of frontline (1L) newly diagnosed AML patients. Concurrent with the European Hematology Association (EHA) Annual Congress held June 8-11, 2023, Aptose held an interim clinical update webcast on June 10, 2023, to present highlights from the ongoing clinical development of tuspetinib. Aptose reported completion of the tuspetinib dose escalation and dose exploration Phase 1/2 trial in 77 R/R AML patients, tuspetinib demonstrated a favorable safety profile, and tuspetinib delivered monotherapy responses across four dose levels with no dose-limiting toxicity in mutationally diverse and difficult to treat R/R AML populations, including patients with highly adverse mutations that typically do not respond to monotherapy or combination therapy: TP53-mutated patients with a CR/CRh = 20% and RAS-mutated patients with a CR/CRh = 22%. Aptose also reported completion of a successful End of Phase 1 Meeting with the US FDA for tuspetinib, that a monotherapy RP2D was selected as 80mg daily, and that all development paths remain open, including the single arm accelerated path. Following completion of the dose escalation and dose exploration phases of the Phase 1/2 clinical program, Aptose focused attention on the tuspetinib APTIVATE expansion trial. The APTIVATE trial is designed to identify patient populations sensitive to tuspetinib monotherapy that may serve as development paths for single arm accelerated approval and to use the TUS+VEN doublet in R/R AML patients and identify patient populations of unmet need that are sensitive to the TUS+VEN doublet and can serve as development paths. A to A for accelerated and full approvals. We reported that patient enrollment in the APTIVATE expansion trial has been brisk and preliminary CR activity had already been reported in patients receiving the TUS+VEN doublet who previously failed therapy with venetoclax. During the interim clinical update webcast Aptose also reviewed clinical findings with the new G3 formulation of luseptinib. Aptose disclosed that continuous dosing with 50mg of the G3 formulation achieves roughly an equivalent pharmacokinetic profile as 900mg original G1 formulation, and that dose escalation with the G3 formulation was anticipated. On March 23, 2023, Aptose announced the APTIVATE Phase 1/2 expansion trial with tuspetinib had been initiated and already had treated several R/R AML patients in the monotherapy arm, and that patient enrollment had been initiated in the doublet combination treatment arm of the APTIVATE trial with the TUS+VEN doublet. Since then, patients have continued to enroll and receive tuspetinib on the monotherapy arm. Plus, enrollment and dosing of patients on the TUS+VEN doublet arm have been brisk. Clinical investigator interest for tuspetinib is evident, and early signs of antileukemic activity during the APTIVATE trial have fueled the level of excitement for the trial. Clinical responses to monotherapy with tuspetinib have been observed in a broad range of mutationally defined populations, including those with mutated forms of NPM1, MLL, TP53, DNMT3A, RUNX1, wild-type FLT3, ITD or TKD mutated FLT3, various splicing factors, and other genes. In the March 23, 2023, announcement, Aptose also highlighted an unexpected observation of a 29% CR/CRh response rate with tuspetinib monotherapy in R/R AML patients having mutations in the RAS gene or other genes in the RAS pathway. Responses in RAS-mutated patients are important because the RAS pathway is often mutated in response to therapy by other agents as the AML cells mutate toward resistance to those other agents. Collectively, these observations of broad clinical activity of tuspetinib, along with its favorable safety profile, position tuspetinib for potential accelerated development paths, as well as for doublet, triplet and maintenance therapy indications. On January 30, 2023, Aptose announced dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib, and that another clinical response has been achieved by a R/R AML patient receiving 40 mg tuspetinib once daily orally in the original dose exploration trial, the second response at the recently launched low-dose 40 mg cohort. In addition, Aptose elucidated a rationale for the superior safety profile of tuspetinib. While several kinase inhibitors require high exposures that exert near complete suppression of a single target to elicit responses, those agents often cause additional toxicity because they also cause extensive inhibition of that target in normal cells. In contrast, tuspetinib simultaneously suppresses a small suite of kinase-driven pathways critical for leukemogenesis. Consequently, tuspetinib achieves clinical responses at lower exposures with less overall suppression of each pathway, thereby avoiding many of the toxicities observed with competing agents. Luseptinib Given current funding and our prioritization of tuspetinib, we have decided to pause funding the development of luseptinib. For further information about the historical development of Luseptinib, please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2023. On March 26, 2024, Aptose announced that during 2023 and early 2024, clinical evaluation of the new G3 formulation of LUX was completed. The G3 formulation was tested in a single dose bioavailability study in 20 patients, including both B-cell cancer and AML patients, and across 5 dose levels (10mg to 200mg). The G3 formulation then was evaluated in R/R AML patients with continuous dosing using two different dose levels (50mg BID and 200mg BID) in a total of 11 patients. Data demonstrated the G3 formulation dosed at 200mg twice daily can achieve 2-3uM steady state plasma levels, with approximately 10-fold better absorption and better tolerability than the original G1 formulation. Thus, the G3 formulation achieved the desired plasma exposure benchmark and can serve as the formulation of choice for future studies with LUX. Aptose is exploring alternative development paths and collaborations to advance LUX as a single agent or in combination with VEN to treat defined R/R patient populations of high unmet need. Other corporate matters On February 29, 2024, the Company received a 2024 Deficiency Letter (the "February Deficiency Letter") from the Nasdaq Listing Qualifications Department of Nasdaq notifying the Company that the Company's private placement of securities to Hanmi (the "Private Placement") violated 5635(d) of the Nasdaq Listing Rules because the Company did not obtain shareholder approval prior to such issuance. Nasdaq stated that the Private Placement involved the issuance of greater than 20% of the issued and outstanding Common Shares of the Company at a discount to the Nasdaq official closing price on January 25, 2024, the date of the subscription agreement between the Company and Hanmi. The February Deficiency Letter had no immediate effect on the listing of the Company's Common Shares. In accordance with the Nasdaq Listing Rules, the Company was given 45 calendar days to submit a plan to regain compliance. The Company submitted a plan to regain compliance on April 15, 2024. On April 25, 2024, the Company received a letter from the Listing Qualifications Department (the "Staff") of Nasdaq notifying the Company of the Staff's determination that the Company's 27A A had regained compliance with Nasdaq Listing Rule 5635(d) and the Staff has determined that the matter is now closed. Pursuant to the Company's plan to regain compliance, on April 26, 2024, the Company announced that it had amended the warrant agreement with Hanmi to prohibit the exercise of the Hanmi warrants in excess of the Nasdaq 19.99% limitation (the "Nasdaq 19.99% Cap"), unless shareholder approval is first obtained to exceed the Nasdaq 19.99% Cap. On April 2, 2024, the Company received a letter (the "Notification Letter") from Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the "Rule") because the stockholders' equity of the Company as of December 31, 2023, as reported in the Company's Annual Report on Form 10-K, was below the minimum requirement of \$2.5 million (the "Stockholders' Equity Requirement"). The Notification Letter had no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. Pursuant to the Notification Letter, the Company had 45 calendar days to submit a plan to evidence compliance with the Rule (a "Compliance Plan"). The Company submitted a Compliance Plan on May 17, 2024. On July 16, 2024, the Company received a deficiency letter (the "Deficiency Letter") from the Staff of the Nasdaq Stock Exchange notifying the Company that, for the prior thirty consecutive business days, the closing bid price for the Company's Common Shares have been below the minimum \$1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Deficiency Letter had no immediate effect on the listing of the Company's Common Shares, and its Common Shares will continue to trade on Nasdaq. The Company's Common Shares continue to trade on the Toronto Stock Exchange (the "TSX") under the symbol "APS." The Company's listing on the TSX is independent and will not be affected by the Nasdaq listing status. The Company has been given 180 calendar days, or until January 13, 2025, to regain compliance with the Minimum Bid Price Requirement. If at any time before January 13, 2025, the bid price of the Company's Common Shares closes at \$1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance with the Minimum Bid Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by January 13, 2025, the Company may, at Nasdaq's discretion, be afforded a second 180 calendar day period to regain compliance, but if Nasdaq does not grant such extension, the Company's common shares could be delisted from Nasdaq. To qualify for the extension, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement. The Company intends to monitor the closing bid price of its Common Shares and may, if appropriate, consider available options, including the possibility of seeking shareholder approval of a reverse stock split, to regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules. On August 1, 2024, the Company filed a preliminary S-1 prospectus to raise complete a proposed financing as part of its Compliance Plan, in addition to funds raised in the June 2024 Registered Direct Offering. On August 2, 2024, the Company implemented a reduction in force with an approximate \$1.2 million per annum decrease in payroll costs. The Company's stockholder's equity as of September 30, 2024 was negative \$9.1 million. As of the date of this report, the Company does not have a market value of listed securities of \$35 million, or net income from continued operations of \$500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years, the alternative quantitative standards for continued listing on the Nasdaq Capital Market. On October 1, 2024, the Corporation received a staff determination letter from the Listing Department stating that the Company did not meet the terms of the extension because it did not complete its proposed financing initiatives to regain compliance. On October 8, 2024, the Company requested an appeal and hearing; such hearing is scheduled for November 21, 2024. The hearing request has automatically stayed Nasdaq's delisting of the Company's Common Shares pending the Panel's decision. At or prior to the hearing, the Company plans to present to Nasdaq information demonstrating that it has regained compliance with the continued listing standards under the Nasdaq Listing Rules, or alternatively a plan to regain compliance and a request for an extension of time to effectuate the plan. Notwithstanding the foregoing, there can be no assurance that the Company will regain compliance with the continued listing standards under the Nasdaq Listing Rules, or that the Panel will grant the Company an extension of time to regain compliance, in the event the Company requests such an extension. On October 30, 2024, the Company filed an Amendment to the S-1 preliminary prospectus filed on August 1 (the "S-1/A") to raise financing as part of its Compliance Plan. The S-1/A relates to the offering of up to 21,528,525 Common Shares, no par value (the "Offered Shares") together with warrants to purchase up to 10,764,263 Common Shares. Each Offered Share, or a pre-funded warrant (the "Pre-Funded Warrants") in lieu thereof, is being sold together with one half (1/2) common warrant (the "Common Warrants") and together, with the Pre-Funded Warrants, the Warrants) exercisable for one Common Share. The assumed combined public offering price for each Offered Share and accompanying Common Warrant is \$0.3716, which is the last reported sale price of the Company's Common Shares on Nasdaq on October 29, 2024. The completion of the offering is conditional upon the approval of the TSX. In addition, this S-1/A relates to the issuance of Placement Agent Warrants (as defined below) to purchase up to 861,141 shares of the Company's Common Shares issuable to the Placement Agent (as defined below), based on an assumed public offering price of the Offered Shares and Warrants and the underlying Common Shares issuable upon the exercise of Placement Agent Warrants. A 28A A Each Common Warrant has an assumed exercise price of \$0.3716 per Common Share, which is the last reported sale price of the Company's Common Shares on Nasdaq on October 29, 2024, will be exercisable immediately upon issuance, subject to certain limitations based on the holder's beneficial ownership of the Company's Common Shares, and will expire five years from the date of issuance. The Offered Shares and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The Company is also offering Pre-Funded Warrants to purchase up to 21,528,525 Common Shares to those purchasers whose purchase of Offered Shares in this offering would result in the purchaser beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of the Company's outstanding Common Shares following the consummation of this offering in lieu of the Offered Shares that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) following the consummation of this offering. Each Pre-Funded Warrant will be exercisable for one Common Share at an exercise price of \$0.0001 per Common Share. Each Pre-Funded Warrant is being issued together with the same Common Warrants described above being issued with each Offered Share. The assumed combined public offering price for each such Pre-Funded Warrant, together with the Common Warrants, is \$0.3715, which is equal to the assumed public offering price in this offering of an Offered Share and accompanying Common Warrant less the \$0.0001 per Common Share exercise price of each such Pre-Funded Warrant. Each Pre-Funded Warrant will be exercisable immediately upon issuance, subject to certain limitations based on the holder's beneficial ownership of the Company's Common Shares, and may be exercised at any time until the Pre-Funded Warrant is exercised in full. The Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. LIQUIDITY AND CAPITAL RESOURCES Aptose is an early-stage development company, and we currently do not generate any revenues from our drug candidates. The continuation of our research and development activities and the commercialization of the targeted therapeutic products are dependent upon our ability to successfully finance and complete our research and development programs through a combination of equity financing and payments from strategic partners. Sources of liquidity: The following table presents our cash and cash equivalents, investments, working capital and stockholders' equity as of September 30, 2024 and December 31, 2023. A (in thousands) A Balances at September 30, 2024 A Balances at December 31, 2023 A Cash and cash equivalents A \$ 7,962 A A \$ 9,252 A Total A \$ 7,962 A A \$ 9,252 A A A A Working capital A \$ 477 A A \$ (3,375 ) A Stockholders' equity A \$ (9,134 ) A A \$ (2,901 ) A Working capital is a non-GAAP measure and represents primarily cash, cash equivalents, investments, prepaid expenses and other current assets less current liabilities. This financial measure provides a fuller understanding of the Company's capital available to fund future operations. All our cash is maintained at high-credit quality institutions. We minimize the cash levels above the insurance levels required by the Federal Deposit Insurance Corporation and the Canada Deposit Insurance Corporation, with excess cash invested in short-term investments with leading financial institutions. Our short-term investments, maturing within 90 days and classified as Cash and cash equivalents, consist of high interest savings accounts. Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing will be necessary. We plan to raise additional funds in order to fund our business operations. We will seek access to financing but there is no assurance that such additional funds will be available for us to finance our operations on acceptable terms, if at all. The Company's current cash, cash equivalents and investments are projected to support operations through January 2025. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Such adjustments could be material. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting year. The Company is in substantial doubt to continue as a going concern; As of September 30, 2024, the Company had negative shareholder's equity of \$9.1 million (December 31, 2023 negative shareholder's equity of \$2.9 million; an accumulated deficit of approximately \$539.4 million (December 31, 2023, \$515.5 million); during the nine months period ended September 30, 2024, the Company incurred a net loss of \$23.8 million (2023 - \$39.3 million) and as of September 30, 2024, the Company had a working capital of approximately \$477 thousand (December 31, 2023, negative working capital of \$3.4 million), including approximately \$8 million (December 31, 2023, \$9.3 million) in cash and cash equivalent balance, and current liabilities of approximately \$9.8 million (December 31, 2023, \$15.3 million). Our ability to raise additional funds could be affected by adverse market conditions, the status of our product pipeline, possible delays in enrollment in our trial, uncertainty regarding our continued listing on NASDAQ, and various other factors and we may be unable to raise capital when needed, or on terms favorable to us. The Company faces increasingly challenging financial and business conditions, including an inability to raise sufficient equity and equity-linked financing to fully fund execution of its business plans and to satisfy the \$2.5 million NASDAQ's shareholder's equity requirement. Since our inception, we have financed our operations and technology acquisitions primarily from equity financing, proceeds from the exercise of warrants and stock options, and interest income on funds held for future investment. During the current period, the Company has explored numerous alternatives to ensure the funding of the Company's clinical trials, services and to repay its outstanding vendors and to increase its equity level. The raising of additional capital, debt refinancing of the Company, collaborations, and/or the trade sale of some of the Company's assets or operations to make bulk payments to repay outstanding debt and accounts payable, if successful, would potentially alleviate any significant doubt on the Company's ability to continue as a going concern.

In the event that capital financing and/or debt refinancing and collaborations is unable to be secured, the Company may need to resolve to other means of protecting its assets in the best interests of its shareholders, including foreclosure or forced liquidation and/or seeking creditors' protection. As there can be no certainty as to the resolution of the above matters, there is material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern, see "Going Concern Risk," see Item II, Part I A below. Our ability to raise additional funds could be affected by adverse market conditions, the status of our product pipeline, possible delays in enrollment in our clinical trials, and various other factors and we may be unable to raise capital when needed, or on terms favorable to us. If the necessary funds are not available, we may need to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates. June 2024 Registered Direct Offering On June 3, 2024, the Company closed a registered direct offering priced at-the-market under Nasdaq rules of 1,800,000 Common Shares at a price of \$1.15 per share and 2,055,000 pre-funded warrants at a purchase price of \$1.149 per pre-funded warrant. Additionally, in a concurrent private placement, Aptose issued unregistered series A warrants to purchase up to 3,855,000 Common Shares and series B warrants to purchase up to 3,855,000 Common Shares, each at an exercise price of \$1.15 per share. The unregistered series A and series B warrants became exercisable beginning on the effective date of shareholder approval of the issuance of the Common Shares issuable upon exercise of the warrants which was obtained on September 5, 2024. The series A warrants will expire five years from September 5, 2024 and the series B warrants will expire eighteen months from September 5, 2024. The gross proceeds to the Company from the offering was approximately \$4.43 million, before deducting the placement agent's fees and other offering expenses. Financing costs of approximately \$408 thousand included underwriting costs of 7% and professional fees. In addition, the underwriter received 192,750 warrants, each at an exercise price of \$1.44. The unregistered warrants became exercisable on September 5, 2024 for the issuance of the shares issuable upon exercise of the warrants and will expire five years from September 5, 2024. On September 5, 2024, the Company held a Special Meeting of Shareholders pursuant to which shareholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Common Shares underlying certain warrants in an amount equal to or in excess of 20% of the Common Shares outstanding immediately prior to the issuance of such warrants issued pursuant to that certain securities purchase agreement dated as of May 30, 2024 by and among the Company and certain institutional and accredited investors in connection with the Company's registered direct offering and private placement which closed on June 3, 2024. On January 11, 2024, the Company issued 1,395,000 Common Shares upon the exercise of 1,395,000 Pre-Funded Warrants for a cash proceeds of \$1 thousand at an exercise price of \$0.001. January 2024 Public Offering and Private Placement On January 31, 2024, the Company announced the closing of a \$9.7 million public offering (the "Public Offering") and a \$4 million private placement (the "Private Placement") with Hanmi. The Public Offering comprised of 5,649,122 Common Shares and warrants at a combined offering price of \$1.71. This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. The Private Placement comprised 2,105,263 Common Shares sold at a price of \$1.90 per share, representing an 11% premium over the price of the Common Shares issued as part of the Public Offering. Financing costs of approximately \$1.4 million included underwriting costs of 7% and approximately \$0.4 million in professional fees. The Company also issued Hanmi warrants to purchase Common Shares at an exercise price of \$1.71 per share. A 30A A Hanmi 2023 Equity Investment On August 10, 2023, the Company entered into a binding term sheet with Hanmi whereby Hanmi agreed at their sole discretion to invest up to a maximum of \$7 million in Aptose up to a total ownership of 19.99 percent of Aptose by Hanmi. On September 6, 2023, the Company entered into a subscription agreement with Hanmi, pursuant to which the Corporation agreed to sell 668,449 Common Shares to Hanmi for proceeds of \$3 million. 2023 Committed Equity Facility On May 25, 2023, the Company and Keystone Capital Partners, LLC ("Keystone") entered into a committed equity facility (the "2023 Committed Equity Facility"), which provides that subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to sell to Keystone, and Keystone is obligated to purchase, up to the Total Commitment during the 24-month term of the 2023 Committed Equity Facility. Under the 2023 Committed Equity Facility, and subject to its terms and conditions set forth, we may sell to Keystone up to the lesser of (i) \$25.0 million of the Common Shares and (ii) a number of Common Shares equal to 19.99% of the Common Shares outstanding immediately prior to the execution of the 2023 Committed Equity Facility (subject to certain exceptions) (the "Total Commitment"), from time to time during the 24-month term of the 2023 Committed Equity Facility. Additionally, on May 25, 2023, we entered into a Registration Rights Agreement with Keystone, pursuant to which the Company agreed to file a registration statement with the SEC covering the resale of Common Shares that are issued to Keystone under the 2023 Committed Equity Facility. This registration statement became effective on June 30, 2023 and the 2023 Committed Equity Facility commencement date was July 12, 2023 (the "Commencement Date"). Upon entering into the 2023 Committed Equity Facility, the Company agreed to issue to Keystone an aggregate of 25,156 Commitment Shares as consideration for Keystone's commitment to purchase Common Shares upon the Company's direction under the 2023 Committed Equity Facility. The Company issued 7,547 Common Shares, or 30% of the Commitment Shares, on the date of the 2023 Committed Equity Facility and an additional 7,547 First Back-End Commitment Shares, or 30% of the Commitment Shares, were issued to Keystone 90 days following the Commencement date for nil cash proceeds. The remaining 10,062 Second Back-End Commitment Shares, or 40% of the Commitment Shares, were issued to Keystone in January 2024, 180 days following the Commencement Date. In the year ended December 31, 2023, the Company's issuance of Common Shares to Keystone comprised 720,494 Common Shares sold to Keystone at an average price of \$2.91 per Common Share for cash proceeds of \$2.1 million and the 15,094 Commitment Shares. During the nine months ended September 30, 2024, the Company issued 510,101 Common Shares to Keystone at an average price of \$1.36 per Common Share for cash proceeds of \$694 thousand and 10,062 Commitment Shares. The Company recognized \$82 thousand of financing costs associated with professional fees during the nine months ended September 30, 2024. Since inception to April 2024, the time the Committed Equity Facility was terminated, the Company's issuance of Common Shares to Keystone comprised of an aggregate of 1,230,595 Common Shares at an average price of \$2.27 per Common Share for aggregate gross cash proceeds of \$2.8 million and 25,156 Commitment Shares. From inception to the termination of the Committed Equity Facility, the Company recognized \$168 thousand of financing costs associated with professional fees. In April 2024, the Company's issuances of Common Shares to Keystone reached the Total Commitment of the Committed Equity Facility, i.e. 19.99% of the Common Shares outstanding immediately prior to the execution of the 2023 Committed Equity Facility Agreement. At-The-Market Facility On December 9, 2022, the Company entered into an equity distribution agreement pursuant to which the Company may, from time to time, sell Common Shares having an aggregate offering value of up to \$50 million through Jones Trading Institutional Services LLC ("Jones Trading") on Nasdaq (the "2022 ATM Facility"). During the year ended December 31, 2023, the Company issued 336,690 Common Shares under the 2022 ATM Facility at an average price of \$5.62 for gross proceeds of \$1.9 million (\$1.8 million net of share issuance costs). During the current year up to May 30, 2024, the date on which the Company terminated the 2022 ATM Facility, the Company issued 81,591 Common Shares under this 2022 ATM Facility at an average price of \$1.22 for gross proceeds of \$100 thousand (\$97 thousand net of share issuance costs). Since inception to May 30, 2024, the date on which the Company terminated the 2022 ATM Facility, the Company raised a total of \$2.1 million of gross proceeds (\$2.0 million net of share issuance costs) under the 2022 ATM Facility. Costs associated with the proceeds consisted of a 3% cash commission. A 31A A Cash flows: The following table presents a summary of our cash flows for the three-month and nine-month periods ended September 30, 2024 and 2023: (in thousands) A Three months ended September 30, A Nine months ended September 30, A 2024 A 2023 A 2024 A 2023 A Net cash provided by/(used in): A Operating activities A \$(10,376) A \$(10,536) A \$(27,917) A \$(35,331) A Investing activities A \$12,953 A \$18,418 A \$8,022 A \$10,008 A \$4,902 A \$26,609 A \$6,056 A Effect of exchange rates changes on cash and cash equivalents A \$1 A \$1 A \$3 A Net increase/(decrease) in cash and cash equivalents A \$(368) A \$7,320 A \$(1,290) A \$(21,250) A Cash used in operating activities: Our cash used in operating activities for the three-month periods ended September 30, 2024 and 2023 was approximately \$10.4 million and \$10.5 million, respectively. Our cash used in operating activities for the nine-month periods ended September 30, 2024 and 2023 was approximately \$27.9 million and \$35.3 million, respectively. Net cash used in operating activities decreased in both the three-month periods and nine-month periods ended September 30, 2024, compared to the same periods in 2023. This was primarily due to reduced operating expenses and accounts payable, with an increase in accrued liabilities over three-month periods and a reduction in accrued liabilities over nine-month periods (see 'Results of Operations'). Our uses of cash for operating activities for both periods consisted primarily of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees and pass-through expenses paid in connection with preclinical and clinical studies, drug manufacturing costs, laboratory supplies and materials, and professional fees. We do not expect to generate positive cash flow from operations for the foreseeable future as we incur additional research and development costs, including costs related to preclinical testing, clinical trials and manufacturing, as well as operating expenses associated with supporting these activities, and potential milestone payments to our collaborators. It is expected that negative cash flows will continue until such time, if ever, that we receive regulatory approval to commercialize any of our products under development and/or royalty or milestone revenue from any such products exceeds expenses. Cash flow from (used in) investing activities: Our cash provided by investing activities for the three-month period ended September 30, 2024 was nil. Our cash provided by investing activities for the three-month period ended September 30, 2023 was \$13 million, and consisted of net maturities of investments. Our cash provided by investing activities for the nine-month period ended September 30, 2024 was \$18 thousand, and consisted of net acquisition of investments and net disposal of property and equipment. Our cash provided by investing activities for the nine-month period ended September 30, 2023, was \$8 million, and consisted of net maturities of investments and net purchases of property and equipment. The composition and mix of cash, cash equivalents and investments is based on our evaluation of conditions in financial markets and our near-term liquidity needs. We have exposure to credit risk, liquidity risk and market risk related to our investments. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1A low or AA low investments. The Company invests only in highly rated financial instruments which are capable of prompt liquidation. The Company manages its liquidity risk by continuously monitoring forecasts and actual cash flows. The Company is subject to interest rate risk on its cash and cash equivalents and investments. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to interest rates on the investments, owing to the relatively short-term nature of the investments. Cash flow from financing activities: Our cash flow from financing activities for the three months ended September 30, 2024, was \$10 million, consisting of \$10 million from the proceeds of a loan payable to related parties and \$8 thousand in cash proceeds from the issuance of shares under the ESPP. Our cash flow from financing activities for the three months ended September 30, 2023, was \$4.9 million, consisting of \$3 million, \$1.2 million and \$694 thousand resulting from Common Shares issued from the Hanmi subscription agreement, the 2023 Committed Equity A Facility, and the 2022 ATM Facility, respectively, \$50 thousand from a stock subscription advance under the 2023 Committed Equity Facility and \$13 thousand in cash proceeds from issuance of shares under the Employee Stock Purchase Plan ("ESPP"). Our cash flow from financing activities for the nine months ended September 30, 2024, was \$26.6 million, consisting of \$10 million from the proceeds of loan payable to related parties, \$4.1 million from the issuance of Common Shares under the registered direct offering, \$8.1 million from the issuance of Common Shares under the S-1 filing, \$3.7 million from the issuance of Common Shares to Hanmi, \$694 thousand from the issuance of Common Shares under the Committed Equity Facility, \$97 thousand in cash proceeds from issuance of Common Shares under the 2022 ATM Facility, \$26 thousand in cash proceeds from issuance of Common Shares under the ESPP, and partly offset by \$177 thousand of financing costs. Our cash flow from financing activities for the nine months ended September 30, 2023 was \$6.1 million, consisting of \$3 million, \$1.8 million and \$1.2 million resulting from Common Shares issued from the Hanmi subscription agreement, the 2022 ATM Facility and the 2023 Committed Equity Facility, respectively, \$50 thousand from a stock subscription advance under the 2023 Committed Equity Facility and \$29 thousand in cash proceeds from issuance of shares under the ESPP. CONTRACTUAL OBLIGATIONS AND COMMITMENTS DESCRIBED UNDER ITEM 7 There were no material changes to our contractual obligations and commitments described under Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which can be found on EDGAR at www.sec.gov/edgar.shtml and on SEDAR+ at www.sedarplus.ca. RESULTS OF OPERATIONS A summary of the results of operations for the three-month and nine-month periods ended September 30, 2024 and 2023 is presented below: A Three months ended September 30, A Nine months ended September 30, A (in thousands) A 2024 A 2023 A 2024 A 2023 A Revenues A \$ A Research and development expenses A \$ A 4,702 A A 8,256 A A 15,560 A A 27,649 A General and administrative expenses A \$ A 2,263 A A 3,425 A A 8,510 A A 12,580 A Other income, net A \$ A 12 A A 234 A A 225 A A 977 A Net loss A \$ (6,953) A \$(11,447) A \$(23,845) A \$(39,252) Other comprehensive income/(loss) A \$ A A A A Comprehensive loss A \$ (6,953) A \$(11,447) A \$(23,845) A \$(39,249) Basic and diluted loss per common share A \$(0.37) A \$(1.76) A \$(1.48) A \$(6.14) Net loss for the three-month period ended September 30, 2024 decreased by \$4.5 million to \$7.0 million, as compared to \$11.4 million for the comparable period in 2023. Net loss for the nine-month period ended September 30, 2024 decreased by \$15.5 million to \$23.8 million, as compared to \$39.3 million for the comparable period in 2023. A Components of net loss are presented below: Research and Development Research and development expenses consist primarily of costs incurred related to the research and development of our product candidates and include: A External research and development expenses incurred under agreements with third parties, such as contract research organizations, consultants, members of our scientific advisory boards, external labs and contract manufacturing organizations; and A Employee-related expenses, including salaries, benefits, travel, and stock-based compensation for personnel directly supporting our clinical trials, manufacturing and development activities. Subject to successful new financing activities, we expect our research and development expenses to be lower during 2024 than in 2023; for the foreseeable future, as we advance tusnetinib into more extensive clinical trials, costs will increase unless the program is partnered. A 33A A The research and development expenses for the three-month and nine-month periods ended September 30, 2024, and 2023 were as follows: A Three months ended September 30, A Nine months ended September 30, A (in thousands) A 2024 A 2023 A 2024 A 2023 A Program costs A \$ A 4,067 A A 5,814 A A 10,656 A A 18,659 A Program costs A \$ A 225 A A 648 A A 287 A A 2,643 A Program costs A \$ A APTO-253 A A A 13 A A 28 A Personnel-related expenses A \$ A 941 A A 1,523 A A 4,274 A A 5,108 A Stock-based compensation A \$ A 81 A A 259 A A 317 A A 1,182 A Depreciation of equipment A \$ A A 10 A A 13 A A 29 A Total A \$ 4,702 A A 8,256 A A 15,560 A A 27,649 A Research and development expenses decreased by \$3.6 million to \$4.7 million for the three-month period ended September 30, 2024, as compared to \$8.3 million for the comparative period in 2023. Changes to the components of our research and development expenses presented in the table above are primarily as a result of the following events: A Program costs for tusnetinib were \$4.1 million for the three-month period ended September 30, 2024, compared with \$5.8 million for the comparative period in 2023. The lower program costs for tusnetinib in the current period represent the reduction of activity in our APTIVATE clinical trial, reduced manufacturing costs, and related expenses. In the comparative period in 2023, tusnetinib program costs included the healthy volunteer study, which was completed in 2023. A Program costs for luxetpinib decreased by approximately \$873 thousand, primarily due to lower clinical trial and manufacturing activities. A Program costs for APTO-253 decreased by approximately \$2 thousand. The Company discontinued further clinical development of APTO-253. A Personnel-related expenses decreased by \$582 thousand, primarily related to fewer employees in the current three-month period. A Stock-based compensation decreased by approximately \$340 thousand in the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to stock options granted with lower grant date fair values, in the current period and option forfeitures recorded in the current period. Research and development expenses decreased by \$12.0 million to \$15.6 million for the nine-month period ended September 30, 2024, as compared to \$27.6 million for the comparative period in 2023. Changes to the components of our research and development expenses presented in the table above are primarily as a result of the following events: A Program costs for tusnetinib were \$10.7 million for the nine-month period ended September 30, 2024, a decrease of \$8 million compared with \$18.7 million for the comparative period in 2023. The lower program costs for tusnetinib in the current period represent the reduction of activity in our APTIVATE clinical trial, reduced manufacturing costs, and related expenses. In the comparative period in 2023, tusnetinib program costs included the healthy volunteer study, which was completed in 2023. A Program costs for luxetpinib decreased by approximately \$2.4 million to \$287 thousand for the nine months ended September 30, 2024, as compared to \$2.6 million in the comparative period, primarily due to lower clinical trial and manufacturing activities. A Program costs for APTO-253 decreased by approximately \$15 thousand, due to the Company's decision on December 20, 2021 to discontinue further clinical development of APTO-253. A Personnel-related expenses decreased by \$834 thousand, primarily related to fewer employees in the current nine-month period and partially offset by salary increases. A Stock-based compensation decreased by approximately \$865 thousand in the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to stock options granted with lower



interest, the date of this Agreement shall be included and the date of payment shall be excluded. 5.Default Interest If the Borrower fails to pay any amount payable by it under this Agreement on its due date, interest shall accrue on the unpaid sum from the due date up to the date of actual payment at a rate which is equal to nine percent (9%) per annum plus the rate which would have been payable if the unpaid sum had, during the period of non-payment, constituted the Loan for successive interest periods, each of a duration selected by the Lender. Any interest accruing under this Clause 5 (Default interest) shall be immediately payable to the Lender by the Borrower on demand by the Lender. Default interest (if unpaid) arising on an unpaid sum will be compounded with the unpaid sum at the end of each interest period applicable to that unpaid sum but will remain immediately due and payable. 6.Payments All payments made by the Borrower to the Lender under this Agreement shall be: (a)paid on the due date for that payment in US dollars and in immediately available cleared funds to the account of the Lender at: A A A A A A A A (b)made in full, without set-off, counterclaim or condition and free and clear of and without any deduction or withholding for, or on account of, tax; provided, the Lender and the Borrower hereby agree to from time to time, to the fullest extent permitted by law, set-off equivalent amounts of loans and other indebtedness they hold against the other party (including, set-off pursuant to the Future Collaboration Agreement defined under Clause 7, and for the avoidance of doubt, any of and all the obligations of the Borrower then due and owing under this Agreement held by the Lender) on an annual basis or at any other intervals mutually agreed to in writing by the Lender and Borrower, in each case, by mutually setting forth in writing the (i) date(s) of incurrence, (ii) reasons for incurrence of any such loans and other indebtedness and (iii) the amount of loans and indebtedness subject to the set-off. 7.Future Collaboration Agreement The Borrower, the Lender and/or its affiliates are currently negotiating a possibility of entering into a collaboration agreement or amending the License Agreement (defined below) (such new agreement or amendment being referred to as the "Future Collaboration Agreement"). Simultaneously with the execution of the Future Collaboration Agreement between the Borrower and the Lender and/or its affiliates, the Loan principal and accrued and unpaid interest under this Agreement (collectively, the "Converted Loan Amount") shall automatically be converted to the Lender's prepayment of future milestone obligations under the Future Collaboration Agreement. Upon such conversion, the Converted Loan Amount shall be deemed fully paid and satisfied under this Agreement, and the future 3 A milestone obligations by the Lender under the Future Collaboration Agreement shall be deemed prepaid by the Lender up to the amount of the Converted Loan Amount. 8.Security Upon the execution of this Agreement and no later than thirty (30) days after the date of this Agreement, the Borrower shall take all necessary actions to provide the Lender with a security interest over all inventory of drug substances and drug products that the Borrower has purchased or manufactured, or will purchase or manufacture, for the purpose of research and development associated with the licensed compound(s) or product(s) under the exclusive license agreement between the Borrower and the Lender as of November 4, 2021 (the "License Agreement"), including all related materials, intermediates, and finished goods (collectively, the "Security"), including but not limited to executing the relevant security agreements and fulfilling all perfection requirements, to the extent permitted and in accordance with applicable law. 9.Representations The Borrower makes the representations and warranties set out in this Clause 9 (Representations) to the Lender on the date of this Agreement. 9.1.Status (a)It is a corporation, duly incorporated and validly existing under the laws of Canada. (b)It has the power to own its assets and carry on its business as it is being conducted. 9.2.Binding obligations The obligations expressed to be assumed by it in each Finance Document to which it is a party are legal, valid, binding and enforceable against it, subject to, in the case of any Security Document to which it is a party, the applicable perfection requirements. 9.3.Non-conflict with other obligations The entry into and performance by it of, and the transactions contemplated by, the Finance Documents and the granting of the security interests pursuant to the Security Documents to which it is a party do not and will not: (a)conflict with: (i)any law or regulation applicable to it (including without limitation, anti-bribery, anti corruption, anti-money laundering and counter terrorism financing laws and regulations); (ii)its constitutional documents; or (iii)any agreement or instrument binding upon it or its assets or would constitute a default or termination event (however described) under any such agreements or instruments; to an extent which would have a Material Adverse Effect; or 4 A (b)(except as permitted under the Finance Documents) result in the existence of, or oblige it to create, any security over any of its assets. 9.4.Power and authority (a)It has the power to enter into, perform and deliver, and has taken all necessary corporate actions to authorise its entry into, performance and delivery of, the Finance Documents to which it is a party and the transactions contemplated by those Finance Documents. (b)No limit on its powers will be exceeded as a result of the borrowing, grant of security or giving of guarantee or indemnities contemplated by the Finance Documents. 9.5.Validity and admissibility in evidence All authorisations required or desirable under any applicable law or regulation: (a)to enable it to lawfully enter into, exercise its rights and comply with and/or perform its obligations in the Finance Documents to which it is a party and the transactions contemplated by those Finance Documents; (b)to make the Finance Documents to which it is a party admissible in evidence in its jurisdiction of incorporation; and (c)to enable it to create the Security to be created by it pursuant to any Security Document to which it is a party and to ensure that such Security has the priority and ranking it is expressed to have, have been obtained or effected and are in full force and effect (save for any applicable perfection requirements which shall be satisfied pursuant to the terms of the relevant Security Documents). 9.6.Governing law and enforcement (a)The choice of the laws of the State of New York, USA, as the governing law of the Finance Documents will be recognised and enforced in its jurisdiction of incorporation. (b)Any judgment obtained in relation to a Finance Document in the jurisdiction of the governing law of that Finance Document will be recognised and enforced in its jurisdiction of incorporation. 9.7.No default (a)No Event of Default is continuing or is reasonably likely to be expected to result from the making of the utilisation or the entry into, the performance of, or any transactions contemplated by, any Finance Document. (b)No other event or circumstance is outstanding which constitutes (or, with the giving of notice, the making of any determination or any combination of any of the foregoing, would constitute) a default or termination event under any other agreement or instrument which is binding on the Borrower or to which its assets are subject which is likely to have a Material Adverse Effect. 5 A 9.8.No misleading information (a)Any factual information contained in or provided by the Borrower was true and accurate in all material respects as at the date it was provided or as at the date (if any) at which it is stated. (b)Any financial projections or forecasts provided by the Borrower have been prepared on the basis of recent historical information and on the basis of reasonable assumptions and was fair and arrived at after careful consideration. (c)The expressions of opinion or intention provided by or on behalf of the Borrower for the purposes of the Finance Documents were made after careful consideration and (as at the date of the relevant report or document containing the expression of opinion or intention) were fair and based on reasonable grounds. (d)No event or circumstance has occurred or arisen and no information has been omitted from the information provided by the Borrower for the purposes of the Finance Documents and no information has been given or withheld that results in the information, opinions, intentions, forecasts or projections provided being untrue or misleading in any material respect. (e)All other information supplied by the Borrower was true, complete and accurate in all material respects as at the date it was given and was not misleading in any material respect. (f)All information provided by the Borrower in accordance with the terms of the Finance Documents: (i)was true, complete and accurate in all material respects as at the date it was given and was not misleading in any material respect; and (ii)no information has been given or withheld that results in the information provided being untrue or misleading in any material respect as at the date it was given. 9.9.Pari passu ranking Without limiting Clause 8 (Security), its payment obligations under the Finance Documents rank at least pari passu in right of priority and payment with the claims of all its other unsecured and unsubordinated creditors, except for obligations mandatorily preferred by law applying to companies generally. 9.10.Insolvency event After the amount loaned hereunder by the Lender to the Borrower hereunder is received from the Borrower, no Insolvency Event is reasonably likely to occur. 9.11.Immunity (a)Neither it nor any of its assets is entitled to immunity from suit, execution, attachment or other legal process. (b)In any proceedings taken in its jurisdiction of incorporation in relation to the Finance Documents, it will not be entitled to claim immunity for itself or any of its assets arising from suit, execution or other legal process. 6 A 9.12.No proceedings pending or threatened (a)No litigation, arbitration or administrative proceedings or investigations (including, without limitation, civil, criminal, antitrust or administrative proceedings) (other than those of a frivolous or vexatious nature and discharged, stayed or dismissed within forty-five (45) days of commencement thereof) or before any court, arbitral body or agency which are reasonably likely to be adversely determined and, if adversely determined, might reasonably be expected to have a Material Adverse Effect, have been started or threatened in writing against the Borrower. (b)Other than as publicly disclosed, no judgment or order of a court, arbitral tribunal or other tribunal or any order or sanction of any governmental or other regulatory body which might reasonably be expected to have a Material Adverse Effect has been made against the Borrower. 9.13.Security Each Security Document to which it is a party creates in favour of the Lender, the Security which it is expressed to create fully perfected and with the ranking and priority it is expressed to have in accordance with its terms. 9.14.Legal and beneficial ownership and good title (a)The Borrower is the sole legal and beneficial owner of, holds good, legal and valid title to its assets over which it purports to grant the Security, free and clear of any security and there is no agreement or arrangement under which it is obliged to share any proceeds of or derived from its assets with any third party. (b)The Borrower has all appropriate authorisations to use its assets necessary to carry on its business as presently conducted (in each case, where failure to have such authorisations has or would be expected to have a Material Adverse Effect). 9.15.Compliance with law The Borrower has not breached and is in compliance with all material laws, regulations and orders applicable to it. 10.Undertakings The undertakings in this Clause 10 (Undertakings) shall remain in force from the date of this Agreement for so long as any amount is outstanding under the Finance Documents. 10.1.Authorisations The Borrower shall promptly obtain, comply with and do all that is necessary to maintain in full force and effect and (upon reasonable request of the Lender) supply certified copies to the Lender of any authorisation required under any applicable law or regulation: (a)to enable it to perform its obligations under the Finance Documents; 7 A (b)to ensure the legality, validity, enforceability or admissibility in evidence in its jurisdiction of incorporation of any Finance Document; and (c)to carry on its business where failure to do so has or is likely to have a Material Adverse Effect. 10.2.Compliance with laws The Borrower shall comply in all respects with all laws to which it may be subject, if failure to comply has or is likely to have a Material Adverse Effect. 10.3.Pari passu The Borrower shall ensure that its payment obligations under the Finance Documents to which it is a party rank and continue to rank at least pari passu in right of priority and payment with the claims of all of its other unsecured and unsubordinated creditors, except for obligations mandatorily preferred by law applying to companies generally. 10.4.Security and further assurance (a)The Borrower shall, at its own expense, promptly do all such acts or execute all such documents: (i)to ensure that each Finance Document is valid, binding and effective and creates the Security which it purports to create; (ii)to create perfect, preserve, register or maintain the relevant Security created or intended to be created under the relevant Security Document(s) and/or the Finance Document(s) and for the purpose of protecting the rights, powers and remedies of the Lender provided by or pursuant to the Finance Documents or by law; and (iii)as the Lender may reasonably require (after the occurrence of an Event of Default which is continuing) for the purpose of facilitating the realisation of the assets which are, or are intended to be, the subject of the Security, including, if necessary, the execution of any mortgage, pledge, transfer, pledge, conveyance, assignment, transfer or assurance of all or any of the assets and the giving of any notice, order or direction, the obtaining of any acknowledgment, and the making of any registration. (b)The Borrower will, at its own costs, promptly register, file, record or enrol any Finance Document with any court or authority, pay any stamp, registration or similar tax payable in respect of any Finance Document, give any notice or take any other step which, in the reasonable opinion of the Lender, is or has become necessary for any Finance Document to be valid, enforceable or admissible in evidence or to ensure or protect the priority of any Security which it creates (subject to the express terms of the Finance Documents). (c)The Borrower shall not do, or consent to the doing of, anything which is reasonably likely to prejudice the validity, enforceability or priority of any of the relevant Security. 8 A 10.5.Negative pledge (a)The Borrower shall not create or permit to subsist any security over any of its assets and equity interest without the prior written consent of the Lender. (b)The Borrower shall not, without the prior written consent of the Lender: (i)sell, transfer or otherwise dispose of any of its receivables on recourse terms; (ii)enter into or permit to subsist any title retention arrangement; (iii)enter into or permit to subsist any arrangement under which money or the benefit of a bank or other account may be applied, set-off or made subject to a combination of accounts; or (iv)enter into or permit to subsist any other preferential arrangement having a similar effect, in circumstances where the arrangement or transaction is entered into primarily as a method of raising financial indebtedness or of financing the acquisition of an asset. 10.6.Disposals Other than in the ordinary course of its business, the Borrower shall not enter into, or permit, a single transaction or a series of transactions (whether related or not and whether voluntary or involuntary) to sell, lease, transfer or otherwise dispose of any of the Security without the prior written consent of the Lender. 10.7.Financial indebtedness The Borrower shall not incur (or agree to incur) or have outstanding any financial indebtedness, other than in the ordinary course of its business, without the prior written consent of the Lender. 10.8.Loans and guarantees (a)The Borrower shall not: (i)make any loan, or provide any form of credit or financial accommodation, to any other person; or (ii)give or issue any guarantee or indemnity to or for the benefit of, or in respect of liabilities or obligations of, any other person or voluntarily assume any liability (whether actual or contingent) of any other person. (b)Paragraph (a) above does not apply to: (i)guarantees or indemnities under the Finance Documents; nor (ii)any other loans, guarantees, advances, indemnities, bonds or letters of credit approved by the Lender. 9 A 10.9.Merger The Borrower shall not, without the prior written consent of the Lender, enter into any amalgamation, demerger, merger, consolidation or corporate reconstruction or business transfer or voluntarily liquidate or dissolve itself. 10.10.Assets The Borrower shall maintain all its assets necessary for the conduct of its business as conducted from time to time in good working order and condition, ordinary wear and tear excepted. 10.11.Taxes (a)The Borrower shall pay all taxes required to be paid by it when due and before any penalty is imposed for late payment. (b)Paragraph (a) above does not apply to any taxes: (i)being contested by the Borrower in good faith; (ii)which have been adequately disclosed in its financial statements, and for which adequate reserves are being maintained in accordance with the laws of the relevant jurisdiction; and (iii)where payment can be lawfully withheld and will not result in the imposition of any penalty described in paragraph (a) above. 10.12.Change of business The Borrower shall not substantially change the general nature of its business from that carried on at the utilisation date without the prior written consent of the Lender. 10.13.Acquisitions, investments and share capital The Borrower shall not, without the prior written consent of the Lender: (a)invest in or acquire any share in or any security issued by any person, or any interest therein or in the capital of any person, or make any capital contribution to any person; (b)invest in or acquire any business or going concern, or the whole or substantially the whole of the assets or business of any person, or any assets that constitute a division or operating unit of the business of any person; or (c)enter into any joint venture, consortium, partnership or similar arrangement with any person. 10.14.Business milestone The Future Collaboration Agreement will be executed in due course, and after such execution, the Borrower shall procure that the business milestones prescribed therein be achieved on each business milestone date. 10 A 10.15.Triplest study The Borrower shall commence dosing of the first patient in the Triplest Study on or before October 31, 2024. Such date can be extended if the Lender consents in writing which consent will not be unreasonably conditioned, delayed or withheld. The Borrower shall maintain key resources necessary to conduct the clinical trials, including, but not limited to, the manpower and the retention of related assets and interests. For the purposes of this Clause, the "Triplest Study" shall mean an open-label clinical trial in frontline acute myeloid leukemia within the United States, which shall be designed and conducted by the Borrower. 11.Events of Default Each of the events or circumstances set out in this Clause 11 (Events of Default) shall constitute an Event of Default. 11.1.Non-payment The Borrower does not pay on the due date any amount payable pursuant to this Agreement unless (a) its failure to pay is caused by administrative or technical error, and (b) payment is made within five (5) Business Days of its due date. 11.2.Specific undertakings Any requirement of Clause 10.4 (Security and further assurance), Clause 10.14 (Business Milestone) and Clause 10.15 (Triplest study) is not satisfied. 11.3.Other obligations (a)The Borrower does not comply with any provision of the Finance Documents to which it is a party (other than those referred to in Clause 11.1 (Non-payment) or Clause 11.2 (Specific undertakings)). (b)No Event of Default under paragraph (a) above will occur if the failure to comply is capable of remedy and is remedied within thirty (30) days of the earlier of (i) the Lender giving notice to the Borrower and (ii) the Borrower becoming aware of the failure to comply. 11.4.Misrepresentation (a)Any representation or statement made or deemed to be made by the Borrower in the Finance Documents to which it is a party or any other document delivered by or on behalf of the Borrower under or in connection with any Finance Document is or proves to have been incorrect or misleading in any material respect when made or deemed to be made. (b)No Event of Default under paragraph (a) above will occur if the event or circumstance resulting in failure to comply is capable of remedy and is remedied within thirty (30) calendar days of the earlier of (i) the Lender giving notice to the Borrower and (ii) the Borrower becoming aware of such misrepresentation. 11 A 11.5.Insolvency (a)The Borrower is unable (or admits its inability to) or is presumed or deemed to be (or is held or otherwise considered by a court to be) unable or admits inability to pay its debts as they fall due or suspends or threatens to suspend making payments on any of its debts or (by reason of actual or anticipated financial difficulties) commences negotiations with one or more of its creditors (excluding the Lender in its capacity as such) with a view to rescheduling any of its indebtedness. (b)A moratorium is declared in respect of any indebtedness of the Borrower. If a moratorium occurs, the ending of the moratorium will not remedy any Event of Default caused by that moratorium. 11.6.Insolvency proceedings Any corporate action, legal proceedings or other procedure or step is taken in relation to: (a)the suspension of payments, a moratorium of any indebtedness, winding-up, dissolution, administration, judicial management, provisional supervision, reorganisation or rehabilitation (by way of voluntary arrangement, scheme of arrangement



link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) (Parent(Theticals) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Note 1 - Reporting Entity link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Note 2 - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Note 3 - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Note 4 - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Note 5 - Right-of-use Assets link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Note 6 - Fair Value Measurements and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Note 7 - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Note 8 - Loan Payable to Related Parties link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Note 8 - Lease Liability link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Note 9 - Related party transactions link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Note 10 - Share Capital link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Note 11 - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Note 12 - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Note 4 - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Note 5 - Right-of-use Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Note 6 - Fair Value Measurements and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Note 7 - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Note 8 - Lease Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Note 10 - Share Capital (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Note 11 - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Note 3 - Cash and Cash Equivalents (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Note 4 - Prepaid Expenses - Prepaid Expenses and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Note 5 - Right-of-use Assets - Schedule of Right-of-use Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Note 6 - Fair Value Measurements and Financial Instruments - Assets Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Note 7 - Accrued Liabilities - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Note 8 - Lease Liability (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Note 8 - Lease Liability - Schedule of Minimum Payments Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Note 8 - Lease Liability - Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Note 8 - Lease Liability - Operating Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Note 9 - Related party transactions (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Note 10 - Share Capital (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Note 10 - Share Capital - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Note 11 - Stock-based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Note 11 - Stock-based Compensation - Stock Option Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Note 11 - Stock-based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parent(Theticals) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Note 11 - Stock-based Compensation - Vesting and Redemption of the RSUs Granted (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Note 11 - Stock-based Compensation - Share-based Payment Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Note 12 - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Options with Three Year Vesting [Member] Information pertaining to options with three year vesting. Plan Name [Domain] Employee Stock Purchase Plan, Stock Purchase Price, Percent apto\_EmployeeStockPurchasePlanStockPurchasePricePercent The percent of stock purchase price under an employee stock purchase plan. Increase (Decrease) in Accounts Payable, Related Parties Accounts payable to related parties Entity Address, Postal Zip Code Hammi Licensing Agreement. Hammi Licensing Agreement [Member] Assets and Liabilities, Lessee [Abstract] Entity Incorporation, State or Country Code Negative shareholder's equity. Negative Shareholder's Equity Negative shareholder's equity Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Tranche One [Member] Schedule of Right-of-use Assets [Table Text Block] Tabular disclosure of the carrying amounts of right-of-use assets. This disclosure includes current assets and noncurrent assets. Schedule of Right-of-use Assets Toronto, Canada. Toronto Canada [Member] Toronto Canada [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share) Stock Issued During Period, Value, Restricted Stock Award, Gross Common shares issued in exchange for RSUs Balance (in shares) Balance (in shares) Shares, Outstanding Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Keystone Capital Partners, LLC. Keystone Capital Partners, LLC [Member] Office Space [Member] Represents leased office space. Shares issuances to Hammi under subscription agreement Shares issuances to Hammi Shares issuances to Hammi. Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 Lessee, Operating Leases [Text Block] Lease liability Stock and warrants issued during period shares subscription agreement. Stock and Warrants Issued During Period Shares Subscription Agreement Common shares and warrants issued under the Hammi Subscription Agreement (in shares) Warrants issued price per share. Warrants Issued Price Per Share Warrants issued price per share Investment, Name [Domain] Depreciation, Depletion and Amortization Depreciation, Depletion and Amortization, Total Depreciation and amortization Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Items not involving cash: Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Information [Table] Equity [Text Block] Share capital Title and Position [Axis] Series A warrants. Series A Warrants [Member] Series A Warrants [Member] Class of Warrant or Right [Axis] Sale of Stock [Domain] Share-based Payment Arrangement, Tranche Four [Member] Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Entity Central Index Key Cash proceeds from issuing common shares Cash Proceeds From Issuing Common Shares Cash proceeds from issuing common shares. Cash Equivalents, at Carrying Value, Total Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Warrant [Member] Warrant [Member] Forfeited, options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period 2023 Committed Equity Facility [Member] Two Thousand Twenty Three Committed Equity Facility [Member] Two thousand twenty three committed equity facility. Increase (Decrease) in Operating Capital [Abstract] Changes in non-cash operating assets and liabilities: Proceeds from loan payable to third party Proceeds from Issuance of Debt Common Stock, Shares, Issued Common Stock, Share issued Loan payable maturity date Loan payable maturity date. Income Statement [Abstract] Entity Address, State or Province Stock Issued During Period, Value, Employee Stock Purchase Plan Common shares issued under the ESPP plan Percentage of shares outstanding Percentage of shares outstanding for issuance of warrant Percentage of shares outstanding for issuance of warrant. Options With Performance Criteria [Member] Information pertaining to options with performance criteria. Options With Performance Criteria [Member] Value of stock issued as a result of licensing fee. Common shares issued pursuant to the Hammi licensing fees Stock Issued During Period, Value, Licensing Fee Subsequent Event [Line Items] Earnings Per Share, Basic Earnings Per Share, Basic, Total Net loss per share - basic Basic loss per common share (in dollars per share) Continuing Vesting Options with No Service Requirement [Member] Information regarding continuing vesting options with no service requirement. Operating Expenses [Abstract] Expenses: Base Shelf [Member] Represents information pertaining to the Base Shelf. Placement Agent Warrants [Member] Placement agent warrants. Common shares and warrants issued in S1 financing amount. Common Shares and Warrants Issued In S1 Financing Amount Common shares and warrants issued in S-1 financing Note To Financial Statement Details Textual Note To Financial Statement Details Textual Share-Based Payment Arrangement, Expense Share-based Payment Arrangement, Expense San Diego, California [Member] Represents San Diego, California. Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and redeemed in period, weighted average grant date fair value. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested and Redeemed in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Vested and redeemed Loan payable Long-Term Debt Long-Term Debt, Total Maturity ((acquisition) of investments, net Payments for (Proceeds from) Investments Payments for (Proceeds from) Investments, Total Maturity (acquisition) of investments, net Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Accumulated deficit Deficit Plan Name [Axis] Outstanding, options (in shares) Outstanding, options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Note 4 - Prepaid Expenses Statement-Statement-Note-4-Prepaid-Expenses-Tables Assets, Current [Abstract] Current assets: Common Stock, Capital Shares Reserved for Future Issuance Common stock capital shares reserved for future issuance Hammi Pharmaceuticals Co., Ltd. Hammi Pharmaceuticals Co Ltd [Member] Hammi Pharmaceuticals Co., Ltd. [Member] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Summary of Prepaid Expenses and Other Assets Cash used in operating activities Net Cash Provided by (Used in) Operating Activities Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Public Offering [Member] Represents information pertaining to public offering. Public Offering [Member] Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Total Property and equipment Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows used in operating activities: Series B warrants. Series B Warrants [Member] Series B Warrants [Member] Vesting [Axis] Common Stock, Par or Stated Value Per Share Common stock, par value Other comprehensive income: Other comprehensive loss: Statement of Cash Flows [Abstract] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase common shares, number of warrants Entity [Domain] Equity Components [Axis] Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Accrued personnel related costs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Number of options, Granted Accrued interest on investments apto\_InterestAccruedOnInvestments The amount of accrual of interest on investments. Warrants issued. Warrants Issued Warrants issued Subsequent Event Type [Axis] Total other income Nonoperating Income (Expense) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Stock issuance program authorized shares. Stock Issuance Program Authorized Shares Stock issuance program authorized shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of options, Beginning Balance Number of options, Ending Balance Amendment Flag Lease liability, long term portion Operating Lease, Liability, Noncurrent Lease liability, operating leases Statement-Statement-Note-11-Stock-based-Compensation-Vesting-Terms-Of-Options-Granted-Details-Parent(Theticals) Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parent(Theticals) Note 11 - Stock-based Compensation - Stock Option Transactions (Details) Statement-Statement-Note-11-Stock-based-Compensation-Stock-Option-Transactions-Details Net loss Net loss Exercised, options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Common shares issued upon exercise of stock options Common shares issued upon exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Research and Development Expense [Member] Percentage of capital beneficial ownership Percentage Of Beneficial Ownership Capital Percentage of beneficial ownership capital. Equity Component [Domain] Second back-end commitment shares. Second Back-End Commitment Shares [Member] Second Back-End Commitment Shares [Member] Statistical Measurement [Domain] General and Administrative Expense General and Administrative Expense, Total General and administrative Interest on lease liabilities The amount of interest expense related to lease liabilities Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Hammi Loan Agreement [Member] Hammi Loan Agreement. The 2020 ATM Offering The 2020 ATM Offering [Member] Information pertaining to the 2020 ATM Offering. Operating lease liabilities Operating cash flows from operating leases Operating Lease, Payments Common shares issued under the ESPP plan (Shares) Common shares issued under the ESPP plan (in shares) Shares issued under ESPP Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Total Other comprehensive gain (loss) Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares Outstanding Purchase Commitment, Remaining Minimum Amount Committed Purchase commitment obligation amount Equity Method Investment, Quoted Market Value Investment for ownership interest Common warrants combined offering price. Common Warrants Combined Offering Price Common warrants offering price Proceeds of sale stock Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Net proceeds Cash Cash Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Share-based Payment Arrangement, Vesting and Redemption of the RSUs Granted Total non-current liabilities Liabilities, Noncurrent Entity Interactive Data Current Accounts payable to related party current. Accounts payable to related party current Accounts payable to related parties Document Quarterly Report Related Party Transaction [Domain] Related party transactions Related Party Transactions Disclosure [Text Block] Statistical Measurement [Axis] Equity Method Investment [Table] Operating lease cost Operating Lease, Cost Share-Based Payment Arrangement, Tranche Three [Member] Assets, Fair Value Disclosure Assets, Fair Value Disclosure, Total Assets, Fair Value Disclosure Nasdaq listing rule minimum requirement for stockholders equity. Nasdaq Listing Rule Minimum Requirement For Stockholders Equity Nasdaq Listing Rule, minimum requirement for stockholders' equity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Summary of Minimum Payments, Undiscounted, Under Operating Leases Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Granted Weighted average grant date fair value, exercise price Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Cost of offering, Cost Of Offering Cost of offering Debt Instrument, Convertible, Threshold Consecutive Trading Days Consecutive business days Prepaid expenses Increase (Decrease) in Prepaid Expense Prepaid expenses Statement of Income Location, Balance [Axis] Information related to HM43239. HM43239 [Member] Number of common shares held Investment Owned, Balance, Shares Total assets Assets Expected life of options (Years) Expected life of options (years) The 2023 Equity Facility [Member] The 2023 equity facility. New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Entity Address, City or Town AOCI Attributable to Parent [Member] Private placement issuance percentage. Private Placement Issuance Percentage Private placement issuance percentage Loan payable maturity date Long-Term Debt, Maturity Date New Incentive Plan [Member] New Incentive Plan [Member] The 2022 atm offering. The 2022 ATM Offering [Member] The 2022 ATM Offering [Member] Loan agreement amount Debt Instrument, Face Amount Private Placement [Member] Private Placement [Member] Share-Based Payment

Arrangement [Text Block] Stock-based compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Maximum number of shares issue or sell. Maximum Number of Shares Issue or Sell Maximum number of shares issue or sell Statement-Statement-Note-11-Stockbased-Compensation-Sharebased-Payment-Expense-Details Note 12 - Stock-based Compensation - Share-based Payment Expense (Details) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - operating leases Fair Value Disclosures [Abstract] Initial commitment shares. Initial Commitment Shares [Member] Initial Commitment Shares [Member] Cash proceeds from issuing shares Stock Issued During Period, Value, New Issues Common shares issued under 2022 ATM/ 2023 Committed Equity Facility Stock Issued During Period, Value, Stock Options Exercised Common shares issued upon exercise of stock options Liabilities, Current [Abstract] Current liabilities: Percentage of common shares outstanding. Percentage of Common Shares Outstanding Percentage of common shares outstanding. Lease Contractual Term [Axis] Document Type Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Lease, Cost [Table Text Block] Summary of Operating Lease Costs and Operating Cash Flows from Operating Leases Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Research and Development Expense Research and Development Expense, Total Research and development Stock options granted in the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) Common stock, Shares authorized Common shares issued under the Hammi Subscription Agreement Stock Issued During Period Value Subscription Agreement 1 Stock issued during period value subscription agreement 1. Asset Class [Domain] Consolidation, Policy [Policy Text Block] Basis of consolidation Subsequent Event Type [Domain] Payment of supply costs Payment Of Supply Costs Payment of supply costs. Prepaid research and development expenses Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Proceeds from issuance of common stock and warrants under registered direct offering. Proceeds From Issuance Of Common Stock and Warrants Under Registered Direct Offering Issuances of common shares and warrants under the Registered Direct Offering Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants to purchase common shares, exchange price Assets, Noncurrent [Abstract] Non-current assets: Sale of Stock [Axis] Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from/(used in) investing activities: Note 11 - Stock-based Compensation Statement-Statement-Note-11-Stockbased-Compensation-Tables Right-of-use Assets Disclosure [Text Block] The entire disclosure for right-of-use assets. This disclosure includes current assets and noncurrent assets. Right-of-use assets Note 5 - Right-of-use Assets Statement-Statement-Note-5-Rightofuse-Assets-Tables Loan payable to Related Parties Loan payable to related parties Loan payable to related parties. Employee Stock Purchase Plan, Maximum Payroll Deduction, Percent apto EmployeeStockPurchasePlanMaximumPayrollDeductionPercent The percent maximum payroll deduction under an employee stock purchase plan. Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and redeemed in period. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested and Redeemed in Period Number of options, Vested and redeemed Other Accrued Liabilities, Current Other accrued expenses Entity Address, Address Line Two Subsequent Event, Description Description of subsequent event Document Period End Date Cash from financing activities Net Cash Provided by (Used in) Financing Activities Prepaid Expense and Other Assets [Abstract] Liabilities, Noncurrent [Abstract] Non-current liabilities: Vested Options [Member] Information related to vested options. Stock Issued During Period, Shares, Restricted Stock Award, Gross Common shares issued in exchange for RSUs (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation Equity Method Investment, Ownership Percentage Percentage of ownership common shares outstanding Percentage of investment Total Accrued Liabilities, Current Accrued liabilities Performance Based Vesting, Performance Based Vesting [Member] Performance Based Vesting [Member] Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Trading Symbol Total shareholdersâ€™ equity Balance Balance Equity, Attributable to Parent Positive shareholder's equity Negative shareholder's equity Convertible debt conversion Debt Conversion, Original Debt, Amount Working capital. Working Capital Working capital Warrants to purchase Class of Warrant or Right, Outstanding Warrants outstanding Restricted Stock Units (RSUs) [Member] Sale of Stock, Number of Shares Issued in Transaction Number of shares sold Related Party Transactions [Abstract] Prepaid Expenses [Text Block] The entire disclosure of the amounts paid in advance during the operating period. Prepaid expenses Loan payable to related parties current Loan payable to related parties current. Cash and Cash Equivalents Disclosure [Text Block] Cash and cash equivalents Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Geographical [Axis] Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Use of Estimates, Policy [Policy Text Block] Significant accounting policies, estimates and judgments Total non-current assets Assets, Noncurrent Options with Four Year Vesting [Member] Information pertaining to options with four year vesting. Lessee Disclosure [Abstract] Scenario [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Security Exchange Name Bank Time Deposits [Member] High Interest Savings Account [Member] Operating expenses Operating Expenses Proceeds from Issuance of Common Stock, Gross apto ProceedsFromIssuanceOfCommonStockGross The gross amount of cash inflow received from the issuance of common stock, before stock issuance costs. Legal Entity [Axis] Fair Value Disclosures [Text Block] Fair value measurements and financial instruments Interest on loan paid Interest Expense, Long-Term Debt Interest Expense, Long-Term Debt, Total Lessee, Operating Lease, Liability, to be Paid, Year Three 2026 Grant date fair value First back-end commitment shares. First Back-End Commitment Shares [Member] First Back-End Commitment Shares [Member] Subsequent Event [Member] Maximum [Member] Total liabilities and shareholdersâ€™ equity Liabilities and Equity Right-of-use assets, NBV Operating Lease, Right-of-Use Asset Right-of-use assets, operating leases Total Prepaid Expense, Current Prepaid expenses Statement-Statement-Note-11-Stockbased-Compensation-Vesting-Terms-Of-Options-Granted-Details Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details) Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net loss per share - diluted Diluted loss per common share (in dollars per share) Stock Issued During Period, Shares, Reverse Stock Splits Pre-consolidation common shares Percentage of underwriting cost. Percentage of Underwriting Cost Underwriting costs (as percent) Total liabilities Liabilities Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net Cash Provided by (Used in) Investing Activities Cash from/(used in) investing activities Forecast [Member] Common shares issued (in shares) Common shares issued under 2022 ATM/ 2023 Committed Equity Facility (in shares) Common shares issued Statement-Statement-Note-11-Stockbased-Compensation-Weighted-Average-Assumptions-Details Note 12 - Stock-based Compensation - Weighted Average Assumptions (Details) Stock and warrants issued during period value registered direct offering. Stock and Warrants Issued During Period Value Registered Direct Offering Shares and warrants issued under the Registered Direct Offering The 2023 CMPO. The 2023 CMPO [Member] The 2023 CMPO [Member] Entity File Category apto OperatingLeaseRightOfUseAssetGross Amount of lessee's right to use underlying asset under operating lease before amortization, depreciation, and depletion. Right-of-use assets, beginning of period Right-of-use assets, end of period Number of securities into warrant Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Reporting entity Nonoperating Income (Expense) [Abstract] Other income/(expense): Deferred financing expenses Deferred Financing Expenses Current Deferred financing expenses current. Current Fiscal Year End Date Maximum amount agreed to pay for reasonable expenses. Maximum Amount Agreed to Pay for Reasonable Expenses Maximum amount agreed to pay for reasonable expenses Warrants purchase price per share. Warrants Purchase Price Per Share Warrants purchase price per share Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Share-Based Payment Arrangement, Noncash Expense, Total Related Party Transaction [Axis] Accrued research and development expenses The amount of research and development liabilities classified as current. Note 11 - Share Capital - Loss Per Share (Details) Statement-Statement-Note-10-Share-Capital-Loss-Per-Share-Details Entity Registrant Name Premium share price percent. Premium Share Price Percent Premium share price (as a percent) Entity Emerging Growth Company Equity Method Investments and Joint Ventures [Abstract] Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average common shares - basic Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) Note 9 - Lease Liability Statement-Statement-Note-9-Lease-Liability-Tables Vesting [Domain] Keystone. Keystone [Member] Keystone [Member] Schedule of Equity Method Investments [Line Items] Accrued liabilities current net. Accrued Liabilities Current Net Total Proceeds from Issuance of Common Stock Issuance of common shares Proceeds from issuance of common stock The 2020 ATM Offering [Member] Information pertaining to the 2020 ATM Offering. Cash and Cash Equivalents [Abstract] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Expenses Costs and Expenses, Related Party Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Loan payable to related parties Loan payable to related parties, Non-current Loan payable to related parties, non-current. Represents total license fee. apto LicenseFeeTotal License Fee, Total Minimum market value of listed securities. Minimum market value of listed securities Minimum market value of listed securities General and Administrative Expense [Member] Share-Based Payment Arrangement [Abstract] Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block] Tabular disclosure of share options granted during the period. Schedule of Share-based Payment Award, Options, Grants in Period Cash proceeds Proceeds from Issuance of Warrants Commitment shares. Commitment Shares [Member] Commitment Shares [Member] Note 7 - Fair Value Measurements and Financial Instruments Statement-Statement-Note-7-Fair-Value-Measurements-And-Financial-Instruments-Tables Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Share-based Payment Arrangement, Option, Activity Note 9 - Lease Liability - Schedule of Minimum Payments Under Operating Leases (Details) Statement-Statement-Note-9-Lease-Liability-Schedule-Of-Minimum-Payments-Under-Operating-Leases-Details Cash and Cash Equivalents [Line Items] Equity, Attributable to Parent [Abstract] Shareholders' equity: Note 11 - Share Capital Statement-Statement-Note-10-Share-Capital-Tables Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Effect of exchange rate fluctuations on cash and cash equivalents Stock Issuance, Percent of Cash Commission to Broker apto StockIssuancePercentOfCashCommissionToBroker The percent of cash commission payable to the broker of a stock issuance. Statement [Table] Note 9 - Lease Liability - Operating Lease Cost (Details) Statement-Statement-Note-9-Lease-Liability-Operating-Lease-Cost-Details Notes To Financial Statements [Abstract] Notes To Financial Statements Abstract Stock Issuance Program, Authorized Amount apto StockIssuanceProgramAuthorizedAmount Amount of stock issuance plan authorized. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Subsequent Event [Table] Revenue from Contract with Customer, Including Assessed Tax Revenue Securities Act File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Increase/(decrease) in cash and cash equivalents Stock and warrants issued during period value subscription agreement1. Stock and Warrants Issued During Period Value Subscription Agreement1 Common shares and warrants issued under the Hammi Subscription Agreement Lessee, Operating Lease Liability and Weighted Average [Table Text Block] Tabular disclosure of lessee's operating lease liability and weighted average of operating lease liability. Summary of Weighted Average Remaining Term of Leases and Weighted Average Discount Rate Warrants expiration period Warrants and Rights Outstanding, Term Warrants, Remaining contractual life Supply Agreement [Member] Supply agreement. Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Future milestone payments Future Milestone Payments Future milestone payments. Common shares issued under the Hammi Subscription Agreement (in shares) Stock Issued During Period Shares Subscription Agreement Stock issued during period shares subscription agreement. Public offering price Shares Issued, Price Per Share Shares issued, price per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Accumulated amortization apto AmortizationOfRightofUseAssets The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of right-of-use assets over their estimated remaining economic lives. Common shares, no par value Common Stock, No Par Value Common Stock, No Par Value Entity Shell Company Stock and warrants issued during period shares registered direct offering. Stock and Warrants Issued During Period Shares Registered Direct Offering Shares and warrants issued under the Registered Direct Offering (in shares) Entity Tax Identification Number Class of Warrant or Right [Domain] Equity method investment second tranche. Equity Method Investment Second Tranche [Member] Second Tranche [Member] Entity Current Reporting Status Loan is repayable date Related Party Transaction, Date Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Note 9 - Lease Liability - Lease Liability (Details) Statement-Statement-Note-9-Lease-Liability-Lease-Liability-Details June 2024 Registered Direct Offering. June 2024 Registered Direct Offering [Member] June 2024 Registered Direct Offering [Member] Subsequent Events [Abstract] Geographical [Domain] Document Fiscal Year Focus Cash, Cash Equivalents, and Short-Term Investments, Total Cash, Cash Equivalents, and Short-Term Investments Cash and investment Share-Based Payment Arrangement, Tranche Two [Member] Increase decrease in accounts payable excluding related parties. Increase Decrease In Accounts Payable Excluding Related Parties Accounts payable Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Note 8 - Accrued Liabilities Statement-Statement-Note-8-Accrued-Liabilities-Tables City Area Code Proceeds from loan payable to related parties Proceeds from Related Party Debt Total current liabilities Liabilities, Current Current liabilities Toronto, Ontario, Canada [Member] Represent Toronto, Ontario, Canada. Offered Shares [Member] Offered Shares [Member] Offered shares. Local Phone Number Additional Paid in Capital Additional Paid in Capital, Total Additional paid-in capital Notes to Financial Statements Disclosure Text Block [Abstract] Payments for (Proceeds from) Productive Assets, Total Payments for (Proceeds from) Productive Assets Disposal/(purchase) of property and equipment, net Common share exercise price Shares, Issued Professional Fees Professional fees Lease liability, current portion Operating Lease, Liability, Current Current portion of lease liability, operating leases Document Information [Line Items] Loan interest rate Debt Instrument, Interest Rate, Stated Percentage Retained Earnings [Member] Over-Allotment Option [Member] Over-Allotment Option [Member] Accrued Liabilities, Current [Abstract] Document Transition Report Unvested Options [Member] Information related to unvested options. Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets, Total Other current assets Other current assets Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Issuance of common shares under the ESPP plan Proceeds from Stock Plans Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of risk Minimum [Member] Minimum [Member] Unrealized (gain)/loss on short-term investment Unrealized (gain)/loss on short-term investment Unrealized Gain (Loss) on Investments Common Shares [Member] Common Stock [Member] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued liabilities Investment, Name [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant date fair value, exercise price Weighted average grant date fair value, Beginning Balance Weighted average grant date fair value, Ending Balance Operating Lease, Right-of-Use Asset, Periodic Reduction Amortization of right-of-use assets Additional Paid-in Capital [Member]

Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign currency 2023 committed equity facility. 2023 Committed Equity Facility [Member] 2023 Committed Equity Facility [Member] Pre-funded warrants. Pre-Funded Warrants [Member] Pre-Funded Warrants [Member] Statement of Income Location, Balance [Domain] Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Represents cash outflow for license fee. apto PaymentsForLicenseFee Payments for License Fee Other prepaid Operating expenses Other Prepaid Expense, Current Other Assets, Current Other current assets Foreign exchange income/(loss) Foreign exchange gain/(loss) Entity Common Stock, Shares Outstanding Officer [Member] Basis of Accounting, Policy [Policy Text Block] Basis of presentation - Going concern Scenario [Domain] Title and Position [Domain] Proceeds from loans restricted to use in connection of related party Proceeds from Loans Restricted to Use in Connection of Related Party Proceeds from loans restricted to use in connection of related party. Common shares, no par value, unlimited authorized shares, 19,521,183 and 7,942,363 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common shares, no par value, unlimited authorized shares, 19,521,183 and 7,942,363 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Lab Space [Member] Represents leased lab space. Investment Income, Interest Interest Income Prepaid Insurance Prepaid insurance Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Cash and Cash Equivalent [Table] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring Basis Assets Measured on a Recurring Basis Common shares and warrants issued in s1 financing. Common Shares and Warrants Issued In S1 Financing Common shares and warrants issued in S-1 financing (in shares) Total Operating Lease, Liability Total Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued liabilities Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares - diluted Weighted average number of common shares outstanding used in the calculation of diluted loss per common share (in shares) Significant Accounting Policies [Text Block] Significant accounting policies Proceeds from issuance of common stock and warrants under S 1 filing. Proceeds From Issuance Of Common Stock and Warrants Under S 1 Filing Issuance of common shares and warrants under the S-1 Filing Lessee, Operating Lease, Renewal Term Lessee, Operating Lease, Renewal Term Deferred financing expenses. Deferred financing expenses Deferred financing expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Lessee, Operating Lease, Liability, to be Paid Total Entity Small Business Pre-Funded warrants exercised Pre-Funded Warrants exercised Pre-Funded warrants exercised. US Treasury Securities [Member] United States Treasury Bills [Member] Investments, Fair Value Disclosure, Total Investments, Fair Value Disclosure Short term investments Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Common shares issued upon redemption of restricted share units, shares Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Asset Class [Axis] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Additions to right-of-use assets Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent, Total Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Net income from continued operations Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Weighted-average remaining term - operating leases (years) Subsequent Events [Text Block] Subsequent events Financing costs including underwriting costs, professional fees and recognition of deferred financing costs. Financing Costs Including Underwriting Costs, Professional Fees and Recognition of Deferred Financing Costs Financing costs including underwriting costs, professional fees and recognition of deferred financing costs OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Unrealized (loss) gain on available-for-sale securities Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Share subscription advance under the 2023 CMPO Proceeds from stock subscription advance Proceeds from stock subscription advance. Negative working capital. Negative Working Capital Negative working capital Accrued liabilities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities, Total XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 08, 2024 Document Information [Line Items] A   Entity Central Index Key 0000882361 A   Entity Registrant Name APTOSE BIOSCIENCES INC. A   Amendment Flag false A   Current Fiscal Year End Date -12-31 A   Document Fiscal Period Focus Q3 A   Document Fiscal Year Focus 2024 A   Document Type 10-Q A   Document Quarterly Report true A   Document Period End Date Sep. 30, 2024 A   Document Transition Report false A   Securities Act File Number 1-32001 A   Entity Incorporation, State or Country Code Z4 A   Entity Tax Identification Number 98-1136802 A   Entity Address, Address Line One 66 Wellington Street West Suite 5300 A   Entity Address, Address Line Two TD Bank Tower Box 48 A   Entity Address, City or Town Toronto A   Entity Address, State or Province ON A   Entity Address, Postal Zip Code M5K 1E6 A   City Area Code 310 A   Local Phone Number 849-8060 A   Title of 12(b) Security Common Shares, no par value A   Trading Symbol APTO A   Security Exchange Name NASDAQ A   Entity Current Reporting Status Yes A   Entity Interactive Data Current Yes A   Entity Filer Category Non-accelerated Filer A   Entity Small Business true A   Entity Emerging Growth Company false A   Entity Shell Company false A   Entity Common Stock, Shares Outstanding A 19,521,183 X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei\_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei\_ Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei\_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei\_ Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details Name: dei DocumentInformationLineItems Namespace Prefix: dei\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei\_ Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a quarterly report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei DocumentTransitionReport Namespace Prefix: dei\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei DocumentType Namespace Prefix: dei\_ Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei\_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Address Line 2 such as Street or Suite number + References No definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei\_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei\_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei\_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei\_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei\_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei\_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityEmergingGrowthCompany Namespace Prefix: dei\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei EntityFileNumber Namespace Prefix: dei\_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityFilerCategory Namespace Prefix: dei\_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei\_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei EntityInteractiveDataCurrent Namespace Prefix: dei\_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityRegistrantName Namespace Prefix: dei\_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityShellCompany Namespace Prefix: dei\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntitySmallBusiness Namespace Prefix: dei\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityTaxIdentificationNumber Namespace Prefix: dei\_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - Definition Local phone number for entity. + References No definition available. + Details Name: dei LocalPhoneNumber Namespace Prefix: dei\_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Title of a 12(b) registered security. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei Security12bTitle Namespace Prefix: dei\_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - Definition Name of the Exchange on which a security is registered. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei SecurityExchangeName Namespace Prefix: dei\_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei TradingSymbol Namespace Prefix: dei\_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: A   Cash and cash equivalents \$ 7,962 \$ 9,252 Prepaid expenses 912 2,042 Other current assets 1,361 600 Total current assets 10,235 11,894 Non-current assets: A   Property and equipment 30 152 Right-of-use assets, operating leases 664 943 Total non-current assets 694 1,095 Total assets 10,929 12,989 Current liabilities: A   Accounts payable to related parties A   2,554 Accounts payable 1,830 3,492 Accrued liabilities 7,512 8,829 Current portion of lease liability, operating leases 416 394 Total current liabilities 9,758 15,269 Non-current liabilities: A   Lease liability, operating leases 305 621 Loan payable to related parties 10,000 A   Total non-current liabilities 10,305 621 Total liabilities 20,063 15,890 Shareholders' equity: A   Common shares, no par value, unlimited authorized shares, 19,521,183 and 7,942,363 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 452,302 444,806 Additional paid-in capital 82,262 72,146 Accumulated other comprehensive loss (4,316) (4,316) Deficit (539,382) (515,537) Total shareholders' equity (9,134) (2,901) Total liabilities and shareholders' equity \$ 10,929 \$ 12,989 X - Definition Accounts payable to related party current. + References No definition available. + Details Name: apto AccountsPayableToRelatedPartyCurrent Namespace Prefix: apto\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Loan payable to related parties, non-current. + References No definition available. + Details Name: apto LoanPayableToRelatedPartiesNonCurrent Namespace Prefix: apto\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type:





[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23):



Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business), + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap NonoperatingIncomeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap OperatingExpenses Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OperatingExpensesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747750/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB 700) (11.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units or other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionXML 14 RS.htm IDEA: XBRL DOCUMENT v.3.24.3 Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD (\$) in Thousands Total Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] 2023 Committed Equity Facility [Member] 2023 Committed Equity Facility [Member] Common Stock [Member] 2023 Committed Equity Facility [Member] Additional Paid-in Capital [Member] The 2022 ATM Offering [Member] The 2022 ATM Offering [Member] Common Stock [Member] The 2022 ATM Offering [Member] Additional Paid-in Capital [Member] Balance (in shares) at Dec. 31, 2022 6,158,000 Á Á Á Á Á Á Á Á Balance at Dec. 31, 2022 37,741 \$ 437,520 \$ 68,869 \$ (4,318) \$ (464,330) Á Á Á Á Common shares issued under the Hanmi Subscription Agreement (in shares) Á 668,000 Á Á Á Á Á Á Á Á Common shares issued under the Hanmi Subscription Agreement 3,000 \$ 3,000 Á Á Á Á Á Á Á Á Common shares issued in exchange for RSUs (in shares) Á 38,000 Á Á Á Á Á Á Á Á Common shares issued in exchange for RSUs Á 376 (376) Á Á Á Á Á Á Á Á Common shares issued under 2022 ATM/ 2023 Committed Equity Facility (in shares) Á Á Á Á Á Á Á Á 336,000 Á Á 337,000 Á Common shares issued under 2022 ATM/ 2023 Committed Equity Facility 1,185 \$ 1,185 Á Á Á Á Á Á 1,828 \$ 1,828 Á Stock-based compensation \$ 3,242 Á 3,242 Á Á Á Á Á Á Common shares issued under the ESPP plan (in shares) 5,991 6,000 Á Á Á Á Á Á Á Á Common shares issued under the ESPP plan \$ 29 \$ 29 Á Á Á Á Á Á Á Á Other comprehensive gain (loss) 3 Á 3 Á Á Á Á Net loss (39,252) Á Á (39,252) Á Á Á Á Balance (in shares) at Sep. 30, 2023 Á 7,543,000 Á Á Á Á Á Á Á Á Balance at Sep. 30, 2023 7,776 \$ 443,938 71,735 (4,315) (503,582) Á Á Á Á Á Á Balance (in shares) at Dec. 31, 2022 Á 6,158,000 Á Á Á Á Á Á Á Á Balance at Dec. 31, 2022 37,741 \$ 437,520 68,869 (4,318) (464,330) Á Á Á Á Balance (in shares) at Dec. 31, 2023 Á 7,942,000 Á Á Á Á Á Á Á Á Balance at Dec. 31, 2023 (2,901) \$ 444,806 72,146 (4,316) (515,537) Á Á Á Á Á Á Shares and warrants issued under the Registered Direct Offering (in shares) Á 3,195,000 Á Á Á Á Á Á Á Á Shares and warrants issued under the Registered Direct Offering 4,140 \$ 1,018 3,122 Á Á Á Á Common shares and warrants issued under the Hanmi Subscription Agreement (in shares) Á 2,105,000 Á Á Á Á Á Á Á Á Common shares and warrants issued under the Hanmi Subscription Agreement 3,702 \$ 2,043 1,659 Á Á Á Á Á Á Common shares and warrants issued in S-1 financing (in shares) Á 5,649,000 Á Á Á Á Á Á Á Á Common shares and warrants issued in S-1 financing 8,127 \$ 3,595 4,532 Á Á Á Á Á Á Common shares issued under 2022 ATM/ 2023 Committed Equity Facility (in shares) Á Á Á Á Á Á Á Á 520,000 Á Á 82,000 Á Common shares issued under 2022 ATM/ 2023 Committed Equity Facility Á Á Á Á Á Á Á Á 635 \$ 717 \$ (82) \$ (21) \$ 97 \$ (118) Stock-based compensation \$ 1,003 Á 1,003 Á Á Á Á Á Á Common shares issued under the ESPP plan (in shares) 27,681 28,000 Á Á Á Á Á Á Á Á Common shares issued under the ESPP plan \$ 26 \$ 26 Á Á Á Á Á Á Á Á Net loss (23,845) Á Á (23,845) Á Á Á Á Á Á Balance (in shares) at Sep. 30, 2024 Á 19,521,000 Á Á Á Á Á Á Á Á Balance at Sep. 30, 2024 \$ (9,134) \$ 452,302 \$ 82,262 \$ (4,316) \$ (539,382) Á Á Á Á Á Á X - DefinitionCommon shares and warrants issued in s1 financing. + ReferencesNo definition available. + Details Name: apto CommonSharesAndWarrantsIssuedInS1Financing Namespace Prefix: apto Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock and warrants issued during period shares registered direct offering. + ReferencesNo definition available. + Details Name: apto StockAndWarrantsIssuedDuringPeriodSharesRegisteredDirectOffering Namespace Prefix: apto Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionStock and warrants issued during period shares subscription agreement. + ReferencesNo definition available. + Details Name: apto StockAndWarrantsIssuedDuringPeriodSharesSubscriptionAgreement Namespace Prefix: apto Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionStock and warrants issued during period value registered direct offering. + ReferencesNo definition available. + Details Name: apto StockAndWarrantsIssuedDuringPeriodValueRegisteredDirectOffering Namespace Prefix: apto Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock and warrants issued during period value subscription agreement1. + ReferencesNo definition available. + Details Name: apto StockAndWarrantsIssuedDuringPeriodValueSubscriptionAgreement1 Namespace Prefix: apto Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period shares subscription agreement. + ReferencesNo definition available. + Details Name: apto StockIssuedDuringPeriodSharesSubscriptionAgreement Namespace Prefix: apto Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI



Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD (\$) \$ in Thousands 3 Months Ended 5 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 May 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Cash flows used in operating activities: \$ 1,447,000 \$ (6,953) \$ (11,447) \$ (23,845) \$ (39,252) \$ Items not involving cash: \$ 1,447,000 \$ 1,447,000 \$ Stock-based compensation (13) 599 \$ 1,003 3,242 \$ Depreciation and amortization 4 20 \$ 28 70 \$ Loss on disposal of property and equipment 0 0 \$ 76 0 \$ Amortization of right-of-use assets 92 91 \$ 279 286 \$ Interest on lease liabilities 15 23 \$ 52 73 \$ Unrealized (gain)/loss on short-term investment 0 (1) \$ 0 (3) \$ Accrued interest on investments 0 (44) \$ 0 (56) \$ Changes in non-cash operating assets and liabilities: \$ 1,447,000 \$ 1,447,000 \$ Prepaid expenses 324 29 \$ 1,130 646 \$ Other current assets (768) (44) \$ (761) (4) \$ Operating lease liabilities (112) (117) \$ (346) (290) \$ Accounts payable to related parties 0 0 \$ (2,554) 0 \$ Accounts payable (5,281) (690) \$ (1,662) (3,515) \$ Accrued liabilities 2,316 1,045 \$ (1,317) 3,472 \$ Cash used in operating activities (10,376) (10,536) \$ (27,917) (35,331) \$ Cash flows from financing activities: \$ 1,447,000 \$ 1,447,000 \$ Proceeds from loan payable to related parties 10,000 0 \$ 10,000 0 \$ Issuances of common shares and warrants under the Registered Direct Offering 0 0 \$ 4,140 0 \$ Issuance of common shares and warrants under the S-1 Filing 0 0 \$ 8,127 0 \$ Shares issuances to Hamni under subscription agreement 0 3,000 \$ 3,702 3,000 \$ Cost of offering 0 (5) \$ (177) (10) \$ Issuance of common shares under the ESPP plan 8 13 \$ 26 29 \$ Cash from financing activities 10,008 4,902 \$ 26,609 6,056 \$ Cash flows from/(used in) investing activities: \$ 1,447,000 \$ 1,447,000 \$ Disposal/(purchase) of property and equipment, net 0 0 \$ 18 (29) \$ Maturity/(acquisition) of investments, net 0 12,953 \$ 0 8,051 \$ Cash from/(used in) investing activities 0 12,953 \$ 18 8,022 \$ Effect of exchange rate fluctuations on cash and cash equivalents 0 1 \$ 0 3 \$ Increase/(decrease) in cash and cash equivalents (368) 7,320 \$ (1,290) (21,250) \$ Cash and cash equivalents, beginning of period 8,330 8,400 \$ 9,252 36,970 \$ 36,970 Cash and cash equivalents, end of period 7,962 15,720 \$ 7,962 15,720 \$ 9,252 The 2023 CMPO 0 50 \$ 0 50 \$ The 2022 ATM Offering [Member] \$ 1,447,000 \$ 1,447,000 \$ Cash flows from financing activities: \$ 1,447,000 \$ 1,447,000 \$ Issuance of common shares 0 1,150 \$ 694 1,150 \$ Share subscription advance under the 2023 CMPO 0 50 \$ 0 50 \$ X - DefinitionCost of offering. + ReferencesNo definition available. + Details Name: apto CostOffering Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionIncrease decrease in accounts payable excluding related parties. + ReferencesNo definition available. + Details Name: apto IncreaseDecreaseInAccountsPayableExcludingRelatedParties Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe amount of accrual of interest on investments. + ReferencesNo definition available. + Details Name: apto InterestAccruedOnInvestments Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe amount of interest expense related to lease liabilities + ReferencesNo definition available. + Details Name: apto InterestOnLeaseLiabilities Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock and warrants under registered direct offering. + ReferencesNo definition available. + Details Name: apto ProceedsFromIssuanceOfCommonStockAndWarrantsUnderRegisteredDirectOffering Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock and warrants under S 1 filing. + ReferencesNo definition available. + Details Name: apto ProceedsFromIssuanceOfCommonStockAndWarrantsUnderS1Filing Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionProceeds from stock subscription advance. + ReferencesNo definition available. + Details Name: apto ProceedsFromStockSubscriptionAdvance Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionShares issuances to Hamni. + ReferencesNo definition available. + Details Name: apto SharesIssuancesToHamni Namespace Prefix: apto Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap DepreciationDepletionAndAmortization Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsPayableRelatedParties Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 640 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic



https://asc.fasb.org/1943274/2147482740/230-10-45-28References: asc. http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17.R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual A Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd\_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd\_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd\_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd\_Rule10b51ArrTrmtdFlag Namespace Prefix: ecd\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd\_TradingArrByIndTable Namespace Prefix: ecd\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18.R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Reporting Entity 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Reporting entity 1.Reporting entity:Apotse Biosciences Inc. (â€œApotse,â€ â€œthe Company,â€ â€œwe,â€ â€œus,â€ or â€œourâ€) is a science-driven, clinical-stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company's executive offices are located in San Diego, California, and our head office address has been changed to 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, Ontario, Canada.We are advancing targeted agents to treat life-threatening hematologic cancers that, in most cases, are not elective for patients and require immediate treatment. We have two clinical-stage investigational products for hematological malignancies: tuspetinib, an oral, potent myeloid kinase inhibitor, and lutexptinib, an oral, dual lymphoid and myeloid kinase inhibitor.Since our inception, we have financed our operations and technology acquisitions primarily from equity financing, proceeds from the exercise of warrants and stock options, and interest income on funds held for future investment. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, licensing fees, drug manufacturing costs, laboratory supplies and materials, and professional fees.Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing will be necessary. We plan to raise additional funds to fund our business operations but there is no assurance that such additional funds will be available for us to finance our operations on acceptable terms, if at all. The Company's current cash and cash equivalents are projected to support operations through January 2025. We have based these estimates on assumptions and plans, which may change and which could impact the magnitude and/or timing of operating expenses and our cash runway, See Note 2(a).Our ability to raise additional funds has been affected by adverse market conditions, the status of our product pipeline, possible delays in enrollment in our trial, and various other factors and we may be unable to raise capital when needed, or on terms favorable to us. The raising of additional capital, and/or the trade sale of some of the Company's operations to make bulk payments to repay accounts payable, if successful, would potentially alleviate any significant doubt on the Company's ability to continue as a going concern. In the event that debt and/or capital financing is unable to be secured or contemplated trade sale fail to materialize, the Company may need to resolve to other means of protecting its assets in the best interests of its shareholders, including foreclosure or forced liquidation and/or seeking creditors' protection. We do not expect to generate positive cash flow from operations for the foreseeable future due to the early stage of our clinical trials. It is expected that negative cash flow will continue until such time, if ever, that we receive regulatory approval to commercialize any of our products under development and/or royalty or milestone revenue from any such products exceeds expenses.The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the use of the going concern assumption on which these unaudited condensed interim consolidated financial statements are prepared may not be appropriate based on the factors described in Note 2(a). Management recognizes that in order to meet the capital requirements, and continue to operate, additional financing will be necessary. The Company plans to raise additional funds to fund our business operations through equity financing under other financing activities, as further described in Note 10 and Note 12. Management continues considering other options for raising capital including debt, equity, collaborations, and reorganization to reduce operational expenses. However, given the decrease in the share price, difficulty for micro-cap market capitalization companies to raise significant capital and the matters in Note 10, Share capital, that may impact the Company's ability to raise significant financing in the capital markets, the Company may be unable to access financing when needed. As such, there can be no assurance that the Company will be able to obtain additional liquidity when needed or under acceptable terms, if at all. These conditions raise substantial doubt about the Company's ability to continue as a going concern, see Note 2(a). The financial statements do not include any adjustments that might result from the outcome of this uncertainty. On May 23, 2023, during the Apotse Annual and Special Meeting of Shareholders, our shareholders voted to approve special resolutions providing for an amendment to our articles of incorporation to effect a reverse share split of our outstanding Common Shares, at a ratio in the range of 1-for-10 to 1-for-20. Our Board of Directors then approved a ratio of 1-for-15 on May 23, 2023. On May 24, 2023, we filed articles of amendment under the Canada Business Corporations Act to give effect to the reverse stock split (consolidation) of our Common Shares on the basis of one post-consolidation Common Share for each 15 pre-consolidation Common Shares (the "Reverse Stock Split"). The Common Shares commenced trading on a post-Reverse Stock Split basis at market open on Tuesday, June 6, 2023. All references in this report to historical Common Share prices, numbers of Common Shares, and earnings per share calculations have been presented to reflect the effect of the Reverse Stock Split. X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19.R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes To Financial Statements [Abstract] A Significant accounting policies 2.Significant accounting policies:a.Basis of presentation - Going concernThese unaudited condensed consolidated interim financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC, related to quarterly reports filed on Form 10-Q, assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and discharge of liabilities in the normal course of operations as they come due. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting year. The Company is in substantial doubt to continue as a going concern; As of September 30, 2024, the Company had negative shareholder's equity of \$9.1 million (December 31, 2023 negative shareholder's equity of \$2.9 million); an accumulated deficit of approximately \$539.4 million (December 31, 2023, \$515.5 million); during the nine months period ended September 30, 2024, the Company incurred a net loss of \$23.8 million (2023 - \$39.3 million) and as of September 30, 2024 we had a working capital of approximately \$477 thousand (December 31, 2023, negative working capital of \$3.4 million), including approximately \$8 million (December 31, 2023, \$9.3 million) in cash and cash equivalent balance, and current liabilities of approximately \$9.8 million (December 31, 2023, \$15.3 million). The Company faces increasingly challenging financial and business conditions, including an inability to raise sufficient equity and equity-linked financing to fully fund execution of its business plans and to satisfy its \$2.5 million Nasdaq shareholder's equity requirement. The Company has financed its activities to date through the issuance of Common Shares and continues to seek capital through various means including the issuance of equity and/or debt. During this year to September 30, 2024, the Company has explored numerous alternatives to ensure the funding of the Company's clinical trials, services and repay its outstanding vendors and increase its equity level, which level has resulted in a major hurdle for the Company to secure required financing.Management recognizes that in order to meet the capital requirements, and continue to operate, additional financing will be necessary. The Company is evaluating strategies to obtain the required additional funding for future operations. These strategies may include, but are not limited to, obtaining equity financing, debt financing, committed equity facilities or other financing instruments and restructuring of operations to decrease expenses. However, given the impact of the volatile financial markets on micro-cap market capitalization companies such as the Company and the matter in Note 10, Share capital and 12, Subsequent events, the Company may be unable to access further equity when needed. As the Company is primarily pursuing one compound that is licensed from a related party with significant licensing payments who will have influence on the Company, other investors may not be willing to invest in the Company. As such, there can be no assurance that the Company will be able to obtain additional liquidity when needed or under acceptable terms, if at all. The Company's current cash and cash equivalents are projected to support operations through January 2025. We have based these estimates on assumptions and plans, which may change and which could impact the magnitude and/or timing of operating expenses and our cash runway. The unaudited condensed consolidated interim financial statements do not reflect any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern. Such adjustments could be material.b.Basis of consolidation:These condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions, balances, revenue, and expenses are eliminated on consolidation. c.Significant accounting policies, estimates and judgments: During the nine months ended September 30, 2024, there have been no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024. The preparation of the unaudited condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the unaudited condensed consolidated interim financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The unaudited condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the unaudited condensed consolidated interim financial statements and may require accounting adjustments based on future occurrences. The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected. d.Recent Accounting Pronouncements We have adopted no new accounting pronouncements during the three months and nine months ended September 30, 2024. There were various accounting standards and interpretations issued recently, none of which are expected to have a material impact on our financial position, operations or cash flows. e.Foreign currency: The functional and presentation currency of the Company is the US dollar. f.Concentration of risk: The Company is subject to credit risk from the Company's cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1â€low or Aâ€low investments and the Company invests only in highly rated corporations and treasury bills, which are capable of prompt liquidation. X - DefinitionNotes To Financial Statements Abstract + ReferencesNo definition available. + Details Name: apto\_NotesToFinancialStatementsAbstract Namespace Prefix: apto\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20.R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Cash and Cash Equivalents 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Cash and cash equivalents 3.Cash and cash equivalents:Cash and cash equivalents as of September 30, 2024, consist of restricted cash of \$1,416 thousand (December 31, 2023 â€\$2,764 thousand) and of restricted deposits in high interest savings accounts, money market funds and accounts with maturities of less than 90 days totaling of \$6,546 thousand (December 31, 2023 â€\$6,488 thousand). On August 27, 2024, the Company received \$10 million from a loan payable to a third party. Under the terms of the loan agreement (the "Hanmi Loan Agreement"), the proceeds of \$10 million are restricted for use solely in connection of Tuspetinib related business operations, unless otherwise authorized by the related party. See Note 9, Related party transactions. X - DefinitionThe entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap CashAndCashEquivalentsDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21.R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Prepaid Expenses 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Prepaid expenses 4.Prepaid expenses:Prepaid expenses as of September 30, 2024 and December 31, 2023 are shown below. Other prepaid expenses primarily consist of subscriptions, software, conference deposits and deposits for general and administrative items. A A September 30, A A December 31, A A 2024 A A 2023 A Prepaid research and development expenses A \$ 662 A A \$ 720 A Prepaid insurance A 71 A A 882 A Other prepaid operating expenses A 179 A A 440 A Total A \$ 912 A A \$ 2,042 A X - DefinitionThe entire disclosure of the amounts paid in advance during the operating period. + ReferencesNo definition available. + Details Name: apto\_PrepaidExpensesTextBlock Namespace Prefix: apto\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22.R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Right-of-use Assets 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Right-of-use assets 5.Right-of-use assets: A A September 30, A A December 31, A A 2024 A A 2023 A Right-of-use assets, beginning of period A \$ 3,124 A A \$ 3,100 A Additions to right-of-use assets A â€ A A 24 A Right-of-use assets, end of period A 3,124 A A 3,124 A Accumulated amortization A (2,460 ) A (2,181 ) Right-of-use assets, NBV A \$ 664 A X - DefinitionThe entire disclosure



compliance with the Minimum Bid Price Requirement. If at any time before January 13, 2025, the bid price of the Company's Common Shares closes at \$1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance with the Minimum Bid Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by January 13, 2025, the Company may, at Nasdaq's discretion, be afforded a second 180 calendar day period to regain compliance, but if Nasdaq does not grant such extension, the Company's common shares could be delisted from Nasdaq. To qualify for the extension, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement. The Company intends to monitor the closing bid price of its Common Shares and may, if appropriate, consider available options, including the possibility of seeking shareholder approval of a reverse stock split, to regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules. As of September 30, 2024, the Company had not gained compliance with the requirement. The Company's stockholder's equity as of September 30, 2024 was negative \$9.1 million. On October 1, 2024, the Company received a staff determination letter from the Listing Department stating that the Company did not meet the terms of the extension because it did not complete its proposed financing initiatives to regain compliance. On October 8, 2024, the Company requested an appeal and hearing; such hearing is scheduled for November 21, 2024. The hearing request has automatically stayed Nasdaq's delisting of the Company's Common Shares pending the Panel's decision. At or prior to the hearing, the Company plans to present to Nasdaq information demonstrating that it has regained compliance with the continued listing standards under the Nasdaq Listing Rules, or alternatively a plan to regain compliance and a request for an extension of time to effectuate the plan. Notwithstanding the foregoing, there can be no assurance that the Company will regain compliance with the continued listing standards under the Nasdaq Listing Rules, or that the Panel will grant the Company an extension of time to regain compliance, in the event the Company requests such an extension. On October 30, 2024, the Company filed Amendment 1 to this S-1, see note 12, Subsequent Events. The Company has authorized share capital of an unlimited number of Common Shares. Equity issuances: (i) June 2024 Registered Direct Offering On June 3, 2024, the Company closed a registered direct offering priced at-the-market under Nasdaq rules of 1,800,000 Common Shares at a purchase price of \$1.15 per share and 2,055,000 pre-funded warrants at a purchase price of \$1.149 per pre-funded warrant. Additionally, in a concurrent private placement, Aptose issued unregistered series A warrants to purchase up to 3,855,000 Common Shares and series B warrants to purchase up to 3,855,000 Common Shares, each at an exercise price of \$1.15 per share. The series A and series B unregistered warrants became exercisable beginning on the effective date of shareholder approval of the issuance of the shares issuable upon exercise of the warrants which was obtained on September 5, 2024. The series A warrants will expire five years from September 5, 2024 and the series B warrants will expire eighteen months from September 5, 2024. The gross proceeds to the Company from the offering was approximately \$4.43 million, before deducting the placement agent's fees and other offering expenses. Financing costs of approximately \$408 thousand included underwriting costs of 7% and professional fees. In addition, the underwriter received 192,750 warrants, each at an exercise price of \$1.44. The unregistered warrants are exercisable on September 5, 2024 and will expire five years from September 5, 2024. On September 5, 2024, the Company held a Special Meeting of Shareholders pursuant to which, shareholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Common Shares underlying certain warrants in an amount equal to or in excess of 20% of the Common Shares outstanding immediately prior to the issuance of such warrants issued pursuant to that certain securities purchase agreement dated as of May 30, 2024 by and among the Company and certain institutional and accredited investors in connection with the Company's registered direct offering and private placement which closed on June 3, 2024. On September 11, 2024, the Company issued 1,395,000 Common Shares upon the exercise of 1,395,000 Pre-Funded Warrants for a cash proceeds of \$1 thousand at an exercise price of \$0.001. (ii) January 2024 Public Offering and Private Placement On January 31, 2024, the Company announced the closing of a \$9.7 million public offering (the "Public Offering") and a \$4 million private placement (the "Private Placement") with Hammi. The Public Offering comprised 5,649,122 Common Shares and warrants at a combined offering price of \$1.71. This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. The Private Placement comprised 2,105,263 Common Shares sold at a price of \$1.90, representing an 11% premium over the price of the Common Shares issued as part of the Public Offering. Nasdaq subsequently issued a letter to the Company regarding the value and the date of the Private Placement, as discussed in this note, below. Financing costs of approximately \$1.4 million included underwriting costs of 7% and approximately \$0.4 million in professional fees. The Company also issued Hammi warrants to purchase Common Shares at an exercise price of \$1.71 per Share. On February 29, 2024, the Company received a deficiency letter (the "February Deficiency Letter") from the Nasdaq Listing Qualifications Department of Nasdaq notifying the Company that the Company's Private Placement violated Nasdaq Listing Rule 5635(d) because the Company did not obtain shareholder approval prior to such issuance. Nasdaq stated that the Private Placement involved the issuance of greater than 20% of the issued and outstanding Common Shares of the Company at a discount to the Nasdaq official closing price on January 25, 2024, the date of the subscription agreement between the Company and Hammi. The February Deficiency Letter had no immediate effect on the listing of the Company's Common Shares. In accordance with the Nasdaq Listing Rules, the Company was given 45 calendar days to submit a plan to regain compliance. The approval of the potential issuance of Common Shares in connection with the Hammi investment, which would exceed 19.99% of the Corporation's outstanding shares as of the closing date of the Hammi investment, as required by Nasdaq listing rules, was approved at the June 2024 Annual and General meeting. In response to a Deficiency Letter from Nasdaq received on February 29, 2024 regarding the private placement with Hammi and the resulting claimed violation of Nasdaq Listing Rule 5635(d), the Company submitted a plan to regain compliance on April 15, 2024. On April 25, 2024, the Company received a letter from the Listing Qualifications Department (the "Staff") of Nasdaq notifying the Company of the Staff's determination that the Company had regained compliance with Nasdaq Listing Rule 5635(d) and the Staff has determined that the matter is now closed. Pursuant to the Company's plan to regain compliance, on April 26, 2024, the Company announced that it had amended the warrant agreement with Hammi to prohibit the exercise of the Hammi warrants in excess of the Nasdaq 19.99% limitation (the "Nasdaq 19.99% Cap"), unless shareholder approval is first obtained to exceed the Nasdaq 19.99% Cap. (iii) Hammi 2023 Investment On August 10, 2023, the Company entered into a binding term sheet with Hammi whereby Hammi agreed at their sole discretion to invest, up to a maximum of \$7 million in Aptose up to a total ownership of 19.99% of Aptose by Hammi. On September 6, 2023, the Company entered into a subscription agreement with Hammi, pursuant to which the Corporation agreed to sell 668,449 Common Shares to Hammi for proceeds of \$3 million. Hammi held 2,989,415 Common Shares of Aptose as of September 30, 2024. (iv) 2023 Committed Equity Facility On May 25, 2023, the Company and Keystone Capital Partners, LLC ("Keystone") entered into a committed equity facility, (the "2023 Committed Equity Facility"), which provides that subject to the terms and conditions set forth therein, we may sell to Keystone up to the lesser of (i) \$25.0 million of the Common Shares and (ii) a number of Common Shares equal to 19.99% of the Common Shares outstanding immediately prior to the execution of the 2023 Committed Equity Facility Agreement, with Keystone which respect to the 2023 Committed Equity Facility (subject to certain exceptions) (the "Total Commitment"), from time to time during the 24-month term of the 2023 Committed Equity Facility. Additionally, on May 25, 2023, the Company entered into a Registration Rights Agreement with Keystone, pursuant to which the Company agreed to file a registration statement with the SEC covering the resale of Common Shares that are issued to Keystone under the 2023 Committed Equity Facility. This registration statement became effective on June 30, 2023 and the 2023 Committed Equity Facility commencement date was July 12, 2023 (the "Commencement Date"). Upon entering into the 2023 Committed Equity Facility, the Company agreed to issue to Keystone an aggregate of 25,156 Common Shares (the "Commitment Shares") as consideration for Keystone's commitment to purchase Common Shares upon the Company's direction under the 2023 Committed Equity Facility. The Company issued 7,547 Common Shares, or 30% of the Commitment Shares, on the date of the 2023 Committed Equity Facility Agreement. An additional 7,547 Common Shares, or 30% of the Commitment Shares, were issued to Keystone in October 2023. In the nine months ended September 30, 2024, the Company's issuance of Common Shares to Keystone consisted of 10,062 Commitment Shares. In the year ended December 31, 2023, the Company's issuance of Common Shares to Keystone comprised 720,494 Common shares sold to Keystone at an average price of \$2.91 per Common share for cash proceeds of \$2.1 million and 15,094 Commitment Shares. During the nine months ended September 30, 2024, the Company issued 510,101 Common Shares to Keystone at an average price of \$1.36 per Common Share for cash proceeds of \$694 thousand and 10,062 Commitment Shares. The Company recognized \$82 thousand of financing costs associated with professional fees during the nine months ended September 30, 2024. Since inception to April 2024, the time the Committed Equity Facility was terminated, the Company's issuance of Common Shares to Keystone comprised of an aggregate of 1,230,595 Common Shares at an average price of \$2.27 per Common Share for aggregate gross cash proceeds of \$2.8 million and 25,156 Commitment Shares. From inception to the termination of the Committed Equity Facility, the Company recognized \$168 thousand of financing costs associated with professional fees. In April 2024, the Company's issuances of Common Shares to Keystone reached the Total Commitment of the Committed Equity Facility, i.e. 19.99% of the Common Shares outstanding immediately prior to the execution of the 2023 Committed Equity Facility Agreement. (v) 2022 At-The-Market Facility ("ATM") On December 9, 2022, the Company entered into an equity distribution agreement pursuant to which the Company may, from time to time, sell Common Shares having an aggregate offering value of up to \$50 million through Jones Trading Institutional Services LLC ("Jones Trading") on Nasdaq (the "2022 ATM Facility"). During the current year up to May 30, 2024, the date on which the Company terminated the 2022 ATM Facility, the Company issued 81,591 Common Shares under this 2022 ATM Facility at an average price of \$1.22 per share for gross proceeds of \$100 thousand (\$97 thousand net of share issuance costs). On May 30, 2024, the Company terminated the 2022 At-The-Market Facility. Since inception to May 30, 2024, the date the Company terminated the 2022 ATM Facility, the Company raised a total of \$2.1 million of gross proceeds (\$2.0 million net of share issuance costs) under the 2022 ATM Facility. Costs associated with the proceeds consisted of a 3% cash commission. b. Loss per share: Loss per share is calculated using the weighted average number of Common Shares outstanding and is presented in the table below: A Three months ended September 30, A Nine months ended September 30, A A 2024 A A 2023 A A 2024 A A 2023 A Net loss A \$ (6,953) A \$ (11,447) A \$ (23,845) A \$ (39,252) Weighted-average common shares A basic and A diluted (in thousands) A 18,560 A A 6,495 A A 16,107 A A 6,391 A Net loss per share A basic and diluted A \$ (0.37) A \$ (1.76) A \$ (1.48) A \$ (6.14) A The effects of any potential exercise of the Company's stock options outstanding during the three-month and nine-month periods ended September 30, 2024, and September 30, 2023 have been excluded from the calculation of diluted loss per share, since such securities would be anti-dilutive. X - References No definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for equity. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/214747968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/214747968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/214747968/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.4-08\(e\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-50-599-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Stock-based Compensation 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Stock-based compensation 11. Stock-based compensation: All references in this report to historical Common Share prices, numbers of Common Shares, and earnings per share calculations have been presented to reflect the effect of the Reverse Stock Split. A Stock option plan and employee stock purchase plan Effective June 1, 2021, the Company adopted a new stock incentive plan (the "New Incentive Plan") and an employee stock purchase plan (the "ESPP"). The New Incentive Plan authorizes the Board of Directors to administer the New Incentive Plan to provide equity-based compensation in the form of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalents. The Corporation currently maintains its existing share option plan ("Share Option Plan") and 2015 Stock Incentive Plan ("2015 SIP"). Effective June 1, 2021 no further grants will be made under the Share Option Plan or 2015 SIP, though existing grants under the Share Option Plan will remain in effect in accordance with their terms. The aggregate number of our Common Shares, no par value, that may be issued under all awards under the New Incentive Plan is (i) 691,400, plus (ii) any of our Common Shares subject to any outstanding award under our prior plans that, after June 1, 2021, are not purchased or are forfeited or reacquired by us, or otherwise not delivered to the participant due to termination, cancellation or cash settlement of such award subject to the share counting provisions of the New Incentive Plan. Under both the Share Option Plan and the New Incentive Plan, the exercise price of each option equals the closing trading price of the Company's stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no greater than ten years from the date of grant. The Company uses the fair value-based method of accounting for employee awards granted under both plans. The Company calculates the fair value of each stock option grant using the Black-Scholes option pricing model at the grant date. The stock-based compensation cost of the options is recognized as stock-based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. The ESPP, which is administered by the Board of Directors, allows eligible employees of the Company to purchase Common Shares through accumulated payroll deductions up to a maximum 15% of eligible compensation. The ESPP is implemented in consecutive offering periods with a new offering period commencing on the first trading day on or after February 1 and August 1 each year, or on such other date as the Board of Directors will determine and continuing thereafter until terminated in accordance with the Plan. Unless the Board of Directors provides otherwise, the purchase price will be equal to eighty-five percent (85%) of the fair market value of a Common Share on the offering date or the exercise date, whichever is lower. The maximum number of Common Shares which will be available for sale under





Balance Type: credit Period Type: instant X - DefinitionNegative working capital. + ReferencesNo definition available. + Details Name: apto\_NegativeWorkingCapital Namespace Prefix: apto\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWorking capital. + ReferencesNo definition available. + Details Name: apto\_WorkingCapital Namespace Prefix: apto\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_AccountingPoliciesAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1:

S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/214747796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/214747796/946-210-45-20 + Details Name: us-gaap\_Cash Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap\_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap\_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap\_TypeOfArrangementAxis=apto\_HanmilLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 -Prepaid Expenses -Prepaid Expenses and Other Assets (Details) -USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Prepaid Expense and Other Assets [Abstract] Å Prepaid research and development expenses \$ 662 \$ 720 Prepaid insurance 71 882 Other prepaid Operating expenses 179 440 Total \$ 912 \$ 2,042 X - DefinitionAmount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: apto\_PrepaidResearchAndDevelopment Namespace Prefix: apto\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap\_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_PrepaidExpenseAndOtherAssetsAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap\_PrepaidExpenseCurrent Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap\_PrepaidInsurance Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 -Right-of-use Assets -Schedule of Right-of-use Assets (Details) -USD (\$) \$ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Assets and Liabilities, Lessee [Abstract] Å A Right-of-use assets, beginning of period \$ 3,124 \$ 3,100 Additions to right-of-use assets 0 24 Right-of-use assets, end of period 3,124 3,124 Accumulated amortization (2,460) (2,181) Right-of-use assets, NBV \$ 664 \$ 943 X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of right-of-use assets over their estimated remaining economic lives. + ReferencesNo definition available. + Details Name: apto\_AmortizationOfRightOfUseAssets Namespace Prefix: apto\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease before amortization, depreciation, and depletion. + ReferencesNo definition available. + Details Name: apto\_OperatingLeaseRightOfUseAssetGross Namespace Prefix: apto\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_AssetsAndLiabilitiesLesseeAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap\_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap\_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 -Fair Value Measurements and Financial Instruments -Assets Measured on a Recurring Basis (Details) -USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets, Fair Value Disclosure \$ 6,546 \$ 6,488 Level 1 [Member] Å A Assets, Fair Value Disclosure 0 0 Level 2 [Member] Å A Assets, Fair Value Disclosure 6,546 6,488 Level 3 [Member] Å A Assets, Fair Value Disclosure 0 0 High Interest Savings Account [Member] Å A Assets, Fair Value Disclosure 6,546 2,002 High Interest Savings Account [Member] | Level 1 [Member] Å A Assets, Fair Value Disclosure 0 0 High Interest Savings Account [Member] | Level 2 [Member] Å A Assets, Fair Value Disclosure 6,546 2,002 High Interest Savings Account [Member] | Level 3 [Member] Å A Assets, Fair Value Disclosure \$ 0 0 United States Treasury Bills [Member] | Level 2 [Member] Å A Assets, Fair Value Disclosure 4,486 United States Treasury Bills [Member] | Level 1 [Member] Å A Assets, Fair Value Disclosure 4 0 United States Treasury Bills [Member] | Level 2 [Member] Å A Assets, Fair Value Disclosure 4,486 United States Treasury Bills [Member] | Level 3 [Member] Å A Assets, Fair Value Disclosure \$ 0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap\_AssetsFairValueDisclosure Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap\_FairValueByFairValueHierarchyLevelAxis=us-gaap\_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_FairValueByFairValueHierarchyLevelAxis=us-gaap\_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_FairValueByFairValueHierarchyLevelAxis=us-gaap\_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_FairValueByAssetClassAxis=us-gaap\_BankTimeDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_FairValueByAssetClassAxis=us-gaap\_UTResuritiesSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 -Accrued Liabilities -Accrued Expenses (Details) -USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Liabilities, Current [Abstract] Å A Accrued personnel related costs \$ 876 \$ 1,989 Accrued research and development expenses 6,466 6,527 Other accrued expenses 170 313 Total \$ 7,512 \$ 8,829 X - DefinitionAccrued liabilities current net. + ReferencesNo definition available. + Details Name: apto\_AccruedLiabilitiesCurrentNet Namespace Prefix: apto\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of research and development liabilities classified as current. + ReferencesNo definition available. + Details Name: apto\_ResearchAndDevelopmentLiabilitiesCurrent Namespace Prefix: apto\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 -Lease Liability -Schedule of Minimum Payments Under Operating Leases (Details) \$ in Thousands Sep. 30, 2024 USD (\$) 2024 \$ 113 2025 462 2026 197 Total \$ 772 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap\_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap\_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap\_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap\_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 -Lease Liability -Lease Liability (Details) -USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Weighted-average remaining term - operating leases (years) 1 year 8 months 12 days 2 years 4 months 24 days Weighted-average discount rate - operating leases 7.90% 7.38% Lease liability, current portion \$ 416 \$ 394 Lease liability, long term portion 305 621 Total \$ 721 \$ 1,015 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap\_OperatingLeaseLiability Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap\_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap\_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap\_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI











service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1:

gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-  
types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1:

















"span": "p", "ix: continuation": "div", "body": "html", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R40": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalLossPerShareDetails", "longName": "995785 - Disclosure - Note 10 - Share Capital - Loss Per Share (Details)", "shortName": "Note 10 - Share Capital - Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C\_37182105-47b2-4b36-b277-a640c5709ff1", "name": "us-gaap:NetIncomeLoss", "unitRef": "U\_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "longName": "995795 - Disclosure - Note 11 - Stock-based Compensation (Details Textual)", "shortName": "Note 11 - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C\_db352f1f-00ea-49a9-8243-fa93e71448f4", "name": "us-gaap:CommonStockNoParValue", "unitRef": "U\_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": null, "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C\_09496e85-a659-46ac-974c-f94b96fb285e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R42": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "longName": "995805 - Disclosure - Note 11 - Stock-based Compensation - Stock Option Transactions (Details)", "shortName": "Note 11 - Stock-based Compensation - Stock Option Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C\_58610393-2382-4ffd-bb1a-9ed7583bdd3c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U\_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R43": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationWeightedAverageAssumptionsDetails", "longName": "995815 - Disclosure - Note 11 - Stock-based Compensation - Weighted Average Assumptions (Details)", "shortName": "Note 11 - Stock-based Compensation - Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C\_09496e85-a659-46ac-974c-f94b96fb285e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U\_pure", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R44": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetails", "longName": "995825 - Disclosure - Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details)", "shortName": "Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C\_09496e85-a659-46ac-974c-f94b96fb285e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U\_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R45": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParenteticals", "longName": "995835 - Disclosure - Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parenteticals)", "shortName": "Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parenteticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parentetical", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C\_c71656a8-1f7e-43bc-89b1-afc2c632a535", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsPercentage", "unitRef": "U\_pure", "xsiNil": "false", "lang": null, "decimals": "-2", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R46": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRSUsGrantedDetails", "longName": "995845 - Disclosure - Note 11 - Stock-based Compensation - Vesting and Redemption of the RSUs Granted (Details)", "shortName": "Note 11 - Stock-based Compensation - Vesting and Redemption of the RSUs Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C\_09496e85-a659-46ac-974c-f94b96fb285e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "U\_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R47": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationSharebasedPaymentExpenseDetails", "longName": "995855 - Disclosure - Note 11 - Stock-based Compensation - Share-based Payment Expense (Details)", "shortName": "Note 11 - Stock-based Compensation - Share-based Payment Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C\_37182105-47b2-4b36-b277-a640c5709ff1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U\_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "R48": { "role": "http://www.apto.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails", "longName": "995865 - Disclosure - Note 12 - Subsequent Events - Additional Information (Details)", "shortName": "Note 12 - Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C\_fc77db84-4751-42a4-ad3f-9878b32e1f16", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U\_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "uniqueAnchor": { "contextRef": "C\_46447f00-2467-4925-b624-5abde82ce6b8", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "apto-20240930.htm", "unique": true }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "label": "Accounting Policies [Abstract]" } }, "auth\_ref": { "r32": "r32", "r34": "r34", "r38": "r38" } }, "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": { "http://www.apto.com/20240930/taxonomy/role/DisclosureNote7AccruedLiabilities": { "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } }, "auth\_ref": { "r32": "r32", "r34": "r34", "r38": "r38" } }, "us-gaap:AccountsPayableCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": { "http://www.apto.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual": { "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Accounts payable", "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } }, "auth\_ref": { "r32": "r32", "r523": "r523" } }, "apto:AccountsPayableToRelatedPartyCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://www.apto.com/20240930", "localname": "AccountsPayableToRelatedPartyCurrent", "crdr": "credit", "presentation": { "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-current-period-unaudited": { "lang": { "en-us": { "role": { "documentation": "Accounts payable to related party current", "label": "Accounts payable to related party current", "terseLabel": "Accounts payable to related parties" } }, "auth\_ref": { "us-gaap:AccruedLiabilitiesCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.apto.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual": { "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-current-period-unaudited": { "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } }, "auth\_ref": { "r34": "r34" } }, "us-gaap:AccruedLiabilitiesCurrentAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": { "http://www.apto.com/20240930/taxonomy/role/DisclosureNote7AccruedLiabilitiesTables": { "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } }, "auth\_ref": { "apto:AccruedLiabilitiesCurrentNet": { "xbrlType": "monetaryItemType", "nsuri": "http://www.apto.com/20240930", "localname": "AccruedLiabilitiesCurrentNet", "crdr": "credit", "presentation": { "http://www.apto.com/20240930/taxonomy/role/DisclosureNote7AccruedLiabilitiesAccruedExpensesDetails": { "lang": { "en-us": { "role": { "documentation": "Accrued liabilities current net", "label": "Accrued Liabilities Current Net", "totalLabel": "Total" } }, "auth\_ref": { "r12": "r12", "r13": "r13", "r48": "r48", "r89": "r89", "r370": "r370", "r387": "r387" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income



gaap/2024", "localname": "AwardTypeAxis", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRsusGrantedDetails", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetails", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParentheticals", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement.", "auth\_ref": "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "ecd\_AwardUnderlygSecuritiesAmt", "xbrlType": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUnderlygSecuritiesAmt", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities", "auth\_ref": "r615", "ecd\_AwardsCloseToMnpiDiscIndName", "xbrlType": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name", "auth\_ref": "r614", "ecd\_AwardsCloseToMnpiDiscTable", "xbrlType": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures [Table]", "auth\_ref": "r613", "ecd\_AwardsCloseToMnpiDiscTableTextBlock", "xbrlType": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "auth\_ref": "r613", "us\_gaap\_BankTimeDepositsMember", "xbrlType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnARecurringBasisDetails", "lang": "en-us", "role": "label", "label": "Bank Time Deposits [Member]", "terseLabel": "High Interest Savings Account [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "auth\_ref": "r71", "apto\_BaseShelfMember", "xbrlType": "domainItem", "nsuri": "http://www.aptosec.com/20240930", "localname": "BaseShelfMember", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote12SubsequentEvent", "lang": "en-us", "role": "label", "label": "Base Shelf [Member]", "documentation": "Represents information pertaining to the Base Shelf.", "auth\_ref": "us\_gaap\_BasisOfAccountingPolicyTextBlock", "xbrlType": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-significant-accounting-policies", "lang": "en-us", "role": "label", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation - Going concern", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "auth\_ref": "us\_gaap\_Cash", "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents-details-textual", "lang": "en-us", "role": "label", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "auth\_ref": "r75", "r368", "r399", "r423", "r523", "r544", "r637", "us\_gaap\_CashAndCashEquivalentsAbstract", "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": "en-us", "role": "label", "label": "Cash and Cash Equivalents [Abstract]", "auth\_ref": "us\_gaap\_CashAndCashEquivalentsAtCarryingValue", "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-current-period-unaudited", "lang": "en-us", "role": "label", "label": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "auth\_ref": "r16", "r87", "r492", "us\_gaap\_CashAndCashEquivalentsDisclosureTextBlock", "xbrlType": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents", "lang": "en-us", "role": "label", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash and cash equivalents", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "auth\_ref": "r87", "r368", "us\_gaap\_CashAndCashEquivalentsFairValueDisclosure", "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnARecurringBasisDetails", "lang": "en-us", "role": "label", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth\_ref": "r694", "r695", "us\_gaap\_CashAndCashEquivalentsLineItems", "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents-details-textual", "lang": "en-us", "role": "label", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth\_ref": "us\_gaap\_CashCashEquivalentsAndShortTermInvestments", "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash and investment", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "auth\_ref": "us\_gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "lang": "en-us", "role": "label", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth\_ref": "r16", "r54", "r108", "us\_gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "lang": "en-us", "role": "label", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase/(decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth\_ref": "r0", "r54", "us\_gaap\_CashEquivalentsAtCarryingValue", "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents-details-textual", "lang": "en-us", "role": "label", "label": "Cash Equivalents, at Carrying Value, Total", "label": "Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "auth\_ref": "r637", "r720", "apto\_CashProceedsFromIssuingCommonShares", "xbrlType": "monetaryItem", "nsuri": "http://www.aptosec.com/20240930", "localname": "CashProceedsFromIssuingCommonShares", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "label", "label": "Cash proceeds from issuing common shares", "documentation": "Cash proceeds from issuing common shares.", "auth\_ref": "ecd\_ChangedPeerGroupFnTextBlock", "xbrlType": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote", "auth\_ref": "ecd\_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "xbrlType": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "auth\_ref": "ecd\_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "xbrlType": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "auth\_ref": "dei\_CityAreaCode", "xbrlType": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "label": "City Area Code", "documentation": "Area code of city", "auth\_ref": "us\_gaap\_ClassOfWarrantOrRightAxis", "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual",







"presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-document-and-entity-information"}, {"label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions for these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."}, {"auth\_ref": "r546"}, {"xbrl\_type": "edgarStateCountryCode", {"url": "http://xbrl.sec.gov/dei/2024"}, {"label": "EntityIncorporationStateCountryCode", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-document-and-entity-information"}, {"lang": {"en-us": {"role": {"label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation."}}, {"auth\_ref": "r11"}, {"dei\_EntityInteractiveDataCurrent": {"xbrl\_type": "yesNoItem", {"url": "http://xbrl.sec.gov/dei/2024"}, {"label": "EntityInteractiveDataCurrent", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-document-and-entity-information"}, {"lang": {"en-us": {"role": {"label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."}}, {"auth\_ref": "r630"}, {"dei\_EntityRegistrantName": {"xbrl\_type": "normalizedString", {"url": "http://xbrl.sec.gov/dei/2024"}, {"label": "EntityRegistrantName", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-document-and-entity-information"}, {"lang": {"en-us": {"role": {"label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."}}, {"auth\_ref": "r546"}, {"dei\_EntityShellCompany": {"xbrl\_type": "booleanItem", {"url": "http://xbrl.sec.gov/dei/2024"}, {"label": "EntityShellCompany", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-document-and-entity-information"}, {"lang": {"en-us": {"role": {"label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."}}, {"auth\_ref": "r546"}, {"dei\_EntitySmallBusiness": {"xbrl\_type": "booleanItem", {"url": "http://xbrl.sec.gov/dei/2024"}, {"label": "EntitySmallBusiness", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-document-and-entity-information"}, {"lang": {"en-us": {"role": {"label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."}}, {"auth\_ref": "r546"}, {"dei\_EntityTaxIdentificationNumber": {"xbrl\_type": "employerIdItem", {"url": "http://xbrl.sec.gov/dei/2024"}, {"label": "EntityTaxIdentificationNumber", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-document-and-entity-information"}, {"lang": {"en-us": {"role": {"label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."}}, {"auth\_ref": "r546"}, {"ecd\_EqtyAwrdsAdjFnTextBlock": {"xbrl\_type": "textBlock", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "EqtyAwrdsAdjFnTextBlock", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Equity Awards Adjustments, Footnote [Text Block]", "documentation": "Equity Awards Adjustments, Footnote"}}, {"auth\_ref": "r585"}, {"ecd\_EqtyAwrdsAdjExclValRprtInSummryCompstnTblMember": {"xbrl\_type": "domainItem", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "EqtyAwrdsAdjExclValRprtInSummryCompstnTblMember", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"}}, {"auth\_ref": "r626"}, {"ecd\_EqtyAwrdsAdjMember": {"xbrl\_type": "domainItem", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "EqtyAwrdsAdjMember", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Equity Awards Adjustments [Member]", "documentation": "Equity Awards Adjustments"}}, {"auth\_ref": "r626"}, {"ecd\_EqtyAwrdsInSummryCompstnTblForApblYrMember": {"xbrl\_type": "domainItem", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "EqtyAwrdsInSummryCompstnTblForApblYrMember", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"}}, {"auth\_ref": "r626"}, {"us\_gaap\_EquityComponentDomain": {"xbrl\_type": "domainItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "EquityComponentDomain", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited"}, {"lang": {"en-us": {"role": {"label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}, {"auth\_ref": "r7", "r83", "r101", "r102", "r103", "r112", "r113", "r114", "r116", "r121", "r123", "r125", "r136", "r154", "r155", "r158", "r193", "r242", "r243", "r245", "r246", "r247", "r249", "r250", "r251", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r291", "r293", "r294", "r295", "r296", "r297", "r301", "r303", "r315", "r375", "r383", "r384", "r385", "r398", "r457"}, {"ort\_EquityMethodInvesteeNameDomain": {"xbrl\_type": "domainItem", {"url": "http://fasb.org/srt/2024"}, {"label": "EquityMethodInvesteeNameDomain", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"}, {"lang": {"en-us": {"role": {"label": "Investment, Name [Domain]", "documentation": "Investment for ownership interest"}, {"auth\_ref": "r150", "r151", "r152", "r244", "r632", "r633", "r634", "r689", "r690", "r691", "r692"}, {"us\_gaap\_EquityMethodInvestmentOwnershipPercentage": {"xbrl\_type": "percentItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "EquityMethodInvestmentOwnershipPercentage", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"}, {"lang": {"en-us": {"role": {"label": "Equity Method Investment Ownership Percentage", "documentation": "Percentage of ownership common shares outstanding", "verboseLabel": "Percentage of investment"}, {"auth\_ref": "r150"}, {"us\_gaap\_EquityMethodInvestmentQuotedMarketValue": {"xbrl\_type": "monetaryItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "EquityMethodInvestmentQuotedMarketValue", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"}, {"lang": {"en-us": {"role": {"label": "Equity Method Investment, Quoted Market Value", "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available."}}, {"auth\_ref": "r152"}, {"apto\_EquityMethodInvestmentSecondTrancheMember": {"xbrl\_type": "domainItem", {"url": "http://www.aptose.com/20240930"}, {"label": "EquityMethodInvestmentSecondTrancheMember", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"}, {"lang": {"en-us": {"role": {"label": "Equity method investment second tranche", "documentation": "Equity method investment second tranche"}, {"label": "Equity Method Investment Second Tranche [Member]", "documentation": "Second Tranche [Member]"}, {"auth\_ref": "r152"}, {"us\_gaap\_EquityMethodInvestmentsAndJointVenturesAbstract": {"xbrl\_type": "stringItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "EquityMethodInvestmentsAndJointVenturesAbstract", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"}, {"lang": {"en-us": {"role": {"label": "Equity Method Investments and Joint Ventures [Abstract]", "documentation": "Equity Method Investments and Joint Ventures [Abstract]"}, {"auth\_ref": "r152"}, {"ecd\_EquityValuationAssumptionDifferenceFnTextBlock": {"xbrl\_type": "textBlock", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "documentation": "Equity Valuation Assumption Difference, Footnote"}}, {"auth\_ref": "r595"}, {"ecd\_ErrCompAnalysisTextBlock": {"xbrl\_type": "textBlock", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "ErrCompAnalysisTextBlock", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Erroneous Compensation Analysis [Text Block]", "documentation": "Erroneous Compensation Analysis"}}, {"auth\_ref": "r553", "r563", "r573", "r605"}, {"ecd\_ErrCompRecoveryTable": {"xbrl\_type": "table", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "ErrCompRecoveryTable", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Erroneously Awarded Compensation Recovery [Table]", "documentation": "Erroneously Awarded Compensation Recovery"}}, {"auth\_ref": "r550", "r560", "r570", "r602"}, {"ecd\_ExecutiveCategoryAxis": {"xbrl\_type": "stringItem", {"url": "http://xbrl.sec.gov/ecd/2024"}, {"label": "ExecutiveCategoryAxis", "presentation": {"url": "http://xbrl.sec.gov/ecd/2024"}, {"lang": {"en-us": {"role": {"label": "Executive Category [Axis]", "documentation": "Executive Category"}}, {"auth\_ref": "r601"}, {"us\_gaap\_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {"xbrl\_type": "textBlock", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsTables"}, {"lang": {"en-us": {"role": {"label": "Fair Value Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Fair Value Assets Measured on Recurring Basis", "verboseLabel": "Assets Measured on a Recurring Basis"}, {"auth\_ref": "r694", "r695"}, {"us\_gaap\_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {"xbrl\_type": "domainItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnRecurringBasisDetails"}, {"lang": {"en-us": {"role": {"label": "Asset Class [Domain]", "documentation": "Class of asset"}, {"auth\_ref": "r273", "r274", "r275", "r276", "r277", "r278", "r283", "r515"}, {"us\_gaap\_FairValueByAssetClassAxis": {"xbrl\_type": "stringItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "FairValueByAssetClassAxis", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnRecurringBasisDetails"}, {"lang": {"en-us": {"role": {"label": "Asset Class [Axis]", "documentation": "Information by class of asset"}, {"auth\_ref": "r273", "r274", "r275", "r276", "r277", "r278", "r283", "r515"}, {"us\_gaap\_FairValueHierarchyLevelAxis": {"xbrl\_type": "stringItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "FairValueHierarchyLevelAxis", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnRecurringBasisDetails"}, {"lang": {"en-us": {"role": {"label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient"}, {"auth\_ref": "r178", "r197", "r198", "r199", "r200", "r201", "r202", "r267", "r269", "r270", "r271", "r272", "r281", "r282", "r284", "r325", "r326", "r327", "r503", "r504", "r507", "r508", "r509", "r514", "r517"}, {"us\_gaap\_FairValueDisclosuresAbstract": {"xbrl\_type": "stringItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "FairValueDisclosuresAbstract", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsTables"}, {"lang": {"en-us": {"role": {"label": "Fair Value Disclosures [Abstract]", "documentation": "Fair Value Disclosures Text Block"}, {"auth\_ref": "r178", "r197", "r198", "r199", "r200", "r201", "r202", "r267", "r269", "r270", "r271", "r272", "r281", "r282", "r284", "r325", "r326", "r327", "r503", "r504", "r507", "r508", "r509", "r514", "r517"}, {"us\_gaap\_FairValueInputsLevel1Member": {"xbrl\_type": "domainItem", {"url": "http://fasb.org/us-gaap/2024"}, {"label": "FairValueInputsLevel1Member", "presentation": {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnRecurringBasisDetails"}, {"lang": {"en-us": {"role": {"label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or







"presentation": {"url": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value"}, {"url": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfRdArrTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement"}, {"url": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock"}, {"url": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote"}, {"url": "http://www.aptose.com/20240930", "localname": "NasdaqListingRuleMinimumRequirementForStockholdersEquity", "crdr": "credit", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "label", "label": "Nasdaq Listing Rule Minimum Requirement for Stockholders Equity", "terseLabel": "Nasdaq Listing Rule, minimum requirement for stockholders' equity"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "Negative Shareholder's Equity", "terseLabel": "Negative Shareholder's Equity"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "Negative Working Capital", "terseLabel": "Negative Working Capital"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "Net Cash Provided by (Used in) Financing Activities", "terseLabel": "Net Cash Provided by (Used in) Financing Activities"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "Net Cash Provided by (Used in) Investing Activities", "terseLabel": "Net Cash Provided by (Used in) Investing Activities"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual", "lang": "en-us", "role": "label", "label": "New Accounting Pronouncements Policy", "terseLabel": "New Accounting Pronouncements Policy"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "lang": "en-us", "role": "label", "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "lang": "en-us", "role": "label", "label": "Nonoperating Income (Expense)", "terseLabel": "Nonoperating Income (Expense)"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual", "lang": "en-us", "role": "label", "label": "Operating Lease Liability", "terseLabel": "Operating Lease Liability"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "lang": "en-us", "role": "label", "label": "Offered Shares [Member]", "terseLabel": "Offered Shares [Member]"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual", "lang": "en-us", "role": "label", "label": "Office Space [Member]", "terseLabel": "Office Space [Member]"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "lang": "en-us", "role": "label", "label": "Operating Expenses", "terseLabel": "Operating Expenses"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual", "lang": "en-us", "role": "label", "label": "Operating Lease Cost", "terseLabel": "Operating Lease Cost"}, {"url": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual", "lang": "en-us", "role": "label", "label": "Present value of lessee's discounted obligation for lease payments from operating lease", "terseLabel": "Present value of lessee's discounted obligation for lease payments from operating lease"}]



"http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "PEO", "label": "PEO", "terseLabel": "PEO", "auth\_ref": "r601", "cd": "PeoName", "normalizedStringItemType": "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "PEO Name", "terseLabel": "PEO Name", "auth\_ref": "r594", "cd": "PeoTotalCompAmt", "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount", "auth\_ref": "r593", "apto\_PercentageOfBeneficialOwnershipCapital": "xbrlType": "percentItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PercentageOfBeneficialOwnershipCapital", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails", "lang": "en-us", "role": "Percentage of beneficial ownership capital", "auth\_ref": "apto\_PercentageOfCommonSharesOutstanding": "xbrlType": "percentItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PercentageOfCommonSharesOutstanding", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Percentage of common shares outstanding", "auth\_ref": "apto\_PercentageOfSharesOutstandingForIssuanceOfWarrant": "xbrlType": "percentItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PercentageOfSharesOutstandingForIssuanceOfWarrant", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Percentage of shares outstanding for issuance of warrant", "documentation": "Percentage of shares outstanding for issuance of warrant", "auth\_ref": "apto\_PercentageOfUnderwritingCost": "xbrlType": "percentItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PercentageOfUnderwritingCost", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Percentage of underwriting cost", "label": "Percentage of Underwriting Cost", "terseLabel": "Underwriting costs (as percent)", "auth\_ref": "apto\_PerformanceBasedVestingMember": "xbrlType": "domainItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PerformanceBasedVestingMember", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetails", "lang": "en-us", "role": "Performance Based Vesting", "label": "Performance Based Vesting [Member]", "terseLabel": "Performance Based Vesting [Member]", "auth\_ref": "apto\_PlacementAgentWarrantsMember": "xbrlType": "domainItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PlacementAgentWarrantsMember", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails", "lang": "en-us", "role": "Placement Agent Warrants [Member]", "documentation": "Placement agent warrants", "auth\_ref": "us-gaap\_PlanNameAxis": "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation", "documentation": "Information by plan name for share-based payment arrangement", "auth\_ref": "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "us-gaap\_PlanNameDomain": "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation", "documentation": "Plan name for share-based payment arrangement", "auth\_ref": "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "cd\_PnsnAdjsPrvSvcCstMember": "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrvSvcCstMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost", "auth\_ref": "r585", "cd\_PnsnAdjsSvcCstMember": "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost", "auth\_ref": "r629", "cd\_PnsnBnftsAdjFnTextBlock": "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote", "auth\_ref": "r584", "apto\_PreFundedWarrantsExercised": "xbrlType": "sharesItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PreFundedWarrantsExercised", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Pre-Funded warrants exercised", "label": "Pre-Funded Warrants exercised", "documentation": "Pre-Funded warrants exercised", "auth\_ref": "apto\_PreFundedWarrantsMember": "xbrlType": "domainItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "documentation": "Pre-Funded warrants", "auth\_ref": "apto\_PremiumSharePricePercent": "xbrlType": "percentItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PremiumSharePricePercent", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Premium share price (as a percent)", "auth\_ref": "us-gaap\_PrepaidExpenseAndOtherAssetsAbstract": "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsAbstract", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-4-prepaid-expenses-tables", "lang": "en-us", "role": "Prepaid Expense and Other Assets [Abstract]", "auth\_ref": "us-gaap\_PrepaidExpenseCurrent": "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-current-period-unaudited", "http://www.aptosec.com/20240930/taxonomy/role/statement-note-4-prepaid-expenses-prepaid-expenses-and-other-assets-details", "lang": "en-us", "role": "Total", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer", "auth\_ref": "r90", "r156", "r157", "r493", "apto\_PrepaidExpensesTextBlock": "xbrlType": "textBlockItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PrepaidExpensesTextBlock", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-4-prepaid-expenses", "lang": "en-us", "role": "Prepaid Expenses [Text Block]", "documentation": "The entire disclosure of the amounts paid in advance during the operating period", "terseLabel": "Prepaid expenses", "auth\_ref": "us-gaap\_PrepaidInsurance": "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-4-prepaid-expenses-prepaid-expenses-and-other-assets-details", "lang": "en-us", "role": "Prepaid insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer", "auth\_ref": "r494", "r502", "r655", "apto\_PrepaidResearchAndDevelopment": "xbrlType": "monetaryItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PrepaidResearchAndDevelopment", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-4-prepaid-expenses-prepaid-expenses-and-other-assets-details", "lang": "en-us", "role": "Prepaid research and development expenses", "documentation": "Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer", "auth\_ref": "apto\_PrivatePlacementIssuancePercentage": "xbrlType": "percentItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "PrivatePlacementIssuancePercentage", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Private placement issuance percentage", "label": "Private Placement Issuance Percentage", "terseLabel": "Private placement issuance percentage", "auth\_ref": "us-gaap\_PrivatePlacementMember": "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "lang": "en-us", "role": "Private Placement [Member]", "terseLabel": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts", "auth\_ref": "us-gaap\_ProceedsFromIssuanceOfCommonStock": "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "lang": "en-us", "role": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity", "auth\_ref": "r2", "apto\_ProceedsFromIssuanceOfCommonStockAndWarrantsUnderRegisteredDirectOffering": "xbrlType": "monetaryItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsUnderRegisteredDirectOffering", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "lang": "en-us", "role": "Proceeds from Issuance of Common Stock and Warrants Under Registered Direct Offering", "label": "Proceeds from Issuance of Common Stock and Warrants Under Registered Direct Offering", "terseLabel": "Proceeds from Issuance of Common Stock and Warrants Under Registered Direct Offering", "auth\_ref": "apto\_ProceedsFromIssuanceOfCommonStockAndWarrantsUnderS1Filing": "xbrlType": "monetaryItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsUnderS1Filing", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "lang": "en-us", "role": "Proceeds from Issuance of Common Stock and Warrants Under S-1 Filing", "label": "Proceeds from Issuance of Common Stock and Warrants Under S-1 Filing", "terseLabel": "Proceeds from Issuance of Common Stock and Warrants Under S-1 Filing", "auth\_ref": "apto\_ProceedsFromIssuanceOfCommonStockGross": "xbrlType": "monetaryItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockGross", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Proceeds from Issuance of Common Stock, Gross", "label": "Proceeds from Issuance of Common Stock, Gross", "documentation": "The gross amount of cash inflow received from the issuance of common stocks before stock issuance costs", "auth\_ref": "us-gaap\_ProceedsFromIssuanceOfDebt": "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents-details-textual", "lang": "en-us", "role": "Proceeds from loan payable to third party", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt", "auth\_ref": "r644", "us-gaap\_ProceedsFromIssuanceOfWarrants": "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": "en-us", "role": "Cash proceeds", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)", "auth\_ref": "r2", "us-gaap\_ProceedsFromIssuanceOrSaleOfEquity": "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "lang": "en-us", "role": "Proceeds of sale stock", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Net proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity", "auth\_ref": "r2", "r393", "apto\_ProceedsFromLoansRestrictedToUseInConnectionOfRelatedParty": "xbrlType": "monetaryItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "ProceedsFromLoansRestrictedToUseInConnectionOfRelatedParty", "crdr": "debit", "presentation": "http://www.aptosec.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents-details-textual", "lang": "en-us", "role": "Proceeds from loans restricted to use in connection of related party", "label": "Proceeds from Loans Restricted to Use in Connection of Related Party", "documentation": "Proceeds from loans restricted to use in connection of related party", "auth\_ref": "r2", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r



"http://www.aptosec.com/20240930/taxonomy/role/statement-note-5-rightofuse-assets-schedule-of-rightofuse-assets-details", "lang": {"en-us": {"role": {"label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Additions to right-of-use assets", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."}}, "auth\_ref": {"r309": "r522"}}, "apto\_RightofuseAssetsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "RightofuseAssetsDisclosureTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/statement-note-5-rightofuse-assets", "lang": {"en-us": {"role": {"label": "Right-of-use Assets Disclosure [Text Block]", "documentation": "The entire disclosure for right-of-use assets. This disclosure includes current assets and noncurrent assets."}, "terseLabel": "Right-of-use assets"}}, "auth\_ref": {"r1": "r1"}, "ecd\_Rule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted"}, "auth\_ref": {"r620": "r620"}}, "ecd\_Rule10b51ArrTrmtdFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated"}, "auth\_ref": {"r620": "r620"}}, "us-gaap\_SaleOfStockNameOfTransactionDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapital", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote12SubsequentEvent", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited", "lang": {"en-us": {"role": {"label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."}}, "auth\_ref": {"r1": "r1"}, "us-gaap\_SaleOfStockNumberOfSharesIssuedInTransaction": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "lang": {"en-us": {"role": {"label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares sold", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."}}, "auth\_ref": {"r1": "r1"}, "apto\_SanDiegoCaliforniaMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "SanDiegoCaliforniaMember", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote8LeaseLiability", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual", "lang": {"en-us": {"role": {"label": "San Diego, California [Member]", "documentation": "Represents San Diego, California."}}, "auth\_ref": {"r1": "r1"}, "srt\_ScenarioForecastMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": {"en-us": {"role": {"label": "Forecast [Member]", "documentation": "ScenarioUnspecifiedDomain", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": {"en-us": {"role": {"label": "Scenario [Domain]", "documentation": "Tabular disclosure of the components of accrued liabilities."}}, "auth\_ref": {"r1": "r1"}, "us-gaap\_ScheduleOfCashAndCashEquivalentsTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents-details-textual", "lang": {"en-us": {"role": {"label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."}}, "auth\_ref": {"r1": "r1"}, "us-gaap\_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalTables", "lang": {"en-us": {"role": {"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per share computations for income from continuing operations."}}, "auth\_ref": {"r652": "r652"}, "us-gaap\_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationTables", "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."}}, "auth\_ref": {"r24": "r24"}, "srt\_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "lang": {"en-us": {"role": {"label": "Investment, Name [Axis]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, "auth\_ref": {"r111": "r111", "r150": "r150", "r151": "r151", "r152": "r152", "r153": "r153", "r289": "r289"}, "us-gaap\_ScheduleOfEquityMethodInvestmentsTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "lang": {"en-us": {"role": {"label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."}}, "auth\_ref": {"r84": "r84", "r111": "r111", "r150": "r150", "r151": "r151", "r152": "r152", "r153": "r153", "r289": "r289"}, "apto\_ScheduleOfRightofuseAssetsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "ScheduleOfRightofuseAssetsTableTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/statement-note-5-rightofuse-assets-tables", "lang": {"en-us": {"role": {"label": "Schedule of Right-of-use Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of right-of-use assets. This disclosure includes current assets and noncurrent assets."}, "terseLabel": "Schedule of Right-of-use Assets"}}, "auth\_ref": {"r1": "r1"}, "us-gaap\_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationTables", "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Vesting and Redemption of the RSUs Granted", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."}}, "auth\_ref": {"r61": "r61"}, "us-gaap\_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationTables", "lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."}}, "auth\_ref": {"r8": "r8", "r9": "r9", "r61": "r61"}, "us-gaap\_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationTables", "lang": {"en-us": {"role": {"label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."}}, "auth\_ref": {"r63": "r63"}, "apto\_ScheduleOfSharebasedPaymentAwardOptionsGrantsInPeriodTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "ScheduleOfSharebasedPaymentAwardOptionsGrantsInPeriodTableTextBlock", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationTables", "lang": {"en-us": {"role": {"label": "Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block]", "documentation": "Tabular disclosure of share options granted during the period."}, "terseLabel": "Schedule of Share-based Payment Award, Options, Grants in Period"}}, "auth\_ref": {"r1": "r1"}, "apto\_SecondBackEndCommitmentSharesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "SecondBackEndCommitmentSharesMember", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": {"en-us": {"role": {"documentation": "Second back-end commitment shares."}, "label": "Second Back-End Commitment Shares [Member]", "terseLabel": "Second Back-End Commitment Shares [Member]"}}, "auth\_ref": {"r1": "r1"}, "dei\_Security12bTitle": {"xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/statement-document-and-entity-information", "lang": {"en-us": {"role": {"label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security."}}, "auth\_ref": {"r545": "r545"}, "dei\_SecurityExchangeName": {"xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/statement-document-and-entity-information", "lang": {"en-us": {"role": {"label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered."}}, "auth\_ref": {"r547": "r547"}, "srt\_SegmentGeographicalDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote8LeaseLiability", "http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual", "lang": {"en-us": {"role": {"label": "Geographical [Domain]", "documentation": "Geographical [Domain]"}}, "auth\_ref": {"r146": "r146", "r147": "r147", "r332": "r332", "r333": "r333", "r334": "r334", "r335": "r335", "r336": "r336", "r337": "r337", "r338": "r338", "r339": "r339", "r340": "r340", "r341": "r341", "r342": "r342", "r343": "r343", "r344": "r344", "r345": "r345", "r346": "r346", "r347": "r347", "r348": "r348", "r349": "r349", "r350": "r350", "r351": "r351", "r352": "r352", "r353": "r353", "r354": "r354", "r355": "r355", "r356": "r356", "r357": "r357", "r358": "r358", "r359": "r359", "r360": "r360", "r361": "r361", "r402": "r402", "r403": "r403", "r404": "r404", "r466": "r466", "r468": "r468", "r472": "r472", "r475": "r475", "r478": "r478", "r480": "r480", "r481": "r481", "r482": "r482", "r483": "r483", "r484": "r484", "r485": "r485", "r486": "r486", "r487": "r487", "r491": "r491", "r506": "r506", "r524": "r524", "r525": "r525", "r526": "r526", "r527": "r527", "r528": "r528", "r529": "r529", "r530": "r530", "r531": "r531", "r533": "r533", "r536": "r536", "r660": "r660", "r721": "r721", "r723": "r723", "r724": "r724", "r725": "r725", "r726": "r726", "r727": "r727", "r728": "r728", "r729": "r729", "r730": "r730", "r731": "r731", "r732": "r732", "r733": "r733", "r734": "r734", "r735": "r735", "r736": "r736", "r737": "r737", "r738": "r738", "r739": "r739", "r740": "r740", "r741": "r741", "r742": "r742", "r743": "r743", "r744": "r744", "r745": "r745", "r746": "r746", "r747": "r747", "r748": "r748", "r749": "r749"}, "apto\_SeriesAWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "SeriesAWarrantsMember", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": {"en-us": {"role": {"documentation": "Series A warrants."}, "label": "Series A Warrants [Member]", "terseLabel": "Series A Warrants [Member]"}}, "auth\_ref": {"r1": "r1"}, "apto\_SeriesBWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aptosec.com/20240930", "localname": "SeriesBWarrantsMember", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "lang": {"en-us": {"role": {"documentation": "Series B warrants."}, "label": "Series B Warrants [Member]", "terseLabel": "Series B Warrants [Member]"}}, "auth\_ref": {"r1": "r1"}, "us-gaap\_ShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": {"http://www.aptosec.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "lang": {"en-us": {"role": {"verboselabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement."}}, "auth\_ref": {"r3": "r3"}, "us-

gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)", "verboseLabel": "Number of options, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "auth\_ref": "r222"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Granted", "verboseLabel": "Weighted average grant date fair value, exercise price", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "auth\_ref": "r222"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRsusGrantedDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodStartLabel": "Number of options, Beginning Balance", "periodEndLabel": "Number of options, Ending Balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "auth\_ref": "r219", "r220"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRsusGrantedDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, exercise price", "periodStartLabel": "Weighted average grant date fair value, Beginning Balance", "periodEndLabel": "Weighted average grant date fair value, Ending Balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "auth\_ref": "r219", "r220"}, {"xbrltype": "apto\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndRedeemedInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndRedeemedInPeriod", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRsusGrantedDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested and Redeemed in Period", "terseLabel": "Number of options, Vested and redeemed", "documentation": "The number of options that have been exercised or otherwise terminated.", "auth\_ref": "r219"}, {"xbrltype": "apto\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndRedeemedInPeriodWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndRedeemedInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRsusGrantedDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested and Redeemed in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Vested and redeemed", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit appreciation rights plan, performance target plan).", "auth\_ref": "r219"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationWeightedAverageAssumptionsDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "auth\_ref": "r231"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationWeightedAverageAssumptionsDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "auth\_ref": "r230"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationWeightedAverageAssumptionsDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "auth\_ref": "r232"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "terseLabel": "Share-Based Payment Award, Number of Shares Authorized", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "auth\_ref": "r513"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "auth\_ref": "r213"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "auth\_ref": "r213"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Forfeited options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "auth\_ref": "r217"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period.", "auth\_ref": "r215"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, exercise price", "periodStartLabel": "Weighted average grant date fair value, Beginning Balance", "periodEndLabel": "Weighted average grant date fair value, Ending Balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "auth\_ref": "r215"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options.", "auth\_ref": "r211", "r212"}, {"xbrltype": "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Outstanding", "documentation": "The weighted-average exercise price of options outstanding as of the balance sheet date.", "auth\_ref": "r211", "r212"}]

"periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. } }", "auth\_ref": { "r211", "r212" }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth\_ref": { "r227" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth\_ref": { "r227" } } }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRusGrantedDetails", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetails", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParentheticals", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth\_ref": { "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233" } } }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth\_ref": { "r216" } } }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Outstanding, weighted average exercise price (in dollars per share)", "verboseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth\_ref": { "r217" } } }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth\_ref": { "r215" } } }, "us-gaap\_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParentheticals", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth\_ref": { } } }, "us-gaap\_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParentheticals", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth\_ref": { } } }, "us-gaap\_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParentheticals", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth\_ref": { } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingNumber", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement." } } }, "auth\_ref": { } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsPercentage", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParentheticals", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth\_ref": { "r661" } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r512" } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationWeightedAverageAssumptionsDetails", "lang": { "en-us": { "role": { "label": "Expected life of options (Years)", "terseLabel": "Expected life of options (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r229" } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r23" } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r62" } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite

service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } ;  
"auth\_ref": { "x227" } } } ; "apto\_SharebasedPaymentArrangementTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.apto.com/20240930",  
"localname": "SharebasedPaymentArrangementTrancheFourMember", "presentation": {  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParenteticals": { "lang": { "en-us": {  
"role": { "label": "Share-based Payment Arrangement, Tranche Four [Member]", "documentation": "Fourth portion of award under share-based payment arrangement  
differentiated by vesting feature, including, but not limited to, performance measure or service period." } } } } ; "auth\_ref": { } } } ; "apto\_SharesIssuancesToHanmi": { "xbrltype":  
"monetaryItemType", "nsuri": "http://www.apto.com/20240930", "localname": "SharesIssuancesToHanmi", "crdr": "debit", "presentation": {  
"http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "terseLabel":  
"Shares issuances to Hanmi under subscription agreement", "label": "Shares Issuances to Hanmi", "documentation": "Shares issuances to Hanmi." } } } } ; "us-  
gaap\_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": {  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common  
share exercise price", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and  
were previously outstanding but which are now held in the treasury." } } } } ; "auth\_ref": { "x7" } } ; "us-gaap\_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType",  
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": {  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"; "lang": { "en-us": { "role": { "verboseLabel": "Public offering  
price", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity  
securities issued." } } } } ; "auth\_ref": { } } } ; "us-gaap\_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"SharesOutstanding", "presentation": { "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-  
equity-unaudited": { "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Outstanding",  
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } } } ; "auth\_ref": { } } } ; "us-gaap\_SignificantAccountingPoliciesTextBlock": {  
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {  
"http://www.apto.com/20240930/taxonomy/role/statement-note-2-significant-accounting-policies": { "lang": { "en-us": { "role": { "label": "Significant Accounting Policies  
[Text Block]", "terseLabel": "Significant accounting policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } } } ;  
"auth\_ref": { "x57", "x109" } } } ; "us-gaap\_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"StatementEquityComponentsAxis", "presentation": { "http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual"; "http://www.apto.com/20240930/taxonomy/role/statement-  
condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "Equity Components [Axis]",  
"documentation": "Information by component of equity." } } } } ; "auth\_ref": { "x7", "x42", "x45", "x46", "x83", "x101", "x102", "x103", "x112", "x113", "x114", "x116", "x121",  
"x123", "x125", "x136", "x154", "x155", "x158", "x193", "x242", "x243", "x245", "x246", "x247", "x249", "x250", "x251", "x257", "x261", "x262", "x264",  
"x291", "x293", "x294", "x295", "x296", "x297", "x301", "x303", "x315", "x375", "x383", "x384", "x385", "x398", "x457" } } } ; "srt\_StatementGeographicalAxis": { "xbrltype":  
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": {  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiability";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual"; "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "auth\_ref": {  
"x146", "x147", "x332", "x333", "x334", "x335", "x336", "x337", "x338", "x339", "x340", "x341", "x342", "x343", "x344", "x345", "x346", "x347", "x348", "x349", "x350", "x351",  
"x352", "x353", "x354", "x355", "x356", "x357", "x358", "x359", "x360", "x361", "x402", "x403", "x404", "x406", "x466", "x468", "x472", "x475", "x478", "x479", "x480", "x481", "x482",  
"x483", "x484", "x485", "x486", "x487", "x491", "x506", "x524", "x525", "x526", "x527", "x528", "x529", "x530", "x531", "x533", "x536", "x660", "x723", "x724", "x725",  
"x726", "x727", "x728", "x729", "x730", "x731", "x732", "x733", "x734", "x735", "x736", "x737", "x738", "x739", "x740", "x741", "x742", "x743", "x744", "x745", "x746", "x747",  
"x748", "x749" } } } } ; "us-gaap\_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation":  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapital";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalLossPerShareDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationSharebasedPaymentExpenseDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRsusGrantedDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParenteticals";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationWeightedAverageAssumptionsDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote12SubsequentEvent";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstruments";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnARecurringBasisDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote7AccruedLiabilities";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote7AccruedLiabilitiesTables"; "http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiability";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityLeaseLiabilityDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityOperatingLeaseCostDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityScheduleOfMinimumPaymentsUnderOperatingLeasesDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LoanPayableToRelatedParties"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-  
consolidated-interim-statements-of-cash-flows-unaudited"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-  
changes-in-shareholders-equity-unaudited"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-  
current-period-unaudited"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-current-period-  
unaudited-parenteticals"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-loss-and-comprehensive-loss-  
unaudited"; "http://www.apto.com/20240930/taxonomy/role/statement-note-1-reporting-entity"; "http://www.apto.com/20240930/taxonomy/role/statement-note-3-cash-and-  
cash-equivalents"; "http://www.apto.com/20240930/taxonomy/role/statement-note-4-prepaid-expenses"; "http://www.apto.com/20240930/taxonomy/role/statement-note-4-  
prepaid-expenses-tables"; "http://www.apto.com/20240930/taxonomy/role/statement-note-5-rightofuse-assets"; "http://www.apto.com/20240930/taxonomy/role/statement-  
note-5-rightofuse-assets-tables": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a  
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } ; "auth\_ref": { "x112",  
"x113", "x114", "x136", "x303", "x331", "x392", "x400", "x408", "x409", "x410", "x411", "x412", "x413", "x415", "x418", "x419", "x420", "x421", "x422", "x424", "x425", "x426",  
"x427", "x429", "x430", "x431", "x432", "x433", "x435", "x438", "x439", "x443", "x444", "x445", "x446", "x447", "x448", "x449", "x450", "x451", "x452", "x453", "x454", "x457",  
"x537" } } } ; "us-gaap\_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract",  
"lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "auth\_ref": { } } } } ; "us-gaap\_StatementOfFinancialPositionAbstract": { "xbrltype":  
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial  
Position [Abstract]", "auth\_ref": { } } } } ; "us-gaap\_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",  
"localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "auth\_ref": { } } } } ;  
"srt\_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": {  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"; "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "auth\_ref": {  
"x126", "x204", "x631", "x635", "x650" } } } } } ; "us-gaap\_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable",  
"presentation": { "http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapital";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalLossPerShareDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationSharebasedPaymentExpenseDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationStockOptionTransactionsDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingAndRedemptionOfTheRsusGrantedDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParenteticals";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationWeightedAverageAssumptionsDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote12SubsequentEvent";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstruments";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnARecurringBasisDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote7AccruedLiabilities";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote7AccruedLiabilitiesTables"; "http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiability";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityDetailsTextual";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityLeaseLiabilityDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityOperatingLeaseCostDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityScheduleOfMinimumPaymentsUnderOperatingLeasesDetails";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LeaseLiabilityTables";  
"http://www.apto.com/20240930/taxonomy/role/DisclosureNote8LoanPayableToRelatedParties"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-  
consolidated-interim-statements-of-cash-flows-unaudited"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-  
changes-in-shareholders-equity-unaudited"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-  
current-period-unaudited"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-financial-position-current-period-  
unaudited-parenteticals"; "http://www.apto.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-loss-and-comprehensive-loss-





"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual", "http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual", "http://www.aptose.com/20240930/taxonomy/role/statement-note-3-cash-and-cash-equivalents-details-textual", "lang": {"en-us": {"role": {"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."}}}, "auth\_ref": {"r252"}}, {"us-gaap-USTreasurySecuritiesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": {}}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote6FairValueMeasurementsAndFinancialInstrumentsAssetsMeasuredOnARecurringBasisDetails": {"lang": {"en-us": {"role": {"label": "US Treasury Securities [Member]", "terseLabel": "United States Treasury Bills [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities – one year or less), treasury notes (intermediate term maturities – two to ten years), and treasury bonds (long-term maturities – ten to thirty years)."}}, "auth\_ref": {"r496", "r507", "r509", "r514", "r718"}}, "ecd-UndrlygSecMktPrcChngPct": {"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecMktPrcChngPct", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": {"en-us": {"role": {"label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change"}}, "auth\_ref": {"r618"}}, "us-gaap-UnrealizedGainLossOnInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited"}, "lang": {"en-us": {"role": {"negatedLabel": "Unrealized (gain)/loss on short-term investment", "terseLabel": "Unrealized (gain)/loss on short-term investment", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment."}}}, "auth\_ref": {"r4"}}, "apto-UnvestedOptionsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "UnvestedOptionsMember", "presentation": {}}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation": {"lang": {"en-us": {"role": {"label": "Unvested Options [Member]", "documentation": "Information related to unvested options."}}}, "auth\_ref": {}}, {"us-gaap-UseOfEstimates": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/statement-significant-accounting-policies"}, "lang": {"en-us": {"role": {"label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Significant accounting policies, estimates and judgments", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."}}}, "auth\_ref": {"r19", "r20", "r21", "r76", "r77", "r79", "r80"}}, "apto-VestedOptionsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "VestedOptionsMember", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensation"}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationDetailsTextual": {"lang": {"en-us": {"role": {"label": "Vested Options [Member]", "documentation": "Information related to vested options."}}}, "auth\_ref": {}}, {"us-gaap-VestingAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParenteticals": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual": {"lang": {"en-us": {"role": {"label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement."}}}, "auth\_ref": {"r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686"}}, "us-gaap-VestingDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote11StockbasedCompensationVestingTermsOfOptionsGrantedDetailsParenteticals": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual": {"lang": {"en-us": {"role": {"label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement."}}}, "auth\_ref": {"r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686"}}, "ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstInCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstInCvrdYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"}}, "auth\_ref": {"r588"}}, {"us-gaap-WarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote9RelatedPartyTransactionsDetailsTextual": {"lang": {"en-us": {"role": {"label": "Warrant [Member]", "terseLabel": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."}}}, "auth\_ref": {"r534", "r535", "r538", "r539", "r540", "r541"}}, {"us-gaap-WarrantsAndRightsOutstandingTerm": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote12SubsequentEventsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Warrants expiration period", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants, Remaining contractual life", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."}}}, "auth\_ref": {"r696", "r697", "r698"}}, {"apto-WarrantsIssued": {"xbrltype": "sharesItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "WarrantsIssued", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual"}, {"lang": {"en-us": {"role": {"documentation": "Warrants issued.", "label": "Warrants Issued", "terseLabel": "Warrants issued"}}, "auth\_ref": {}}, {"apto-WarrantsIssuedPricePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "WarrantsIssuedPricePerShare", "presentation": {"http://www.aptose.com/20240930", "localname": "WarrantsIssuedPricePerShare", "presentation": {}}, {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual": {"lang": {"en-us": {"role": {"documentation": "Warrants issued price per share", "label": "Warrants Issued Price Per Share", "terseLabel": "Warrants issued price per share"}}, "auth\_ref": {}}, {"apto-WarrantsPurchasePricePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "WarrantsPurchasePricePerShare", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalDetailsTextual": {"lang": {"en-us": {"role": {"documentation": "Warrants purchase price per share", "label": "Warrants Purchase Price Per Share", "terseLabel": "Warrants purchase price per share"}}, "auth\_ref": {}}, {"us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalLossPerShareDetails": {"http://www.aptose.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-loss-and-comprehensive-loss-unaudited"}, "lang": {"en-us": {"role": {"totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Weighted average common shares - diluted", "terseLabel": "Weighted average number of common shares outstanding used in the calculation of diluted loss per common share (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."}}}, "auth\_ref": {"r128", "r133"}}, {"us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote10ShareCapitalLossPerShareDetails": {"http://www.aptose.com/20240930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-loss-and-comprehensive-loss-unaudited"}, "lang": {"en-us": {"role": {"label": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Weighted average common shares - basic", "terseLabel": "Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."}}}, "auth\_ref": {"r127", "r133"}}, {"apto-WorkingCapital": {"xbrltype": "monetaryItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "WorkingCapital", "crdr": "debit", "presentation": {"http://www.aptose.com/20240930/taxonomy/role/DisclosureNote2SignificantAccountingPoliciesDetailsTextual": {"lang": {"en-us": {"role": {"documentation": "Working capital", "label": "Working Capital", "terseLabel": "Working capital"}}, "auth\_ref": {}}, {"ecd-YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstDmMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstDmMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"}}, "auth\_ref": {"r586"}}, {"apto-statement-statement-note-10-share-capital-loss-per-share-details": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-10-share-capital-loss-per-share-details", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-10-share-capital-loss-per-share-details", "presentation": {}}, {"statement-statement-note-10-share-capital-loss-per-share-details": {"lang": {"en-us": {"role": {"label": "Note 11 - Share Capital - Loss Per Share (Details)", "documentation": "Statement-Statement-Note-10-Share-Capital-Loss-Per-Share-Details"}}, "auth\_ref": {}}, {"apto-statement-statement-note-10-share-capital-tables": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-10-share-capital-tables", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-10-share-capital-tables", "presentation": {}}, {"statement-statement-note-10-share-capital-tables": {"lang": {"en-us": {"role": {"label": "Note 11 - Share Capital", "documentation": "Statement-Statement-Note-10-Share-Capital-Tables"}}, "auth\_ref": {}}, {"apto-statement-statement-note-11-stockbased-compensation-sharebased-payment-expense-details": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-sharebased-payment-expense-details", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-sharebased-payment-expense-details", "presentation": {}}, {"statement-statement-note-11-stockbased-compensation-sharebased-payment-expense-details": {"lang": {"en-us": {"role": {"documentation": "Statement-Statement-Note-11-Stockbased-Compensation-Sharebased-Payment-Expense-Details", "label": "Note 12 - Stock-based Compensation - Share-based Payment Expense (Details)}}, "auth\_ref": {}}, {"apto-statement-statement-note-11-stockbased-compensation-stock-option-transactions-details": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-stock-option-transactions-details", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-stock-option-transactions-details", "presentation": {}}, {"statement-statement-note-11-stockbased-compensation-stock-option-transactions-details": {"lang": {"en-us": {"role": {"label": "Note 11 - Stock-based Compensation - Stock Option Transactions (Details)", "documentation": "Statement-Statement-Note-11-Stockbased-Compensation-Stock-Option-Transactions-Details"}}, "auth\_ref": {}}, {"apto-statement-statement-note-11-stockbased-compensation-tables": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-tables", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-tables", "presentation": {}}, {"statement-statement-note-11-stockbased-compensation-tables": {"lang": {"en-us": {"role": {"label": "Note 11 - Stock-based Compensation", "documentation": "Statement-Statement-Note-11-Stockbased-Compensation-Tables"}}, "auth\_ref": {}}, {"apto-statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-details": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-details", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-details", "presentation": {}}, {"statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-details": {"lang": {"en-us": {"role": {"documentation": "Statement-Statement-Note-11-Stockbased-Compensation-Vesting-Terms-Of-Options-Granted-Details", "label": "Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details)}}, "auth\_ref": {}}, {"apto-statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-parenteticals": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-parenteticals", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-parenteticals", "presentation": {}}, {"statement-statement-note-11-stockbased-compensation-vesting-terms-of-options-granted-parenteticals": {"lang": {"en-us": {"role": {"documentation": "Statement-Statement-Note-11-Stockbased-Compensation-Vesting-Terms-Of-Options-Granted-Details-Parenteticals", "label": "Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parenteticals)}}, "auth\_ref": {}}, {"apto-statement-statement-note-11-stockbased-compensation-weighted-average-assumptions-details": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-weighted-average-assumptions-details", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-11-stockbased-compensation-weighted-average-assumptions-details", "presentation": {}}, {"statement-statement-note-11-stockbased-compensation-weighted-average-assumptions-details": {"lang": {"en-us": {"role": {"documentation": "Statement-Statement-Note-11-Stockbased-Compensation-Weighted-Average-Assumptions-Details", "label": "Note 12 - Stock-based Compensation - Weighted Average Assumptions (Details)}}, "auth\_ref": {}}, {"apto-statement-statement-note-4-prepaid-expenses-tables": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-4-prepaid-expenses-tables", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-4-prepaid-expenses-tables", "presentation": {}}, {"statement-statement-note-4-prepaid-expenses-tables": {"lang": {"en-us": {"role": {"label": "Note 4 - Prepaid Expenses", "documentation": "Statement-Statement-Note-4-Prepaid-Expenses-Tables"}}, "auth\_ref": {}}, {"apto-statement-statement-note-5-rightofuse-assets-tables": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-5-rightofuse-assets-tables", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-5-rightofuse-assets-tables", "presentation": {}}, {"statement-statement-note-5-rightofuse-assets-tables": {"lang": {"en-us": {"role": {"label": "Note 5 - Right-of-use Assets", "documentation": "Statement-Statement-Note-5-Rightofuse-Assets-Tables"}}, "auth\_ref": {}}, {"apto-statement-statement-note-7-fair-value-measurements-and-financial-instruments-tables": {"xbrltype": "stringItemType", "nsuri": "http://www.aptose.com/20240930", "localname": "statement-statement-note-7-fair-value-measurements-and-financial-instruments-tables", "presentation": {"http://www.aptose.com/20240930", "localname": "statement-statement-note-7-fair-value-measurements-and-financial-instruments-tables", "presentation": {}}, {"statement-statement-note-7-fair-value-measurements-and-financial-instruments-tables": {"lang": {"en-us": {"role": {"label": "Note 7 - Fair Value Measurements and Financial Instruments", "documentation": "Statement-Statement-Note-7-Fair-Value-Measurements-And-Financial-Instruments-Tables"}}, "auth\_ref": {}}, {"apto-statement-statement-note-8-accrued-liabilities





















































apto:OptionsWithFourYearVestingMemberapto:ShareBasedPaymentArrangementTrancheFourMember 2023-01-012023-09-30 0000882361 apto:SupplyAgreementMember 2021-11-042024-09-30 0000882361 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000882361 2024-09-30 0000882361  
apto:CommittedEquityFacilityMemberapto:CommitmentSharesMember 2023-01-012023-12-31 0000882361 us-gaap:USTreasurySecuritiesMemberus-  
gaap:FairValueInputsLevel1Member 2023-12-31 0000882361 apto:OptionsWithFourYearVestingMemberapto:ShareBasedCompensationAwardTrancheTwoMember 2024-01-  
012024-09-30 0000882361 apto:June2024RegisteredDirectOfferingMember 2024-06-032024-06-03 0000882361 apto:HanniLoanAgreementMember 2024-01-012024-09-30  
0000882361 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000882361 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31  
0000882361 apto:CommittedEquityFacilityMemberapto:CommitmentSharesMember 2024-01-012024-09-30 0000882361 us-gaap:AdditionalPaidInCapitalMember 2024-01-  
012024-09-30 0000882361 us-gaap:RetainedEarningsMember 2023-09-30 0000882361 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-12-  
31 0000882361 apto:HanniLicensingAgreementMember 2021-11-04 0000882361 us-gaap:BankTimeDepositsMember 2024-09-30 0000882361 us-  
gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000882361 apto:SeriesAWarrantsMemberus-gaap:PrivatePlacementMember 2024-06-03  
0000882361 apto:HanniLoanAgreementMember 2024-09-022024-09-02 0000882361 apto:KeystoneMemberapto:CommittedEquityFacilityMember 2024-09-30 0000882361  
srt:ScenarioForecastMemberus-gaap:CommonStockMember 2025-01-092025-01-13 0000882361 us-gaap:CommonStockMemberus-  
gaap:SubsequentEventMemberapto:OfferedSharesMember 2024-10-302024-10-30 0000882361 apto:OptionsWithFourYearVestingMemberus-  
gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-012023-09-30 0000882361 us-gaap:CommonStockMemberapto:The2024AtmOfferingMember 2023-01-  
012023-09-30 0000882361 apto:OptionsWithFourYearVestingMember 2023-01-012023-09-30 0000882361 us-gaap:CommonStockMember 2023-09-30 0000882361 2024-09-  
112024-09-11 0000882361 apto:OptionsWithThreeYearVestingMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-012024-09-30 0000882361 us-  
gaap:OverAllotmentOptionMember 2024-01-312024-01-31 0000882361 apto:PreFundedWarrantsMemberus-gaap:SubsequentEventMemberapto:OfferedSharesMember 2024-  
10-30 0000882361 us-gaap:RetainedEarningsMember 2024-09-30 0000882361 apto:OptionsWithFourYearVestingMember 2024-01-012024-09-30 0000882361  
apto:KeystoneMemberapto:CommittedEquityFacilityMemberapto:CommitmentSharesMember 2023-05-252024-04-30 0000882361 2024-01-012024-09-30 0000882361 2023-  
01-012023-09-30 0000882361 srt:ScenarioForecastMemberus-gaap:CommonStockMember 2025-01-13 0000882361 us-gaap:RetainedEarningsMember 2023-01-012023-09-30  
0000882361 apto:KeystoneMemberapto:CommittedEquityFacilityMember 2024-04-01 0000882361 2024-09-05 0000882361 us-gaap:USTreasurySecuritiesMemberus-  
gaap:FairValueInputsLevel3Member 2023-12-31 0000882361 apto:The2023CmpoMember 2023-07-012023-09-30 0000882361  
srt:MaximumMemberapto:SeriesAWarrantsMemberus-gaap:PrivatePlacementMember 2024-06-03 0000882361 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31  
0000882361 us-gaap:PrivatePlacementMember 2024-06-03 0000882361 apto:CommittedEquityFacilityMemberapto:FirstBackEndCommitmentSharesMember 2023-05-25  
0000882361 srt:MinimumMember 2024-02-29 0000882361 apto:TwoThousandTwentyThreeCommittedEquityFacilityMember 2024-01-012024-09-30 0000882361 us-  
gaap:FairValueInputsLevel1Member 2024-09-30 0000882361 apto:OptionsWithThreeYearVestingMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-  
01-012023-09-30 0000882361 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0000882361 apto:The2023CmpoMember 2024-01-012024-09-30  
0000882361 apto:The2022AtmOfferingMember 2024-07-012024-09-30 0000882361 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0000882361  
apto:The2022AtmOfferingMember 2023-01-012023-09-30 0000882361 us-gaap:CommonStockMember 2024-01-012024-09-30 0000882361 us-gaap:WarrantMemberus-  
gaap:SubsequentEventMemberapto:OfferedSharesMember 2024-10-30 0000882361 us-gaap:CommonStockMember 2023-12-31 0000882361  
apto:The2022AtmOfferingMember 2024-09-30 0000882361 apto:PreFundedWarrantsMemberus-gaap:SubsequentEventMemberapto:OfferedSharesMember 2024-10-302024-  
10-30 0000882361 apto:KeystoneMemberapto:CommittedEquityFacilityMember 2024-04-30 0000882361 apto:HanniLoanAgreementMember 2024-09-30 0000882361  
apto:HanniPharmaceuticalsCoLtdMember 2024-09-30 0000882361 srt:MaximumMemberapto:SeriesBWarrantsMemberus-gaap:PrivatePlacementMember 2024-06-03  
0000882361 apto:PreFundedWarrantsMemberapto:June2024RegisteredDirectOfferingMember 2024-06-032024-06-03 0000882361 2024-06-032024-06-03 0000882361 2024-  
07-012024-09-30 0000882361 us-gaap:WarrantMemberus-gaap:CommonStockMember 2024-01-31 0000882361 apto:HanniPharmaceuticalsCoLtdMember 2021-11-04  
0000882361 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000882361 2024-11-08 0000882361 apto:The2022AtmOfferingMember 2024-01-  
012024-09-30 0000882361 apto:The2022AtmOfferingMember 2022-12-09 0000882361 2024-06-30 0000882361 apto:HanniLoanAgreementMember 2024-08-272024-08-27  
0000882361 apto:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000882361 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member  
2024-09-30 0000882361 apto:CommittedEquityFacilityMember 2023-05-25 0000882361 apto:HanniPharmaceuticalsCoLtdMember 2024-01-01 0000882361 us-  
gaap:SubsequentEventMemberapto:OfferedSharesMember 2024-10-30 0000882361 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000882361  
apto:HanniPharmaceuticalsCoLtdMemberus-gaap:PrivatePlacementMember 2024-01-312024-01-31 0000882361 us-gaap:FairValueInputsLevel2Member 2023-12-31  
0000882361 us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000882361 apto:The2022AtmOfferingMember 2022-12-092024-05-30  
0000882361 apto:The2023CmpoMember 2023-01-012023-09-30 0000882361 apto:HanniPharmaceuticalsCoLtdMember 2024-01-312024-01-31 0000882361 us-  
gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000882361 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000882361  
apto:HanniLoanAgreementMember 2024-08-27 0000882361 2023-12-31 0000882361 apto:OptionsWithThreeYearVestingMember 2023-01-012023-09-30 0000882361  
srt:MaximumMemberapto:NewIncidentPlanMember 2021-06-01 0000882361 apto:CommittedEquityFacilityMemberapto:FirstBackEndCommitmentSharesMember 2023-05-  
252023-05-25 0000882361 us-gaap:WarrantMemberus-gaap:SubsequentEventMemberapto:OfferedSharesMember 2024-10-29 0000882361  
apto:HanniLicensingAgreementMember 2021-11-042021-11-04 0000882361 apto:SupplyAgreementMember 2024-09-30 0000882361  
apto:OptionsWithThreeYearVestingMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-012023-09-30 0000882361 us-  
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000882361 apto:HanniPharmaceuticalsCoLtdMemberus-gaap:CommonStockMember 2023-09-062023-  
09-06 0000882361 apto:CommittedEquityFacilityMemberapto:InitialCommitmentSharesMember 2023-05-25 0000882361 srt:MinimumMember 2024-07-16 0000882361  
apto:SeriesBWarrantsMemberus-gaap:PrivatePlacementMember 2024-06-03 0000882361 2023-06-30 0000882361 us-gaap:GeneralAndAdministrativeExpenseMember 2024-  
07-012024-09-30 0000882361 apto:CommittedEquityFacilityMemberapto:InitialCommitmentSharesMember 2023-05-252023-05-25 0000882361  
apto:OptionsWithFourYearVestingMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-012023-09-30 0000882361 us-  
gaap:FairValueInputsLevel3Member 2023-12-31 0000882361 apto:OptionsWithFourYearVestingMemberapto:ShareBasedPaymentArrangementTrancheFourMember 2024-01-  
012024-09-30 0000882361 apto:CommittedEquityFacilityMember 2023-12-31 0000882361 apto:PublicOfferingMember 2024-01-312024-01-31 0000882361  
apto:CommittedEquityFacilityMember 2023-01-012023-12-31 0000882361 us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberapto:OfferedSharesMember 2024-  
10-30 0000882361 us-gaap:BankTimeDepositsMember 2023-12-31 0000882361 us-gaap:CommonStockMemberapto:The2022AtmOfferingMember 2024-01-012024-09-30  
0000882361 apto:SupplyAgreementMember 2024-01-012024-09-30 pure shares apto:Days iso4217:USD iso4217:USD sharesfalse0000882361falsefalsefalse-12-  
31Q30.16670.16670.16670.16670.16670.510-Qtrue2024-09-302024false1-32001APTOSE BIOSCIENCES INC. Z498-113680266-Wellington Street WestSuite 5300TD  
Bank Tower Box 48TorontoONM5K 1E6310849-8060CommonShares, no par valueAPTONASDAQYesNo-accelerated  
Filtertruefalse19521183796200092520009120002042000136100060000010235000118940003000015200066400094300069400010950001092900012989000255400018300  
4316000-4316000-539382000-515537000-9134000-

29010001092900012989000000470200082560000155600002764000022630003425000851000012580000696500011681000240700004022900012000232000226000980000021  
1000-3000120000234000225000977000-6953000-11447000-23845000-392520000003000-6953000-11447000-23845000-39249000-0.37-0.37-1.76-1.76-1.48-1.48-6.14-  
6.141856000195600006495000649500016107000161070006391000639100079420004480060007216000-4316000-515537000-  
2901000319500010180003122000414000021050002043000165900037020005649000359500045320008127000520000717000-820006350008200097000-118000-  
21000100030001003000280002600026000-23845000-23845000195210005230200082262000-4316000-539382000-9134000615800043752000068869000-4318000-  
4643300003771400066800030000003000000376000-376000330001185000118500033700018280001828000324200032420006000290002900030003000-39252000-  
39252000754300044393800071735000-4315000-5035820007776000-6953000-11447000-23845000-39252000-13000599000100300032420004000200028000700000-  
760000929000910002790002600015000230005200073000010000300004000056000-324000-29000-1130000-  
64600076000440007610004400011200011700034600029000000-25540000-5281000-690000-1662000-351500023160001045000-13170003472000-10376000-10536000-  
27917000-  
353310001000000000100000000004140000000812700000300000037020003000000011500006940001150000050000050000069400097000183700005000177000100008000131  
18000290000-129530000-80510000129530001800080220000100003000-3680007320000-1290000-  
2125000083300008400000925200036970000796200015720000796200015720000<div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-  
content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-  
size:10pt;font-family:Times New Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1</span><div  
style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-  
content;">Reporting entity:</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-  
align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aptose Biosciences Inc. ("Aptose," "the  
Company," "we," "us," or "our") is a science-driven, clinical-stage biotechnology company committed to the development and commercialization of precision medicines  
addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to  
provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company's executive offices are  
located in San Diego, California, and our head office address has been changed to 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, Ontario, Canada.  
</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span  
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing targeted agents to treat life-threatening  
hematologic cancers; that in most cases, are not effective for patients and require immediate treatment. We have two clinical-stage investigational products for hematological  
malignancies: tuspentinib, an oral, potent myeloid kinase inhibitor, and luxetintinib, an oral, dual lymphoid and myeloid kinase inhibitor.</span></p><p style="text-  
indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-  
size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have financed our operations and technology acquisitions primarily from equity  
financing, proceeds from the exercise of warrants and stock options, and interest income on funds held for future investment. Our uses of cash for operating activities have  
primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and  
clinical studies, licensing fees, drug manufacturing costs, laboratory supplies and materials, and professional fees.</span></p><p style="text-indent:4.533%;font-  
size:10pt;margin-top:12pt;font-family:Times New Roman;min-width:fit-content;">Management recognizes that in order for us to meet our capital requirements, and continue to operate, additional financing  
will be necessary. We plan to raise additional funds to fund our business operations but there is no assurance that such additional funds will be available for us to finance our  
operations on acceptable terms, if at all. The Company's current cash and cash equivalents are projected to support operations through January 2025. We have based these  
estimates on assumptions and plans, which may change and which could impact the magnitude and/or timing of operating expenses and our cash runway. See Note 2(a).  
</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span  
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to raise additional funds has been affected by  
adverse market conditions, the status of our product pipeline, possible delays in enrollment in our trial, and various other factors and we may be unable to raise capital when  
needed, or on terms favorable to us. The raising of additional capital, and/or the trade sale of some of the Company's operations to make bulk payments to repay accounts  
payable, if successful, would potentially alleviate any significant doubt on the Company's ability to continue as a going concern. In the event that debt and/or capital financing  
is unable to be secured or contemplated trade sale fail to materialize, the Company may need to resolve to other means of protecting its assets in the best interests of its  
shareholders, including foreclosure or forced liquidation and/or seeking creditors' protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-  
family:Times New Roman;min-width:fit-content;"></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-  
bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not expect to  
generate positive cash flow from operations for the foreseeable future due to the early stage of our clinical trials. It is expected that negative cash flow will continue until such  
time, if ever, that we receive regulatory approval to commercialize any of our products under development and/or royalty or milestone revenue from any such products exceeds  
expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span  
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's financial statements are prepared using  
generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of  
liabilities in the normal course of business. However, the use of the going concern assumption on which these unaudited condensed financial statements



































Company may, at Nasdaq's discretion, be afforded a second 180 calendar day period to regain compliance, but if Nasdaq does not grant such extension, the Company's common shares could be delisted from Nasdaq.

To qualify for the extension, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement. The Company intends to monitor the closing bid price of its Common Shares and may, if appropriate, consider available options, including the possibility of seeking shareholder approval of a reverse stock split, to regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.

As of September 30, 2024, the Company had not gained compliance with the requirement. The Company's stockholder's equity as of September 30, 2024 was negative \$0.91 million.

On October 1, 2024, the Company received a staff determination letter from the Listing Department stating that the Company did not meet the terms of the extension because it did not complete its proposed financing initiatives to regain compliance. On October 8, 2024, the Company requested an appeal and hearing; such hearing is scheduled for November 21, 2024. The hearing request has automatically stayed Nasdaq's delisting of the Company's Common Shares pending the Panel's decision. At or prior to the hearing, the Company plans to present to Nasdaq information demonstrating that it has regained compliance with the continued listing standards under the Nasdaq Listing Rules, or alternatively a plan to regain compliance and a request for an extension of time to effectuate the plan. Notwithstanding the foregoing, there can be no assurance that the Company will regain compliance with the continued listing standards under the Nasdaq Listing Rules, or that the Panel will grant the Company an extension of time to regain compliance, in the event the Company requests such an extension.

On October 30, 2024, the Company filed Amendment 1 to this S-1, see note 12, Subsequent Events.

On October 30, 2024, the Company has authorized share capital of an unlimited number of Common Shares.

(i) June 2024 Registered Direct Offering

On June 3, 2024, the Company closed a registered direct offering priced at the market under Nasdaq rules of 1,800,000 common shares at a purchase price of \$1.15 per share and 2,035,000 common shares at a purchase price of \$1.149 per share. The series A and series B unregistered warrants became exercisable beginning on the effective date of shareholder approval of the issuance of the shares issuable upon exercise of the warrants which was obtained on September 5, 2024. The series A warrants will expire five years and the series B warrants will expire eighteen months from September 5, 2024. The gross proceeds to the Company from the offering was approximately \$2.43 million, before deducting the placement agent's fees and other offering expenses. Financing costs of approximately \$408 thousand included underwriting costs of \$750 and approximately \$192,750 of warrants, each at an exercise price of \$1.44. The unregistered warrants are exercisable on September 5, 2024 and will expire five years from September 5, 2024.

On September 5, 2024, the Company held a Special Meeting of Shareholders pursuant to which shareholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Common Shares underlying certain warrants in an amount equal to or in excess of \$20 million, before deducting the placement agent's fees and other offering expenses. Financing costs of approximately \$1.395 million included underwriting costs of \$1,395,000 and approximately \$5,649,122 of warrants at a combined offering price of \$1.71. This included 736,842 common shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. The Private Placement comprised 5,649,122 common shares and warrants at a combined offering price of \$2,105,263.

On February 29, 2024, the Company received a deficiency letter (the "February Deficiency Letter") from the Nasdaq Listing Qualifications Department of Nasdaq notifying the Company that the Company's Private Placement violated Nasdaq Listing Rule 5635(d) because the Company did not obtain shareholder approval prior to such issuance. Nasdaq stated that the Private Placement involved the issuance of greater than 20% of the issued and outstanding Common Shares of the Company at a discount to the Nasdaq official closing price on January 25, 2024, the date of the subscription agreement between the Company and Hanmi. The February



















1	Nine months ended September 30, 2024
2	Weighted average grant date fair value
3	Number of options (in thousands)
4	Number of options (in thousands)
5	Outstanding, beginning of period
6	Weighted average grant date fair value
7	Number of options (in thousands)
8	Number of options (in thousands)
9	Outstanding, ending of period
10	Vested and redeemed
11	Vested and redeemed
12	Vested and redeemed
13	Vested and redeemed
14	Vested and redeemed
15	Vested and redeemed
16	Vested and redeemed
17	Vested and redeemed
18	Vested and redeemed
19	Vested and redeemed
20	Vested and redeemed
21	Vested and redeemed
22	Vested and redeemed
23	Vested and redeemed
24	Vested and redeemed
25	Vested and redeemed
26	Vested and redeemed
27	Vested and redeemed
28	Vested and redeemed
29	Vested and redeemed
30	Vested and redeemed
31	Vested and redeemed
32	Vested and redeemed
33	Vested and redeemed
34	Vested and redeemed
35	Vested and redeemed
36	Vested and redeemed
37	Vested and redeemed
38	Vested and redeemed
39	Vested and redeemed
40	Vested and redeemed
41	Vested and redeemed
42	Vested and redeemed
43	Vested and redeemed
44	Vested and redeemed
45	Vested and redeemed
46	Vested and redeemed
47	Vested and redeemed
48	Vested and redeemed
49	Vested and redeemed
50	Vested and redeemed
51	Vested and redeemed
52	Vested and redeemed
53	Vested and redeemed
54	Vested and redeemed
55	Vested and redeemed
56	Vested and redeemed
57	Vested and redeemed
58	Vested and redeemed
59	Vested and redeemed
60	Vested and redeemed
61	Vested and redeemed
62	Vested and redeemed
63	Vested and redeemed
64	Vested and redeemed
65	Vested and redeemed
66	Vested and redeemed
67	Vested and redeemed
68	Vested and redeemed
69	Vested and redeemed
70	Vested and redeemed
71	Vested and redeemed
72	Vested and redeemed
73	Vested and redeemed
74	Vested and redeemed
75	Vested and redeemed
76	Vested and redeemed
77	Vested and redeemed
78	Vested and redeemed
79	Vested and redeemed
80	Vested and redeemed
81	Vested and redeemed
82	Vested and redeemed
83	Vested and redeemed
84	Vested and redeemed
85	Vested and redeemed
86	Vested and redeemed
87	Vested and redeemed
88	Vested and redeemed
89	Vested and redeemed
90	Vested and redeemed
91	Vested and redeemed
92	Vested and redeemed
93	Vested and redeemed
94	Vested and redeemed
95	Vested and redeemed
96	Vested and redeemed
97	Vested and redeemed
98	Vested and redeemed
99	Vested and redeemed
100	Vested and redeemed

















size:10pt;font-family:Times New Roman,min-width:fit-content;"> Common Shares. Each Offered Share, or a pre-funded warrant (the "Pre-Funded Warrants" in lieu thereof, is being sold together with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="sec-ix-hidden:F 4747709b-9b55-49dc-bee2-59d4aba700f5;"><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">one half</span></span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> (1/2) common warrant (the "Common Warrants" and together, with the "Pre-Funded Warrants", the "Warrants") exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">one </span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> Common Share. The assumed combined public offering price for each Offered Share and accompanying Common Warrant is \$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">0.3716</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">, which is the last reported sale price of the Company's Common Shares on Nasdaq on October 29, 2024. The completion of the offering is conditional upon the approval of the TSX. In addition, this S-1/A relates to the issuance of Placement Agent Warrants (as defined below) to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">861,141</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> shares of the Company's Common Shares issuable to the Placement Agent (as defined below), based on an assumed public offering price of the Offered Shares and Warrants and the underlying Common Shares issuable upon the exercise of Placement Agent Warrants.</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">Each Common Warrant has an assumed exercise price of \$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">0.3716</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> per Common Share, which is the last reported sale price of the Company's Common Shares on Nasdaq on October 29, 2024, will be exercisable immediately upon issuance, subject to certain limitations based on the holder's beneficial ownership of the Company's Common Shares, and will expire </span><span style="font-size:10pt;font-family:Times New Roman;"> </span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> five years</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> from the date of issuance. The Offered Shares and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The Company is also offering Pre-Funded Warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">21,528,525</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> Common Shares to those purchasers whose purchase of Offered Shares in this offering would result in the purchaser beneficially owning more than</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">4.99</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">% (or, at the election of the purchaser, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">9.99</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">% of the Company's outstanding Common Shares following the consummation of this offering in lieu of the Offered Shares that would result in ownership in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">4.99</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">% following the consummation of this offering. Each Pre-Funded Warrant will be exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">one</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> Common Share at an exercise price of \$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">0.3715</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> per Common Share. Each Pre-Funded Warrant is being issued together with the same Common Warrants described above being issued with each Offered Share. The assumed combined public offering price for each such Pre-Funded Warrant, together with the Common Warrants, is \$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">0.3715</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">, which is equal to the assumed public offering price in this offering of an Offered Share and accompanying Common Warrant less the \$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content;">0.0001</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> per Common Share exercise price of each such Pre-Funded Warrant. Each Pre-Funded Warrant will be exercisable immediately upon issuance, subject to certain limitations based on the holder's beneficial ownership of the Company's Common Shares, and may be exercised at any time until the Pre-Funded Warrant is exercised in full. The Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering.</span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;"> </span></p></div>